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Abstract
Dietary fibres, the edible parts of plants that are resistant to digestion and absorption 
in the human small intestine, were shown to be important in the prevention of 
obesity and the metabolic syndrome. This association can partially be attributed 
to a fibre-induced increase in satiety. Dietary fibres can be fermented by bacteria, 
collectively referred to as the microbiota, in the large intestine (i.e. caecum and 
colon), resulting in the production of the short-chain fatty acids (SCFAs) acetate, 
propionate and butyrate. Part of the effect of dietary fibres on satiety is thought to 
be mediated via the production of SCFAs.
The objective of the research described in this thesis was to reveal the effects of 
fermentation in the large intestine using comprehensive approaches with focus on 
metabolism and satiety.
The effect of 2-wk-consumption of resistant starch (RS), a dietary fibre highly 
fermentable by the gut microbiota, was studied in 2 pig experiments. In the first 
experiment, performed in adult female pigs, intestinal samples were collected 
from different areas of the gastrointestinal tract to measure luminal microbiota 
composition, luminal SCFA concentrations and the expression of host genes 
involved in SCFA uptake, SCFA signalling, and satiety regulation in mucosal tissue. 
In an additional study the effects of RS were investigated in young growing pigs 
fitted with a cannula in the proximal colon for repeated collection of tissue biopsies 
for whole-genome expression profiling and luminal content for measurement of 
SCFA concentrations and microbiota composition. To limit inter-individual variation, 
the RS diet was provided to the pigs in a 2 x 2 crossover design for 2 wk per diet. 
Furthermore, the behaviour of the pigs was monitored and the postprandial plasma 
response of satiety-related hormones and metabolites was measured at the end of 
each 2 wk period using repeated peripheral blood sampling via catheters. 
 In order to determine the potential differences in post-prandial plasma 
protein profiles, minipigs were assigned to a control (C) diet or a diet containing the 
bulky fibre lignocellulose (LC), the viscous and fermentable fibre pectin (PEC) or RS 
for periods of 8 d in a 4 x 4 Latin square design. Portal and carotid blood samples 
were collected from catheters on d 8 of each treatment, both before and at several 
time points after an ad libitum morning meal.
 Male C57BL/6J mice were used to study the effect of background diet and 
SCFAs on colonic gene expression. Mice were fed a semi-synthetic low fat or high fat 
diet starting 2 wk before the treatment period. During treatment, mice received a 
rectal infusion of either an acetate, propionate, butyrate, or a control saline solution 
on 6 consecutive days, after which colon was collected to perform comprehensive 
gene expression profiling.
RS enhanced satiety based on behavioural observations, as RS-fed pigs showed less 
feeder-directed and drinking behaviours than pigs fed a digestible starch (DS) diet. 
In both caecum and colon, differences in microbiota composition were observed 
between RS-fed pigs and DS-fed pigs. In the colon these included the induction of the 
healthy gut-associated butyrate-producing Faecalibacterium prausnitzii, whereas 
potentially pathogenic members of the Gammaproteobacteria were reduced in 
relative abundance in RS-fed pigs. Caecal and colonic SCFA concentrations were 
significantly higher in RS-fed pigs. Gene expression profiling of the proximal colon 
revealed a shift upon RS consumption from the regulation of immune response 
towards lipid and energy metabolism. The nuclear receptor PPARG was identified 
as a potential key upstream regulator. At plasma level, SCFA concentrations were 
higher in RS-fed pigs throughout the day. Postprandial glucose, insulin and glucagon-
like peptide 1 (GLP-1) responses were lower in RS-fed than in DS-fed pigs, whereas 
triglyceride levels were higher in RS-fed than in DS-fed pigs.
 In minipigs, plasma protein profiles were found to be most similar with 
C and LC consumption and with PEC and RS consumption, indicating that the 
consumption of diets with fermentable fibres results in a different plasma protein 
profile compared to a diet containing non-fermentable fibres or a diet without 
fibres.
 In mice we observed that dietary fat content had a major impact on 
colonic gene expression responses to SCFAs, especially after propionate treatment. 
Moreover, the diet- and SCFA-dependent gene expression changes pointed towards 
the modulation of several metabolic processes. Genes involved in oxidative 
phosphorylation, lipid catabolism, lipoprotein metabolism and cholesterol transport 
were suppressed by acetate and butyrate treatment, whereas propionate resulted 
in changes in fatty acid and sterol biosynthesis, and in amino acid and carbohydrate 
metabolism. Furthermore, SCFA infusion on the high fat diet background appeared 
to partially reverse the gene expression changes induced by high fat feeding without 
SCFA infusion.
In conclusion, this thesis showed that the consumption of RS changed the 
microbiota composition in the colonic lumen, with a decrease in the abundance of 
potentially pathogenic bacteria and an increase in the abundance of SCFA-producing 
populations. Furthermore, colonic gene expression changes were observed after 
RS consumption and after colonic administration of SCFAs. With both treatments, 
among the changes in the transcriptional profile of the host were adaptations in 
metabolic processes, such as energy and lipid metabolism, and immune response. 
We also showed that fat content in the background diet had a major impact on 
gene expression responses to SCFAs in colon. Overall, this thesis supports the 
implementation of fermentable dietary fibres into the human diet to improve 
colonic health and to reduce energy intake and body weight gain, which ultimately 
may prevent obesity and type 2 diabetes. Additional research is required to further 
elucidate the mechanisms via which fermentable dietary fibres can improve human 
health.
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Chapter 1
Background 
Obesity and metabolic syndrome
Obesity has become a major public health issue, affecting a large part of the global 
population. According to the World Health Organization, the worldwide prevalence 
of obesity nearly doubled between 1980 and 2008, with more than 1.4 billion adults 
(age ≥20) being overweight (BMI ≥25) in 2008. Of these adults, over 200 million men 
and nearly 300 million women were obese (BMI ≥30) (1). In Europe, over 50% of 
men and women were overweight in 2008, of which approximately 23% of women 
and 20% of men were obese (2). In addition, overweight and obesity cause more 
than 1 million deaths and 12 million life-years of ill health each year, and obesity is 
responsible for up to 6% of national health care costs in Europe (3).
 Obesity is associated with the metabolic syndrome, a combination of 
risk factors that act together and can ultimately lead to chronic diseases such as 
cardiovascular disease and type 2 diabetes. The main risk factors are central obesity 
(defined as waist circumference), dyslipidemia, increased blood pressure and 
increased fasting plasma glucose. In the United States, the prevalence of metabolic 
syndrome has increased as the prevalence of obesity increased, affecting over 30% 
of the population (4, 5). The development of metabolic syndrome is a complex 
process involving various lifestyle factors, of which diet is a major one (6). During 
the agricultural revolution and industrialization of food production, the composition 
of foods dramatically changed, which has been linked to some of the problems of 
overeating. Modification of dietary patterns can have tremendous impact on health 
outcomes.
Dietary fibres
Dietary fibre is an extensively studied food component regarding its potential health 
benefits. Fibres have been shown to be protective against cardiovascular disease 
and important for normal laxation (7). Fibres are mostly known for their importance 
for colonic health and functionality because of their fermentation by bacteria 
in the colon. In addition, fibres are considered to be useful in the prevention of 
obesity and metabolic syndrome. A number of studies provided evidence that the 
consumption of dietary fibre increases insulin sensitivity (8, 9) and that it can help 
with the reduction of body weight in overweight and obese subjects (10, 11). Part 
of these observations can be attributed to effects on appetite control, since dietary 
fibre consumption has been linked to an increase in satiety (12-14).
 Because there is no universally agreed and reliable method to quantify all 
of the dietary fibre components, there is still a lot of debate about its definition (15). 
A highly accepted definition was formulated by the American Association of Cereal 
13
1
General introduction and outline 
Chemists (AACC) in 2000: Dietary fibre is the edible parts of plants or analogous 
carbohydrates that are resistant to digestion and absorption in the human small 
intestine with complete or partial fermentation in the large intestine. Dietary fibre 
includes polysaccharides, oligosaccharides, lignin, and associated plant substances. 
Dietary fibres promote beneficial physiological effects including laxation, and/or 
blood cholesterol attenuation, and/or blood glucose attenuation (16).
 Many different types of dietary fibre have been identified and characterised. 
One of the means by which fibres can be classified is according to their 
physicochemical properties. There are for instance viscous fibres, which form a gel-
like paste in the stomach, bulky fibres with a high water-binding capacity and fibres 
that are highly fermentable by bacteria in the large intestine (17). Identification 
of the physicochemical properties of a fibre is essential, especially when studying 
satiety regulation.
Satiety
The modern Westernized human diets provide the majority of calories from fat and 
carbohydrates (18). These nutrients are rapidly digested and absorbed as fatty acids 
and monosaccharides in the small intestine and provide a relatively short period 
of satiety (19, 20). For developing nutritional advice regarding the control of food 
intake, knowledge on satiety regulation is required.
 Satiety is defined as the state of fullness, resulting from the combined 
action of regulatory feedback mechanisms throughout the gastrointestinal tract. 
Variation in the regulation of satiety is caused by diet- and subject-related factors. 
Diet-related factors are for instance the nutritional composition of a diet and the 
physicochemical properties of food components. Examples of subject-related 
factors are level of energy expenditure and the presence of obesity or metabolic 
syndrome. Currently, the interplay between dietary feedback mechanisms and diet- 
and subject-related factors is poorly understood.
 Satiety signals arise from multiple sites in the gastrointestinal tract. These 
nutrient sensing signals can be mediated by multiple signalling molecules including 
intestinal peptides, hormones and their corresponding receptors. Also post-
absorptive actions of products of digestion and fermentation play an important 
role. The stomach and small intestine have been extensively studied, whereas 
information on the potential contribution of the large intestine, i.e. caecum and 
colon, to regulation of satiety is limited. 
 Dietary fibres can affect energy intake and satiety in several ways. First of all, 
fibres decrease the energy density of foods, which may reduce energy intake (21). 
In addition, it usually takes longer to chew food products with a high fibre content, 
which may enhance sensory satiety and reduce meal size (22). Moreover, fibres may 
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reduce intestinal passage rate, which slows down nutrient absorption and prolongs 
feelings of satiety (23). Fibres may also decrease energy absorption by reducing the 
bioavailability of nutrients (24). Last but not least, dietary fibres can be fermented 
by bacteria in the large intestine, which may result in a shift in composition and 
activity of the microbiota, and concomitant increased production of short-chain 
fatty acids (SCFAs). These SCFAs can enhance satiety via various mechanisms (25).
Satiety-related hormones
It has been suggested that gut hormones play a key role in appetite, satiety and 
glucose homeostasis. Examples of these hormones are amylin, cholecystokinin 
(CCK), ghrelin, glucose-dependent insulinotropic polypeptide (GIP) and pancreatic 
polypeptide (PP). These hormones may be influenced by specific dietary fibres. 
Numerous studies have been performed on the effect of dietary fibres on gut 
hormone release (26-30). Because this thesis primarily focusses on events occurring 
in the large intestine, the 2 main hormones that are released in the large intestine 
are described in more detail: glucagon-like peptide 1 (GLP-1) and peptide tyrosine-
tyrosine (PPY).
 GLP-1 and PYY are gut hormones released by endocrine L-cells in the 
distal small intestine and colon in response to food intake. Both hormones play 
an important role in the ‘ileal brake’, a mechanism that regulates the flow of 
nutrients from the stomach to the small intestine. This ileal brake eventually slows 
gastric emptying and promotes digestive activities to increase nutrient absorption. 
Furthermore, there is strong evidence that GLP-1 and PYY are involved in the 
regulation of satiety (20, 31, 32).
 GLP-1 is an incretin hormone that enhances glucose-dependent insulin 
release, inhibits glucagon secretion, and increases pancreatic β-cell growth. Food 
intake results in a rapid increase in GLP-1 concentrations in plasma. A number of 
studies have shown that dietary fibres can modify this postprandial GLP-1 response. 
However, the direction and the degree of this changed response depend on the 
type and the amount of dietary fibre. Elevated (29), inhibited (33) and unaffected 
GLP-1 responses (34) have been reported.
 Like GLP-1, PYY is involved in the regulation of insulin secretion and glucose 
homeostasis. Plasma concentrations of PYY increase after a meal and decrease 
upon fasting. PYY secretion already occurs before nutrients have reached the PYY-
releasing cells and is proportional to caloric intake. Meal composition, including 
the presence of dietary fibre, also affects postprandial PYY release. However, the 
direction and the magnitude of the effect of fibres on PYY levels highly depend on 
the fibre type used (31).
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Microbiota
The microorganisms that inhabit the intestine of an organism, including bacteria, 
viruses, fungi and Archaea, are collectively referred to as the gut microbiota. The 
human gut contains an enormous amount and variety of these microorganisms, 
including at least 1014 bacteria belonging to approximately 1000 species (35). The 
general awareness that the microbial composition is an important factor in health 
and disease is increasing. Modulation of microbial composition by probiotics was 
shown to attenuate the development of inflammatory bowel disease and irritable 
bowel syndrome (36). Besides the consumption of probiotics, faecal transplantation 
of microbiota from a healthy individual was found to be a useful therapy for these 
gastrointestinal disorders (37).
 Evidence suggesting that gut microbiota are also highly important in the 
regulation of energy homeostasis and fat storage is accumulating (38, 39). For 
instance, it was shown that conventionally raised mice have 42% more total body 
fat than germ-free mice. After conventionalizing the germ-free mice, a 57% increase 
in total body fat was observed (40). In addition, germ-free mice were found to be 
protected from the development of obesity after consuming a high fat diet (41). The 
relationship between microbiota composition and fat storage was also studied in 
humans, showing that the Firmicutes/Bacteroidetes ratio is related to adiposity, as 
obese people have fewer Bacteroidetes compared to lean controls. In addition, the 
relative abundance of Bacteroidetes increased while the abundance of Firmicutes 
decreased with weight loss in obese subjects (42).
 One of the main factors affecting intestinal microbiota composition is diet 
composition (35, 43-50). For example, mice consuming a Western-type diet rich 
in saturated fat had a different gut microbiota composition compared to mice 
consuming diets rich in unsaturated fat (51). It has also been reported that mice 
fed a high fat diet have reduced numbers of Bacteroidetes and increased numbers 
of Firmicutes and Proteobacteria (43). In turn, the microbial composition might 
determine how an individual responds to a diet. Recently, it was suggested that the 
human gut microbiome can be classified into so-called enterotypes. This finding 
indicates that a number of well-balanced symbiotic states between microbiota and 
host exist, which might respond differently to diet (52).
 Although the total microbial profile of the intestine can provide information 
on the health status of the gut, the exact function of many microbial species is 
poorly understood. However, for some particular microbial groups the role in gut 
health is elucidated rather well. For instance, within the group of Proteobacteria 
several species are known to be pathogenic. These pathogenic bacteria include 
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Escherichia, Salmonella, and Vibrio. Among the bacteria known to be beneficial for 
health are Bifidobacteria and Lactobacillus, which are therefore frequently used as 
probiotics.
 Microbiota can also be classified into saccharolytic and proteolytic 
bacteria, according to the substrates they preferably ferment. Saccharolytic 
bacteria metabolise carbohydrates, which mainly yields SCFAs, lactate, pyruvate, 
and ethanol. This process and especially the production of SCFAs is regarded as 
beneficial for the host (53). Proteolytic bacteria can metabolise undigested and 
endogenous proteins, peptides, and amino acids present in the large intestine. This 
process mainly occurs in the distal colon, where carbohydrates are depleted. The 
fermentation of proteins results in the production of metabolites such as SCFAs 
and branched-chain fatty acids, but also the potentially toxic substances ammonia, 
amines, phenols and indols are produced (54).
Short-chain fatty acids
As mentioned previously, some dietary fibres can be fermented by bacteria in 
the large intestine, resulting in the production of SCFAs. SCFAs are absorbed by 
enterocytes either via facilitated diffusion, or mediated by transporters such as 
monocarboxylate transporter type 1 (MCT1) and sodium-coupled MCT1 (SMCT1). 
More than 95% of the SCFAs are rapidly absorbed from the colonic lumen and 
metabolised by the host (55). However, data on the exact production and uptake 
rates of SCFAs is limited, in particular in mice and humans.
 An increasing amount of evidence suggests that the health benefits 
observed with dietary fibre consumption are partly due to the action of SCFAs 
(53). For instance, SCFAs are agonists for FFAR2 and FFAR3, G protein-coupled 
receptors (GPCRs) highly present in enteroendocrine cells in the gut epithelium. It 
is suggested that SCFAs can stimulate the production and release of GLP-1 and PYY 
by enteroendocrine L-cells via FFAR2 and FFAR3 (56-58), thereby playing a role in 
satiety regulation.
 Acetate, propionate and butyrate are the main SCFAs produced. Butyrate 
is almost entirely utilised by colonocytes as their preferred energy substrate (59), 
while acetate and propionate are also transported to the liver via the portal vein (60). 
Propionate is metabolized by the liver and used for gluconeogenesis, while acetate 
may serve as a substrate for cholesterol synthesis and lipogenesis (61). In addition, 
acetate is taken up by muscle and adipose tissue (62). Since these individual SCFAs 
have very distinct properties, their effects on metabolism and health outcomes are 
under current review.
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Animal models
To gain knowledge on the effect of nutrition on biological processes in humans, 
animal experiments have proven to be highly valuable. Use of animal models allows 
standardization of experimental factors such as age, body weight and food intake. 
The advantages of the 2 animal models used in this thesis, namely mice and pigs, 
are described below. 
Mice
Mice are a frequently used animal model, because they are cheap, small, easy to 
house and to handle, and they have a high reproduction rate. Furthermore, inbred 
strains to limit inter-individual genetic variation and transgenic mouse models 
are available (63, 64). Although mice share 99% of their genes with humans, data 
obtained from mouse experiments may not be directly translated to humans 
because of large contributions of the genetic background caused by the breeding 
selection (65). However, to comprehensively understand basal mechanisms of 
metabolism and the role of nutrition and nutrient-activated transcription factors in 
metabolic regulation, mouse models are indispensable.
Pigs
For answering certain research questions, the pig can be a more suitable model 
for humans compared to mice. The use of the pig as an experimental model allows 
precise and highly relevant dietary intervention studies for humans. First of all, 
the domestic pig is a valuable invasive model for the digestive function in humans, 
because the anatomy and physiology of the gastrointestinal tract of pigs has a lot 
of similarities with those in humans (66). In addition, extensive conservation exists 
between the pig and human genome sequence (67-70) and recently developed 
techniques are available for the pig including industry standard Affymetrix porcine 
microarrays (71).
18
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Figure 1 Overview of the 4 main omics technologies.
Tools
Several techniques are available to increase our understanding of physiological and 
molecular mechanisms. In this paragraph some background information will be 
given about the techniques that were applied to obtain the results described in this 
thesis. 
 With so-called ‘omics technologies’ it is possible to make a snapshot of the 
entire genome, transcriptome, proteome or metabolome of an organism or tissue. 
Previous studies have shown the value of these techniques in identifying new 
potential mechanisms via which nutrients can affect health outcomes (72-75). In 
the studies described in this thesis, transcriptomics, proteomics and metabolomics 
techniques were applied to gain knowledge on the host response, of which 
transcriptomics is the most unbiased methodology. Furthermore, a metagenomics 
technique was used in order to measure the microbiota composition of the pig 
intestine.
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Metagenomics
Several methods have been developed to determine the intestinal microbiota 
composition of an organism. With these techniques the metagenome, the collective 
genome of the microbial community, is studied. In principal, 2 techniques can be 
applied to study the gut metagenome: sequencing techniques such as deep   of 16S 
rRNA gene fragments or next-generation parallel sequencing, and the phylogenetic 
microarray.
 Phylogenetic microarrays have been developed to analyse the intestinal 
microbiota composition of several species, including humans (HITChip), mice 
(MITChip) and pigs (PITChip). In the pig experiments described in this thesis, 
the PITChip (Pig Intestinal Tract Chip) was used, which contains oligonucleotides 
targeting the 16S rRNA gene sequences of porcine intestinal microbial species-
level phylotypes. It provides a very deep and reproducible phylogenetic analysis. 
Compared with deep pyrosequencing of 16S rRNA gene fragments (76) and next-
generation parallel sequencing of intestinal metagenomes (77), PITChip has a similar 
resolution and a higher sensitivity.
 Chapter 2 and 3 of this thesis describe the results of PITChip analysis. 
In Chapter 2, the first generation PITChip, containing >2,900 oligonucleotides 
based on 16S rRNA gene sequences of 627 porcine intestinal microbial species-
level phylotypes, was used. In Chapter 3, samples were analysed on the second 
generation PITChip. This is an updated version of the original phylogenetic 
microarray, comprised of >3,200 oligonucleotides targeting the 16S rRNA gene 
sequences of 781 porcine intestinal microbial phylotypes.
Transcriptomics
The transcriptome is the complete and dynamic set of RNA transcripts produced 
by the genome. Characterization of the transcriptome via measurement of mRNA 
levels has long been of interest to researchers. Basically, 2 techniques are available 
to measure gene expression levels of large numbers of genes simultaneously.
 The first technique is the DNA microarray, currently the most frequently 
used method. By comparing the gene expression profile of samples obtained after 
different treatments, it is possible to determine which genes are differentially 
expressed. The arrays used for microarray analysis consist of DNA oligonucleotides, 
each containing a specific DNA sequence called a probe. The oligonucleotide probes 
were synthesised in situ using photolithography. The mRNA present in the samples 
of interest can hybridise to these probes. Subsequently, probe-target hybridization 
is detected and quantified by fluorescence to determine the relative abundance of 
nucleic acid sequences in the target. 
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 The second technique is called RNA-Seq, a recently developed approach for 
transcriptome profiling that uses high-throughput deep-sequencing technologies. 
In principle, a population of RNA is converted to a library of cDNA fragments with 
adaptors attached to one or both ends. Each molecule is then sequenced in a high-
throughput manner to obtain short sequences. The resulting reads are either aligned 
to a reference genome or reference transcripts, or assembled de novo without the 
genomic sequence to produce a genome-scale transcription map that consists of 
both the transcriptional structure and/or level of expression for each gene (78).
 Compared with microarray, RNA-Seq has lower background noise and the 
possibility to distinguish the different isoforms and allelic expression. Moreover, a 
limitation of microarrays is that sequence information is required in order to detect 
and evaluate transcripts (78). On the other hand, the microarray technique has 
a number of advantages compared to RNA-Seq. The amount of time to retrieve 
results is shorter, RNA-Seq protocols still suffer from unknown biases and with RNA-
Seq high abundance transcripts are responsible for the majority of the sequencing 
data.
 In Chapter 3, the Affymetrix Porcine Gene 1.0 ST array was used to measure 
the full gene expression profile in colonic tissue of pigs. This array contains 595,966 
probes, representing 17,116 unique genes. The Affymetrix Mouse Gene 1.1 ST array, 
containing 828,268 probes representing 21,225 unique genes, was used to measure 
the gene expression profile in colonic tissue of mice as described in Chapter 4.
Proteomics
The proteome is the entire set of proteins expressed by a genome, cell, tissue 
or organism. Several techniques can be applied to measure this highly dynamic 
proteome. Methods to determine the proteome can be separated into 2 groups: 
Gel-based proteomics and mass spectrometry (MS)-based proteomics (79).
 Among the gel-based approaches are one-dimensional and two-dimensional 
polyacrylamide gel electrophoresis (1D-PAGE and 2D-PAGE respectively). For simple 
pre-separation of complex protein mixtures before mass spectrometric analysis, 
1D-PAGE is often used. 2D-PAGE allows the separation of up to 10,000 protein 
species for global differential proteome analysis. In MS-based proteomics, the 
chemical compounds of a sample are ionized and the resulting charged molecules 
(ions) are analysed according to their mass-to-charge (m/z) ratios (79).
 The proteomics results described in Chapter 6 of this thesis were obtained 
by using the SELDI-TOF-MS technique. SELDI-TOF-MS is the abbreviation of Surface-
enhanced laser desorption/ionization time-of-flight mass spectrometry. It is an 
ionization method in MS that is especially used for the high-throughput analysis 
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of protein mixtures, such as blood or urine. For analysis of plasma, samples are 
first processed to get rid of highly abundant proteins (e.g. albumin) that complicate 
the detection of medium and low abundance proteins. Subsequently, the samples 
are spotted on the surface of ProteinChip arrays. Some proteins in the sample 
bind to the surface of the array while others are removed by washing. Usually 
each sample is analysed on multiple arrays, with each array having the capacity 
to bind specific proteins. For instance, CM10 arrays are used to analyse molecules 
that have a positive charge on the surface, H50 arrays capture larger proteins 
through hydrophobic interactions and IMAC30 arrays capture molecules that bind 
polyvalent metal ions. Each array is irradiated with a laser, resulting in ionization of 
the adherent molecules. The ions travel through a vacuum flight tube and their m/z 
ratios are calculated from their time of flight through the vacuum chamber.
Metabolomics
The metabolome refers to the complete and dynamic set of small-molecule 
metabolites found in a biological sample. The 2 most commonly used techniques 
to measure the metabolome are MS and 1H-nuclear magnetic resonance (1H-NMR) 
spectroscopy. MS is a very sensitive technique which is usually performed after 
separation of the metabolites by gas chromatography (GC) or high-performance 
liquid chromatography (HPLC). 
 NMR spectroscopy is a technique that applies the magnetic properties of 
certain atomic nuclei. It determines the physical and chemical properties of atoms 
or the molecules in which they are contained, relying on the phenomenon of 
nuclear magnetic resonance.
 When NMR active nuclei (e.g. 1H or 13C) are placed in a magnetic field, they 
absorb electromagnetic radiation at a frequency characteristic of the isotope. The 
resonant frequency, the energy of the absorption, and the intensity of the signal 
are proportional to the strength of the magnetic field. The chemical environment 
determines the position of the metabolite. With NMR spectroscopy, all kinds of small 
molecule metabolites can be measured simultaneously. Therefore, this technique 
does not require pre-separation of the metabolites, making sample preparation 
relatively simple. Another advantage of NMR is its high analytical reproducibility.
 We used 1H-NMR spectroscopy to measure the metabolome of plasma 
collected from pigs (Chapter 3, 5 and 6). Plasma samples were first ultra-filtrated to 
remove large molecules and then metabolites were determined by using an Avance 
III NMR spectrometer. 
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Thesis outline and aims
The work presented in this thesis was embedded in a larger IP/OP funded program 
entitled “Satiety & Satisfaction”. The main objective of the subproject ‘Fermentation 
in the gut prolongs satiety’ was to estimate the potential contribution of fermentable 
dietary fibres to the regulation of satiety and to elucidate their mode of action, using 
the pig as a model for humans. Therefore, a number of experiments was conducted 
at the research facilities of Wageningen University in Wageningen and Lelystad. 
 Three fibre types, i.e. lignocellulose, pectin and resistant starch, were 
screened for satiating properties in pigs using behavioural tests. Since pigs 
consuming a diet high in resistant starch (RS) showed the highest degree of satiety, 
this fibre type was selected for more detailed analysis at the level of the intestine. 
Pigs were either assigned to an RS diet or a digestible starch (DS) diet for 2 wk, after 
which intestinal samples along the proximal-distal axis were collected for measuring 
luminal microbiota composition, luminal SCFA concentrations and the expression 
of host genes involved in SCFA uptake, SCFA signalling, and satiety regulation in 
mucosal tissue. Study outcomes of this experiment are described in Chapter 2. 
 Because the results from the first study were promising, an additional 
experiment was performed on the effects of RS, in which 10 young growing pigs 
were fitted with catheters for repeated blood sampling and with a cannula in the 
proximal colon for repeated collection of tissue biopsies and luminal content. 
Peripheral blood samples were collected before and at several time points after 
the morning meal, and luminal content (microbiota composition, SCFAs) and colon 
biopsies (whole-genome expression profiling) were collected from the cannula. To 
limit inter-individual variation, the DS and RS diet were provided to the pigs in a 2 x 2 
crossover design for 2 wk per diet. Results from this study are described in Chapter 
3 and 5, with each chapter having a specific focus. In Chapter 3, we aimed to identify 
genes regulated by RS in the proximal colon using microarray analysis, to elucidate 
which metabolic pathways were affected, and to correlate gene expression changes 
with alterations in microbiota composition and SCFA concentrations. The objective 
of Chapter 5 was to assess the time-course of RS-induced changes in physical activity 
and behaviour, satiety-related hormones and metabolites in peripheral blood, and 
to relate those to feeding behaviour and meal size during an ad libitum meal. In 
addition, satiating effects of RS were evaluated in the presence of extra dietary fat. 
 The results of a proteomics analysis of portal and arterial plasma samples 
are described in Chapter 6. This study was performed in minipigs provided with 4 
different fibre diets (Control, Lignocellulose, Pectin and Resistant starch) in a 4x4 
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Latin square design. The main study objective was to determine the effect of fibres 
with different physicochemical properties on postprandial plasma protein and 
metabolite profiles.
 In addition to the pig studies that have been performed, an experiment 
was conducted in mice. Chapter 4 describes the results of this mouse study, which 
aimed to determine the effect of dietary fat content on colonic gene expression 
profile after colonic acetate, propionate and butyrate administration. Mice on a low 
fat or a high fat diet background received a rectal infusion of a control solution or 
a solution containing acetate, propionate or butyrate for 6 consecutive days, after 
which colon was collected for whole-genome expression profiling.
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Abstract
Resistant starch (RS) is highly fermentable by microbiota in the colon, resulting in 
the production of SCFAs. RS is thought to mediate a large proportion of its health 
benefits, including increased satiety, through the actions of SCFAs. The aim of 
this study was to investigate the effects of a diet high in RS on luminal microbiota 
composition, luminal SCFA concentrations and the expression of host genes involved 
in SCFA uptake, SCFA signalling and satiety regulation in mucosal tissue obtained 
from small intestine, caecum and colon. Twenty adult female pigs were either 
assigned to a digestible starch (DS) diet or a diet high in RS (34%) for a period of 2 
wk. After the intervention, luminal content and mucosal scrapings were obtained 
for detailed molecular analysis. RS was completely degraded in caecum. In both the 
caecum and colon, differences in microbiota composition were observed between 
DS- and RS-fed pigs. In the colon these included the stimulation of the healthy gut-
associated butyrate-producing Faecalibacterium prausnitzii, whereas potentially 
pathogenic members of the Gammaproteobacteria, including Escherichia coli and 
Pseudomonas spp., were reduced in relative abundance. Caecal and colonic SCFA 
concentrations were significantly greater in RS-fed pigs, and caecal gene expression 
of monocarboxylate transporter 1 (SLC16A1) and glucagon (GCG) was induced 
by RS. In conclusion, our data show that RS modulates microbiota composition, 
SCFA concentrations and host gene expression in pig intestine. Combined, our data 
provide an enhanced understanding of the interaction between diet, microbiota 
and host.
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Introduction
Obesity and related disorders, such as cardiovascular diseases and type 2 diabetes, 
have become major public health issues (4, 5). Various lifestyle factors, of which 
diet is a major one, play an important role in the development of these disorders (6, 
80). A large amount of research has reported an inverse relationship between fibre 
consumption and the risk of obesity and diabetes (81). Moreover, consumption 
of dietary fibre prevents the accumulation of fat mass (82, 83), increases insulin 
sensitivity (9, 84) and can enhance feelings of satiety (12).
 Resistant starch (RS) is a type of dietary fibre that includes all starch and 
starch degradation products that are not absorbed in the small intestine of healthy 
humans (15). It is known to be fermented to a large extent by microbiota in the 
colon, resulting in the production of SCFAs (53, 85). These SCFAs can diffuse across 
the epithelial cell membrane, but SCFA absorption by the enterocytes is also 
mediated by the monocarboxylate transporter 1 (SLC16A1, also known as MCT1) 
and sodium-coupled monocarboxylate transporter 1 (SLC5A8 or SMCT1) (86).
 Enhanced SCFA production provides an important link between dietary 
fibre consumption and health benefits. First, SCFAs lower the pH in the colon, which 
can prevent the overgrowth of pathogenic bacteria (87). Acetate, propionate and 
butyrate are the major SCFAs produced in the colon, of which butyrate is thought 
to be most beneficial for health. Among the health benefits observed with butyrate 
are the prevention and inhibition of colon carcinogenesis, protection against 
mucosal oxidative stress, strengthening of the colonic defence barrier and butyrate 
also has anti-inflammatory properties (55). Propionate has the potential to reduce 
cholesterol concentrations in blood (88).
 In addition to these health benefits, SCFAs are thought to be involved in 
the increase in satiety observed with fibre consumption (25). Studies in rodents 
have provided evidence that fermentation of RS is an important mechanism for 
increased endogenous secretion of the gut hormones glucagon-like peptide 1 
(GLP-1) and peptide YY (PYY) (29, 82, 89, 90). GLP-1 and PYY are satiety-stimulating 
hormones that are released in response to nutrient intake, mainly in the ileum and 
colon. SCFAs are agonists for free fatty acid receptor 2 and 3 (FFAR2 and FFAR3 
respectively), 2 G protein-coupled receptors present in the gastrointestinal tract. 
Both of these G protein-coupled receptors are expressed in enteroendocrine cells 
in the gut epithelium. It has been proposed that the activation of these receptors 
trigger the production and release of GLP-1 and PYY by enteroendocrine L-cells (91, 
92).
 In the experiments described in this chapter, we investigated the effects of a 
diet high in RS on luminal microbiota composition, luminal SCFA concentrations and 
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the expression of host genes involved in SCFA uptake, SCFA signalling and satiety 
regulation in mucosal tissue obtained from small intestine, caecum and colon. Adult 
pigs were used as a model for humans because the anatomy and physiology of the 
gastrointestinal tract of pigs and the pig genome are similar to those of humans 
(66, 93). Because we recently reported that a diet high in RS decreases feeding 
motivation in pigs (17), special attention was given to selected genes involved in 
SCFA sensing and regulation of satiety. 
Materials and Methods
Experimental design, pigs and housing
Two independent studies were performed. First, a pilot experiment was carried 
out to ascertain whether the gene expression profile along the intestine of pigs is 
similar to the sites of expression in humans and rodents. Three multiparous female 
pigs with a mean (± SEM) body weight of 273 ± 1.15 kg were included is this study.
 The main study had a parallel design. Two groups of 10 female pigs (PIC 
Benelux B.V.), aged 22 mo, with an initial body weight of 268 ± 3.85 kg were assigned 
to 1 of 2 treatments. Treatments differed with regard to the type of starch in the 
diet: digestible starch (DS) or RS. Siblings were equally distributed between the 2 
groups. Pigs were individually fed and housed in pairs that received the same diet. 
The area of each pen was 11 m2 and contained 2 drinking nipples and 2 feeding 
troughs. Artificial lights were on from 06:30 h until 22:00 h and dimmed during 
the dark period. The animal protocol was approved by the Animal Care and Use 
Committee of Wageningen University. The same pigs were used previously for 
feeding motivation studies (17).
Diets and feeding
The 2 experimental diets used in the main study were identical except for type of 
starch. The main source of starch in the DS diet was pregelatinized potato starch 
(Paselli WA4; AVEBE), which was replaced on a dry matter basis in the RS diet by 
retrograded tapioca starch (Actistar; Cargill). According to the supplier, this starch 
was ≥50% resistant to digestion in the small intestine. On the basis of physical and 
chemical characteristics, the RS used in this study can be classified as RS type 3 (RS3) 
(15). Diets were isoenergetic on a gross energy basis. The detailed composition of 
the experimental diets is presented in Supplemental Table 1. Each diet was given to 
10 pigs in pelleted form at 07:00 h and 17:00 h for a period of 14 d. The daily feed 
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allowance was 1.13 times the energy requirements for maintenance [net energy = 
293 kJ/(kg0.75 • d)], and pigs were allowed 1 h to consume the meal. All pigs had free 
access to water throughout the entire day.
Blood collection
Blood was collected 5 h postprandially on 2 separate days. Blood sampling was 
performed before the start of the treatment period when all pigs had consumed the 
DS diet for 2 d and at the end of the dietary intervention when pigs had been fed the 
DS or RS diet for 12 d. Blood was drawn from the jugular vein and collected in a BD 
Vacutainer EDTA tube with protease (Complete, EDTA-free; Roche) and dipeptidyl 
peptidase-4 (Millipore) inhibitors. Tubes were centrifuged for 10 min at 1300 g at 
4°C immediately after blood collection. Plasma was separated into aliquots and 
stored at -80°C.
Collection of digesta and tissue
Digesta and tissue samples were collected 5 h after the morning meal. This time 
point was selected on the basis of a previous study in which an increase in SCFA 
concentration was observed 4-5 h after feeding (94). Pigs were stunned and 
exsanguinated, after which the abdominal cavity was opened. The gastrointestinal 
tract from stomach to anus was removed from the cavity and the length of the small 
intestine and colon was determined. The small intestine was divided into 10 parts 
of equal length, the caecum was divided into 2 parts and the colon into 4 parts. The 
luminal content was collected from the 4 most distal parts of the small intestine 
(segment 7 to 10) and from all caecal and colonic parts. For subsequent analysis of 
SCFA concentrations, part of the content was collected in tubes with 1 mL of H
3
PO
4
, 
after which the samples were thoroughly mixed and stored at -20°C. Luminal content 
was also stored in empty tubes at -20°C to determine dry matter and degradation 
of RS. The remaining amount of digesta was collected in 1.5 mL Eppendorf tubes to 
determine microbiota composition. These tubes were immediately frozen in liquid 
nitrogen and stored at -80°C until further analyses. In addition, a small piece from 
the middle of each intestinal segment was excised and rinsed in PBS. Epithelial cells 
were collected from these tissues by scraping the mucosal lining with a glass slide. 
These samples were immediately snap-frozen in liquid nitrogen and then stored at 
-80°C for subsequent RNA isolation.
Analysis of RS in luminal samples
RS was analysed according to methods used by Goñi et al. (95), adapted for 
intestinal samples, including extra washing steps and the total volume set at 35-40 
mL. Impurities were removed by deionization of the sample by using equal amounts 
30
Chapter 2
of Q-sepharose and S-sepharose beads equilibrated with phosphate buffer, 20 
mmol/L, pH 7. An aliquot (100 µL) of the sample obtained in step 9 of the procedure 
was combined with an equal amount of the ion exchange mix and thoroughly mixed 
for 5 min at room temperature. For the glucose assay, 100 µL supernatant obtained 
after 5 min of centrifugation at 14,000 g was used. Glucose was determined in the 
samples by using the Glucose Assay Kit from Sigma-Aldrich (product no. GAGO20). 
The amount of RS in the sample was calculated by using the method as described 
(95).
Microbiota analysis
Microbial DNA was extracted from 250 mg of intestinal contents by using a faecal 
DNA extraction protocol (96). Denaturing gradient gel electrophoresis (DGGE) 
analysis was performed for a preliminary scanning of the microbial profile. Briefly, 
universal primers S-D-Bact-0968-a-S-GC and S-D-Bact-1401-a-A-17 (97) were used 
to amplify the V6 to V8 variable regions of the bacterial 16S rRNA gene. The V6-V8 
PCR amplicons were separated by DGGE according to the specifications of Muyzer 
et al. (98) by using a DCode system (Bio-Rad Laboratories). Gel images were digitally 
normalized by comparison with an external standard pattern by using Bionumerics 
software package version 4.5 (Applied MathS). Observed bands were classified 
across all samples, and band class information, including relative band intensity, 
was used for multivariate analysis. 
 After the preliminary scanning of microbiota composition by DGGE analysis, 
the luminal contents from the first part of caecum (from 9 DS-treated and 7 RS-
treated pigs) and colon (from 7 DS-treated and 8 RS-treated pigs) were selected 
for further analysis by using the Pig Intestinal Tract Chip (PITChip). The PITChip is 
a phylogenetic microarray with >2900 oligonucleotides based on 16S rRNA gene 
sequences of 627 porcine intestinal microbial species-level phylotypes (99). The 
PITChip provides a very deep and reproducible phylogenetic analysis that has been 
compared with deep pyrosequencing of 16S rRNA gene fragments (76, 99, 100) 
and next-generation parallel sequencing of intestinal metagenomes (77), indicating 
comparable resolution and a higher sensitivity of the chip-based analysis.
 The protocol for hybridization and analysis of the generated data was 
performed essentially as previously described for the Human Intestinal Tract Chip 
(101). The bacterial 16S rRNA gene was amplified by using the primers T7prom-Bact-
27-for and Uni-1492-rev (101). The PCR products were transcribed into RNA and the 
purified resultant RNA was coupled with CyDye (GE Healt hcare Life Sciences) before 
fragmentation and hybridization to the array. Microarray images were processed 
using Agilent’s Feature Extraction Software, version 9.1 (Agilent Technologies). Data 
normalization and processing were performed as described (99, 101). 
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Dry matter and SCFA measurement 
Dry matter was determined by drying the intestinal content to a constant weight 
at 103°C (ISO standard 6496; International Organization for Standardization, 1999). 
 The digesta samples collected in tubes with H
3
PO
4
 were thawed, mixed 
on a vortex and centrifuged at 20,000 g for 5 min. The supernatant was collected 
and diluted 1:1 with a solution containing isocaproic acid. SCFA concentrations 
were determined in the effluent by gas chromatography (Fisons HRGC Mega 2; CE 
Instruments) at 190°C by using a glass column fitted with Chromosorb 101 (Supelco). 
The carrier gas was N
2
 saturated with methanoic acid, and isocaproic acid was used 
as an internal standard.
RNA isolation and quality control
Total RNA was isolated from intestinal scrapings using TRIzol reagent (Life 
Technologies) according to the manufacturer’s instructions. Concentrations and 
purity of RNA samples were determined on a NanoDrop ND-1000 spectrophotometer 
(Isogen Life Science). RNA quality was verified with an Agilent 2100 Bioanalyzer 
(Agilent Technologies) by using 6000 Nano Chips (Agilent Technologies) according 
to the manufacturer’s instructions.
 
qRT-PCR
Single-stranded cDNA was synthesized from 1 µg of total RNA by using the First 
Strand cDNA Synthesis Kit (Fermentas Life Sciences) according to the supplier’s 
protocol. qRT-PCR was performed on a CFX384 Real-Time PCR Detection System 
(Bio-Rad) by using SensiMix SYBR No-ROX (Bioline). Primers were designed in 
Beacon Designer 7.6 by using sequences obtained from the ENSEMBL pig database. 
Specificity of the amplification was verified by melt curve analysis and evaluation 
of efficiency of PCR amplification. The primer sequences are listed in Supplemental 
Table 2. Samples were analysed in duplicate and mRNA expression of all genes 
reported was standardized to RPLP0 gene expression.
Plasma measurements
All plasma measurements were performed in duplicate. Glucose was measured 
by using an enzymatic glucose assay (Glucose PAP SL; Elitech Group). Triglyceride 
(TG) and cholesterol concentrations were determined by using the enzymatic 
methods (Triglycerides Liquicolor, Cholesterol Liquicolor; INstruchemie). Insulin 
and PYY concentrations were measured by EIA [insulin: (porcine/canine) EIA; 
ALPCO Diagnostics; peptide YY (3-36): (rat, mouse, porcine, canine) EIA kit; Phoenix 
Pharmaceuticals]. GLP-1 was analysed with ELISA [Glucagon-like Peptide-1 (active) 
ELISA Kit; Millipore].
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Statistical methods
Results are expressed as means ± SEM. The significance of differences between the 
2 treatment groups of the variables determined at the end of the experimental 
period was evaluated by Student’s t test. ANOVA was used to test for differences in 
RS content in the small intestine, caecum and colon. Significance of differences of 
plasma variables, which were measured before and after the experimental period, 
was determined by linear mixed-model analysis treating pig as a random effect. 
Analyses were performed in GraphPad Prism, version 5.04, and IBM SPSS Statistics, 
version 19. Differences were considered significant if P <0.05.
 Multivariate analysis was applied for DGGE and PITChip data interpretation. 
To relate changes in total bacterial community composition to environmental 
variables, redundancy analysis (RDA) was used as implemented in the CANOCO 
4.5 software package (Biometris). RDA is the canonic form of principle component 
analysis and is a multivariate linear regression method in which several response 
variables are related to the same set of environmental variables and in which the 
estimated matrix of regression coefficients is of reduced rank (102). The relative 
abundance of bands on DGGE gels and signal intensities for 144 genus-level 
phylogenetic groups of PITChip were used as responsive variables. Treatment 
class (DS or RS), SCFA concentration and gene expression values of GCG and 
SLC16A1 were introduced as environmental (explanatory) variables. The latter 
were included because these variables were significantly different between the 
2 treatment groups in the caecum and colon (see Results). RDA was performed 
by focusing on intersamples correlation, and the Monte Carlo permutation test 
was applied to evaluate whether treatment class, SCFA concentration and gene 
expression had significant influence on the microbial composition (103, 104). 
Because the experiment had a randomized design, we used the unrestricted 
permutation option that yields completely random permutations. Treatment class 
or other environmental variables were considered to significantly affect microbial 
composition with P values <0.05. Diagrams were plotted as biplots for DGGE data 
and as triplots for PITChip data by using CanoDraw (Biometris). 
 Univariate testing of differences for individual microbial groups was 
processed by using a Mann–Whitney U signed-rank test. P values were corrected 
for multiple testing by using Benjamini-Hochberg’s approach (105).
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Results
Longitudinal distribution of gene expression
In the pilot experiment, the expression of several genes involved in luminal uptake 
and sensing of nutrients and metabolites was measured in mucosal scrapings of 3 
female pigs (Supplemental Fig. 1). As expected, the expression of apical sodium-
dependent bile salt transporter (SLC10A2) was restricted to terminal ileum (106). 
mRNA levels of fatty acid transport protein 4 (SLC27A4), liver-type fatty acid 
binding protein (FABP1) and intestine-type fatty acid binding protein (FABP2) were 
highest in the proximal jejunum and resembled the pattern observed in mice (107). 
Furthermore, the gene expression pattern of glucagon (GCG; in the intestine the 
precursor for GLP-1 and GLP-2) and PYY (PYY) in the small intestine closely resembled 
the peptide concentrations found in pig intestine (108). Taken together, these data 
show the validity of our gene expression measurements in the gastrointestinal tract 
of pigs. Moreover, we found that the distal part of the small intestine, the caecum, 
and the colon showed the highest expression of genes involved in SCFA uptake 
(SLC16A1, SLC5A8), SCFA sensing (FFAR2, FFAR3) and satiety (GCG, PYY). Therefore, 
these segments were sampled in the main experiment described in this chapter.
Anthropometric variables
Body weight and fat depth were measured in all pigs at the end of the experimental 
period. The lengths of the small intestine and colon were determined at section. 
No significant differences were found between the treatment groups with 
respect to body weight, fat depth, and the length of the small intestine and colon 
(Supplemental Table 3).
 
Degradation of RS
The amount of RS was measured in the intestinal content collected at section (5 h 
postprandially). In RS-fed pigs, 20-40 times more RS was found in the small intestine 
compared with that in DS-fed pigs (Fig. 1). Furthermore, in the caecum of RS-fed 
pigs, the concentration of RS was significantly lower compared with that in the 
small intestine, whereas in the colon, RS concentrations were significantly lower 
than in the caecum and were comparable to background concentrations, i.e., those 
measured in DS-fed pigs (Fig. 1). From these observations we conclude that RS was 
fully degraded in the caecum.
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Microbiota analysis
Multivariate analysis of the DGGE data revealed a significant effect of RS treatment 
on the composition of the microbiota in the caecum (P = 0.016) and colon (P = 
0.002), whereas no significant effect of treatment was found in the small intestine 
(P = 0.18) (Supplemental Fig. 2).
 Because treatment effects were observed in the caecum and colon, the 
luminal contents of the proximal part of caecum (P1 caecum) and colon (P1 colon) 
were selected for further analysis using the superior PITChip technique. RDA of the 
PITChip data showed a visual treatment effect on the microbiota in both caecum 
and colon. Caecal samples of RS-fed pigs were separated from those of DS-fed pigs 
except for pig 24 (Fig. 2A). The treatment-centered separation was more obvious 
for the colonic samples (Fig. 2B). Moreover, Monte Carlo Permutation testing 
showed that, of the environmental variables, only luminal propionate concentration 
Figure 1 RS concentrations in luminal content of pigs fed the DS or RS diet for 2 
wk. Values are means ± SEM, n = 1-4 pigs per treatment. Different letters indicate 
that segments differ significantly from each other, P <0.01 (a > b > c). From left to 
right, bars represent areas of the gastrointestinal tract from proximal to distal. The 
small intestine was divided into 10 equal parts; parts 7-10 refer to the 4 most distal 
segments of the small intestine, whereas the caecum and colon were divided into 2 
respectively 4 segments of equal length. White horizontal bars indicate the intestinal 
parts that were combined for statistical analysis to determine differences between 
anatomic locations. CA, caecum; CO, colon; DS, digestible starch; RS, resistant starch; 
SI, small intestine.
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significantly (P = 0.018) contributed to explaining the observed variation in 
microbiota composition in the colon. 
 To determine which microbial groups were changed by RS treatment, 
univariate analysis was employed (Tables 1 and 2). In the caecum, we found 
that microbial groups of Actinobacteria, Bacilli, Clostridium cluster IV and XIVa, 
Alphaproteobacteria, Betaproteobacteria and Spirochaetes changed in relative 
abundance, albeit at corrected P values of 0.81 (Table 1). More specifically, 
Streptococcus intermedius-like group, Streptococcus salivarius-like group, 
Streptococcus suis-like group and Neisseria-like group decreased by the RS treatment, 
whereas the uncultured Clostridia cluster IV and Rhodobacter-like microorganisms 
increased in relative abundance (Table 1). 
 In the colon, 30 microbial groups were significantly changed by the RS 
treatment (corrected P value <0.05), whereas a trend toward significance was 
observed for 13 additional microbial groups (corrected P value between 0.05 and 
0.07) (Table 2). Members of the Actinobacteria, Weissella-like group, Clostridium 
cluster IV, IX, XV,XVI and XVII, Mollicutes, Fusobacteria and Betaproteobacteria 
increased in relative abundance in pigs fed the RS diet. In contrast, groups within the 
classes of Bacilli (e.g. Allofustis, Lactobacillus acidophilus-like group and Lactobacillus 
plantarum-like group), Clostridium cluster XI and XIVa, Deltaproteobacteria and 
Gammaproteobacteria decreased upon RS consumption (Table 2).
 Despite the change in relative abundance of several microbial groups, 
treatment with RS for 14 d did not significantly alter the microbial diversity in 
caecum and colon as indicated by Shannon’s and Simpson’s indices for diversity 
(data not shown).
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Figure 2 Triplots of RDA results, representing the principal component analysis of 
the microbiota composition as measured by the mean hybridization signals for 144 
genus-level phylogenetic groups in the luminal content of caecum (A) and colon 
(B) of pigs fed the DS or RS diet for 2 wk. Samples are grouped by treatment class. 
Each symbol represents 1 pig, and numbers represent pig identifiers. The average of 
the nominal environmental variables DS and RS are represented by triangles. GCG 
(expression), SLC16A1 (expression), acetate, propionate and butyrate concentrations 
are also included as environmental variables. For clarity, the microbial groups that 
contributed to the first 2 principal components used as explanatory axes were 
omitted in these triplots. Combined, both axes explain 30.9% of the total variance in 
the data set for (A) and 41.6% for (B). DS, digestible starch; RS, resistant starch.
Figure 2 
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Table 1 Phylogenetic groups in the luminal content of the P1 caecum of pigs fed the DS or RS diet for 
2 wk that were significantly affected by diet according to univariate analysis of PITChip data1 
    ARC3 
Phylogenetic group  Corr. P value2 P value DS RS  Effect4
Actinobacteria   
   Actinobacteria   
      Bifidobacterium  0.81 0.071 0.390 ± 0.037  0.355 ± 0.031 ‐
      Olsenella et rel.  0.81 0.091 0.007 ± 0.002  0.010 ± 0.004 +
Firmicutes   
   Bacilli   
      Streptococcus intermedius et rel.  0.81 0.042 0.399 ± 0.190  0.251 ± 0.077 ‐
      Streptococcus salivarius et rel. 0.81 0.031 0.374 ± 0.178  0.244 ± 0.085 ‐
      Streptococcus suis et rel.  0.81 0.016 0.353 ± 0.111  0.245 ± 0.047 ‐
      Uncultured Bacilli  0.81 0.091 1.273 ± 0.056  1.331 ± 0.071 +
   Clostridium cluster IV   
      Uncultured Clostridia IV  0.81 0.042 1.961 ± 0.358  2.218 ± 0.283 +
   Clostridium cluster XIVa   
      Butyrivibrio crossotus et rel.  0.81 0.071 0.851 ± 0.108  0.763 ± 0.094 ‐
      Clostridium sphenoides et rel. 0.81 0.091 0.820 ± 0.094  0.971 ± 0.095 +
      Eubacterium rectale et rel.  0.81 0.091 0.746 ± 0.060  0.690 ± 0.060 ‐
      Ruminococcus ganvus et rel. 0.81 0.055 0.854 ± 0.086  0.937 ± 0.080 +
Proteobacteria   
   Alphaproteobacteria   
      Rhodobacter et rel.  0.81 0.042 1.263 ± 0.128  1.383 ± 0.118 +
   Betaproteobacteria   
      Bordetella et rel.  0.81 0.091 1.052 ± 0.093  0.974 ± 0.095 ‐
      Neisseria et rel.  0.81 0.042 0.904 ± 0.071  0.817 ± 0.081 ‐
Spirochaetes   
   Spirochaetes   
      Brachyspira  0.81 0.091 0.009 ± 0.003  0.011 ± 0.003 +
      Leptospira  0.81 0.071 0.642 ± 0.071  0.728 ± 0.082 +
1 DS, digestible starch; P1, part 1; PITChip, Pig Intestinal Tract Chip; RS, resistant starch. 
2 Corr. P  value  indicates  the P  value  corrected  for multiple  testing  according  to  the procedure of  
Benjamini‐Hochberg. 
3 ARC  is the Average Relative Contribution of a microbial group. Values are means ± SEM, n = 9 for 
DS‐fed pigs and n = 7 for RS‐fed pigs. 
4 ”+” or “‐”  indicates whether the average relative contribution of the microbial group  increased or 
decreased by the RS treatment. 
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Table 2 Phylogenetic groups in the luminal content of the P1 colon of pigs fed the DS or RS diet for 2 
wk that were significantly affected by diet according to univariate analysis of PITChip data1 
    ARC3 
Phylogenetic group  Corr. P value2 P value DS RS  Effect4
Actinobacteria   
   Actinobacteria    
      Eggerthella et rel.  0.045 0.009 0.731 ± 0.033 0.823 ± 0.081 +
      Microbacterium  0.040 0.006 0.785 ± 0.057 0.911 ± 0.076 +
      Micrococcus et rel.  0.045 0.009 0.806 ± 0.048 0.897 ± 0.069 +
      Propionibacterium  0.069 0.021 1.258 ± 0.081 1.403 ± 0.093 +
      Tonsillophilus  0.058 0.014 0.694 ± 0.035 0.791 ± 0.082 +
Firmicutes   
   Bacilli   
      Allofustis  0.058 0.014 0.694 ± 0.043 0.622 ± 0.052 ‐
      Lactobacillus acidophilus et rel. 0.069 0.021 0.956 ± 0.151 0.736 ± 0.173 ‐
      Lactobacillus plantarum et rel. 0.040 0.006 2.083 ± 0.178 1.835 ± 0.124 ‐
      Weissella et rel.  0.045 0.009 0.660 ± 0.032 0.735 ± 0.052 +
   Clostridium cluster IV   
      Faecalibacterium et rel.  0.020 0.001 1.402 ± 0.188 1.748 ± 0.137 +
      Faecalibacterium prausnitzii et rel.  0.020 0.001 1.648 ± 0.232 2.062 ± 0.134 +
      Ruminococcus bromii et rel.  0.069 0.021 0.294 ± 0.049 0.367 ± 0.049 +
      Sporobacter termitidis et rel.  0.015 0.001 3.300 ± 0.364 4.358 ± 0.283 +
      Uncultured Clostridia IV  0.021 0.002 1.799 ± 0.107 2.232 ± 0.294 +
   Clostridium cluster IX   
      Phascolarctobacterium faecium et rel.  0.015 <0.001 0.896 ± 0.098 1.134 ± 0.068 +
      Veilonella  0.015 0.001 0.602 ± 0.088 0.793 ± 0.066 +
   Clostridium cluster XI   
      Anaerovorax et rel.  0.045 0.009 1.078 ± 0.150 0.851 ± 0.111 ‐
   Clostridium cluster XIVa   
      Bryantella et rel.  0.045 0.009 2.022 ± 0.110 1.810 ± 0.172 ‐
      Dorea et rel.  0.069 0.021 0.913 ± 0.106 0.760 ± 0.105 ‐
      Eubacterium plexicaudatum et rel.  0.045 0.009 0.371 ± 0.033 0.324 ± 0.024 ‐
      Eubacterium ventriosum et rel. 0.058 0.014 0.363 ± 0.032 0.321 ± 0.022 ‐
      Roseburia intestinalis et rel.  0.040 0.006 1.047 ± 0.112 0.898 ± 0.065 ‐
      Ruminococcus ganvus et rel.  0.045 0.009 0.934 ± 0.110 0.769 ± 0.079 ‐
      Uncultured Clostridia XIVa  0.040 0.006 2.002 ± 0.127 1.744 ± 0.141 ‐
   Clostridium cluster XV   
      Eubacterium et rel.  0.015 0.001 0.604 ± 0.088 0.793 ± 0.066 +
   Clostridium cluster XVI   
      Eubacterium biforme et rel.  0.021 0.002 0.732 ± 0.048 0.833 ± 0.053 +
   Clostridium cluster XVII   
      Catenibacterium  0.021 0.002 0.274 ± 0.021 0.333 ± 0.024 +
   Mollicutes   
      Acholeplasma et rel.  0.045 0.009 0.690 ± 0.039 0.778 ± 0.072 +
      Bulleidia moorei et rel.  0.021 0.002 0.336 ± 0.035 0.407 ± 0.032 +
      Erysipelothrix  0.015 0.001 0.715 ± 0.119 0.995 ± 0.081 +
      Solobacterium moorei et rel.  0.040 0.006 0.525 ± 0.091 0.714 ± 0.149 +
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Fusobacteria 
   Fusobacteria     
      Fusobacterium  0.045 0.009 0.077 ± 0.003 0.090 ± 0.013 +
Proteobacteria   
   Betaproteobacteria   
      Bordetella et rel.  0.069 0.021 0.932 ± 0.105 1.076 ± 0.081 +
      Neisseria et rel.  0.069 0.021 0.795 ± 0.094 0.916 ± 0.083 +
      Oxalobacter et rel.  0.069 0.021 0.723 ± 0.091 0.832 ± 0.058 +
      Sutterella wadsorthia et rel.  0.058 0.014 0.822 ± 0.098 0.943 ± 0.070 +
   Deltaproteobacteria   
      Uncultured Deltaproteobacteria  0.021 0.002 0.094 ± 0.019 0.067 ± 0.009 ‐
   Gammaproteobacteria   
      Escherichia coli et rel.  0.040 0.006 1.423 ± 0.108 1.161 ± 0.161 ‐
      Pseudomonas et rel.  0.020 0.001 1.306 ± 0.154 0.975 ± 0.161 ‐
      Psychrobacter et rel.  0.021 0.002 1.022 ± 0.062 0.870 ± 0.099 ‐
      Uncultured Gammaproteobacteria  0.015 <0.001 1.314 ± 0.136 1.027 ± 0.134 ‐
      Vibrio et rel.  0.058 0.014 0.673 ± 0.077 0.537 ± 0.098 ‐
Spirochaetes   
   Spirochaetes   
      Uncultured Spirochaetes  0.069 0.021 0.518 ± 0.043 0.456 ± 0.048 ‐
1 DS, digestible starch; P1, part 1; PITChip, Pig Intestinal Tract Chip; RS, resistant starch. 
2 Corr. P  value  indicates  the P  value  corrected  for multiple  testing  according  to  the procedure of  
Benjamini‐Hochberg. 
3 ARC  is the Average Relative Contribution of a microbial group. Values are means ± SEM, n = 7 for 
DS‐fed pigs and n = 8 for RS‐fed pigs. 
4 ”+” or “‐”  indicates whether the average relative contribution of the microbial group  increased or 
decreased by the RS treatment. 
SCFA concentrations 
SCFA concentrations were measured in the intestinal contents collected at section (5 
h postprandially). Total SCFA concentration was highest in the caecum and gradually 
decreased along the colon (Fig. 3A). In the caecum and colon, SCFA concentrations 
were significantly higher in RS-fed pigs compared with DS-fed pigs (Fig. 3A). The 
most abundant SCFAs in the intestine were acetate, propionate and butyrate. The 
increase in total SCFA concentration on RS could mainly be attributed to higher 
concentrations of acetate and propionate (Fig. 3B, C). Butyrate concentration was 
significantly higher only in RS-treated pigs in the colon part 2 (P2 colon) (Fig. 3D). 
Although concentrations of valerate were low, the values for caecum and colon 
were significantly higher in RS-fed pigs (Fig. 3E). However, in the caecum we found 
significantly higher concentrations of isobutyrate and isovalerate in DS-fed pigs (Fig. 
3F, G).
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Differential gene expression mucosal scrapings
The expression of several genes was determined in the mucosal scrapings collected 
at section (5 h postprandially). We observed a significant increase in GCG gene 
expression in RS-fed pigs in the caecum (Fig. 4A), whereas PYY gene expression was 
not modulated (Fig. 4B). In the most distal part of the small intestine, an increase 
in angiopoietin-like 4 (ANGPTL4) expression was found with RS (Fig. 4C). In the 
caecum and P2 colon, expression of SLC16A1 was higher in RS-fed pigs compared 
with DS-fed pigs (Fig. 4G). However, the expression of the SCFA receptors FFAR2, 
FFAR3, G protein-coupled receptor 119 (GPR119) and the SCFA transporter SLC5A8 
was not different between the pigs fed RS or DS (Fig. 4D, E, F and H, respectively).
Figure 3 Total SCFAs (A), acetate (B), propionate (C), butyrate (D), valerate (E), 
isobutyrate (F) and isovalerate (G) concentrations in luminal contents of pigs fed the 
DS or RS diet for 2 wk. Values are means ± SEM, n = 6-10 pigs per treatment. *, ** DS 
and RS differ within the intestinal segment, P <0.05 and P <0.01, respectively. # , ## 
DS and RS differ within the total caecum or colon, P <0.05 and P <0.01, respectively. 
From left to right, bars represent areas of the gastrointestinal tract from proximal 
to distal. The small intestine was divided into 10 equal parts; parts 7-10 refer to 
the 4 most distal segments of the small intestine, whereas the caecum and colon 
were divided into 2 respectively 4 segments of equal length. White horizontal bars 
indicate the intestinal parts that were combined for statistical analysis to determine 
differences between treatments. CA, caecum; CO, colon; DS, digestible starch; RS, 
resistant starch; SI, small intestine. 
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Plasma analyses
Blood samples were taken from all pigs, both before and after the intervention. 
Glucose, insulin, cholesterol and GLP-1 concentrations were not affected by dietary 
treatment (Supplemental Fig. 3A, B, D and E, respectively). However, at the end of 
the intervention period, plasma TG concentrations were significantly higher in RS-
fed pigs compared with pigs fed DS (Supplemental Fig. 3C). In addition, in DS-fed 
pigs, plasma PYY was significantly lower at the end of the experimental period than 
at the start (Supplemental Fig. 3F).
Figure 4 Relative gene expression of GCG (A), PYY (B), ANGPTL4 (C), FFAR2 (D), FFAR3 
(E), GPR119 (F), SLC16A1 (G) and SLC5A8 (H) in mucosal scrapings along the proximal-
distal axis of the intestine of pigs fed the DS or RS diet for 2 wk, as determined by 
qRT-PCR. Messenger RNA levels were standardized to RPLP0. Values are presented 
as means ± SEM, n = 6-9 pigs per treatment. *, ** DS and RS differ within the intestinal 
segment, P <0.05 and P <0.01, respectively; ## DS and RS differ within the total 
caecum, P <0.01. From left to right, bars represent areas of the gastrointestinal 
tract from proximal to distal. The small intestine was divided into 10 equal parts; 
parts 7-10 refer to the 4 most distal segments of the small intestine, whereas the 
caecum and colon were divided into 2 respectively 4 segments of equal length. White 
horizontal bars indicate the intestinal parts that were combined for statistical analysis 
to determine differences between treatments. CA, caecum; CO, colon; DS, digestible 
starch; RS, resistant starch; SI, small intestine. 
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Discussion
In the set of experiments reported in this chapter we investigated the effects of 
a diet high in RS in pigs. We found that RS was completely degraded in caecum, 
changed caecal and colonic microbiota composition, increased caecal and colonic 
SCFA concentrations, and increased the expression of SLC16A1 and GCG in caecum. 
RS had no effect on plasma concentrations of GLP-1 and PYY measured 5 h 
postprandially.
 Our data on RS contents in intestinal segments show that RS was completely 
degraded in caecum, which is in line with observations on the degradation of inulin in 
the gastrointestinal tract of pigs (109). As a result, the composition of the microbiota 
differentially changed in porcine caecum and colon, as also has been reported for 
inulin (110). However, the RS-induced changes in the gut microbiota depend on the 
initial composition of an individual’s gut microbiota (50), which could explain why RS-
fed pigs 24 (caecum) and 1 (colon) were not clearly separated from the DS-fed pigs 
on the RDA triplots. Moreover, specific bacterial groups can be selectively affected 
by a certain type of RS (111, 112) and even by different crystalline polymorphism of 
the same type of RS (113) in different locations of the intestine. Young et al. (114) 
fed type 2 RS (RS2) to rats and found blooms of Bacteroidetes and Actinobacteria in 
colonic digesta. However, Martínez et al. (111) reported that type 4 RS but not RS2 
significantly induced Bacteroidetes and Actinobacteria while decreasing Firmicutes 
at the phylum level. At the species level, type 4 RS increased Bifidobacterium 
adolescentis and Parabacteroides distasonis, whereas RS2 significantly raised the 
proportions of Ruminococcus bromii and Eubacterium rectale. In a study on RS3, 
the relatives of R. bromii (R-ruminococci) and E. rectale were found to be increased 
in the colon of most volunteers (50). Moreover, when the effects of structural 
variation of RS3 on fermentability by human gut microbiota were studied, it was 
found that retrograded RS3 that formed a B-type pattern induced Bifidobacterium 
spp., whereas A-type pattern RS3 induced Atopobium spp. (113). 
 In our study, the pigs were fed RS3, and we observed a clear change in 
caecal and colonic microbiota composition compared with pigs fed DS. The relative 
abundance of R. bromii was increased in the colonic samples of RS-fed pigs, which 
is consistent with previous research (50). However, E. rectale was not significantly 
changed in our study and its relative contribution in the RS group even decreased 
slightly. Interestingly, in addition to E. rectale, other bacterial groups that belong 
to Clostridium cluster XIVa showed either a significant decrease or a trend toward 
a decrease in RS-fed pigs, whereas bacterial groups belonging to Clostridium 
cluster IV , IX, XV, XVI and XVII increased in RS-fed pigs. This may be due to a low 
competitiveness of Clostridium cluster XIVa, because previous research indicated 
43
2
Resistant starch and microbiota, SCFAs and gene expression in pig intestine 
the Roseburia/E. rectale group was particularly dependent on residual dietary 
carbohydrate and pH to maintain its competitiveness in the colon (115). It may also 
be related to the fact that we could not detect a significant effect of the RS diet on 
butyrate concentration in P1 colon, because several members of this group have been 
shown to produce butyrate (116). In turn, we found increased relative abundance 
of populations related to the butyrate-producing Faecalibacterium prausnitzii, 
previously suggested as a health-promoting bacterium (117). Furthermore, we 
found an increase in several propionate-producing microorganisms, including 
members of the genera Propionibacterium, Veilonella and Phascolarctobacterium. 
Propionate has previously been indicated as another health-promoting metabolite 
being produced in the large intestine (88). In contrast, several groups of potentially 
pathogenic taxa within the Gammproteobacteria, including Escherichia coli and 
Pseudomonas spp., were found to be decreased in relative abundance in the colon.
 Currently, most studies focus on the colonic and faecal microbiota (50, 111, 
114), whereas research on the effect of RS on caecal microbiota is limited. This 
study is the first to our knowledge to use comprehensive microarray-based profiling 
to detect the RS effect on caecal microbiota in an animal model. We observed major 
differences between caecum and colon with respect to microbial changes, possibly 
due to the change in the chemical structure of RS in colon compared with caecum, 
which determined the RS accessibility by groups of bacteria (111). 
 We found that a diet high in RS increased SCFA concentrations in the 
luminal content compared with a DS diet, as was also observed previously in pigs 
(85). However, because >95% of the SCFAs are rapidly absorbed from the colonic 
lumen and metabolized by the host, the total production of SCFAs is difficult to 
determine (60, 118). Butyrate is almost entirely used by colonocytes as their 
preferred energy substrate, whereas acetate and propionate move to the liver via 
the portal vein. Propionate is metabolized by the liver and used for gluconeogenesis, 
whereas acetate is a substrate for cholesterol synthesis and lipogenesis. In addition, 
acetate is taken up by muscle and adipose tissue (60, 62). It has been observed 
that RS especially results in an increased production of butyrate (53). However, 
our experimental setup did not allow us to quantify total butyrate production, for 
which preferably isotope dilution studies or direct measurements of arteriovenous 
differences in SCFA concentrations across the gut are required (60, 118). Moreover, 
it has been suggested that butyrate is taken up by the colonocytes more rapidly 
than acetate and propionate (60). This might explain why we did not observe a very 
profound increase in butyrate concentrations in pigs fed RS.
 We found that SLC16A1 was induced in pigs consuming the RS diet. This 
observation can be explained by the increased intestinal SCFA concentrations (119, 
120). Induction of SLC16A1 gene expression was also observed by Zhou et al (89), 
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who measured gene expression in epithelial cells of the gastrointestinal tract from 
rats fed a DS or an RS diet for 4 wk. They found that SLC16A1, PYY and GCG gene 
expression was induced in the caecum and colon. The fact that our study did not 
show an increase in GCG or PYY gene expression with RS consumption could be 
due to the different animal model used and the different duration of the dietary 
treatment.
 The presence of SCFA-activated FFA receptors in the intestinal mucosa 
could provide a link between intestinal SCFAs and appetite and energy homeostasis. 
FFAR2 immunoreactivity was found to be almost completely colocalized with GLP-
1 in terminal ileum, caecum and colon of rats (121). Furthermore, it was shown 
in proximal colon that the densities of FFAR2-immunoreactive enteroendocrine 
cells and GLP-1-producing cells were increased >2-fold by fermentable fibre 
supplementation compared with control (121). In addition, the activation of FFAR2 
by SCFAs is suggested to facilitate or modify PYY secretion (57). In this study, no 
significant differences in FFAR2 and FFAR3 gene expression were observed between 
the 2 diet groups. However, this observation does not exclude the possibility that 
the receptors were activated in RS-fed pigs, because gene expression levels do not 
necessarily reflect protein levels. Our experiment showed that GPR119, like GCG, 
is most abundantly expressed in the distal small intestine. GPR119 is expressed in 
intestinal endocrine L-cells and has been shown to stimulate the release of GLP-
1 (122, 123). However, in our study the expression of GPR119 and GCG was not 
modified upon RS feeding.
 TG concentrations in plasma were found to be higher in RS-fed pigs compared 
with control pigs. Two mechanisms might be responsible for this increase. At first, 
acetate resulting from fermentation of RS in the intestine is taken up by the liver, 
where it can serve as a substrate for TG synthesis (60). A second explanation is 
that RS increases plasma ANGPTL4 concentrations, because we observed increased 
ANGPTL4 gene expression in the distal part of the small intestine of RS-fed pigs. 
Because ANGPTL4 is an inhibitor of lipoprotein lipase, increased concentrations of 
ANGPTL4 result in increased plasma TG concentrations (124). 
 In conclusion, we showed that a diet high in RS modulates microbiota 
composition, SCFA concentrations and gene expression in pig intestine. These 
findings provide a detailed insight on the interaction between diet, microbiota, 
and host and may provide leads for designing functional food strategies that aim 
to reduce the risk of obesity and type 2 diabetes in humans. However, additional 
investigation is required to further elucidate the underlying molecular mechanisms 
and the link to satiety. 
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Supplemental Tables and Figures
Supplemental Table 1. Composition of the DS and RS diet, expressed as g/kg diet1 
Ingredient  DS RS 
Native potato starch (Paselli WA4)  350.0 ‐ 
Retrograded tapioca starch (Actistar, Cargill)  ‐ 338.8 
Wheat  249.0 249.0 
Barley  150.0 150.0 
Corn gluten meal  100.0 100.0 
Potato protein (Protastar)  50.0 50.0 
Soy bean oil  15.0 15.0 
Animal fat  15.0 15.0 
Vitamin mineral premix2  10.0 10.0 
CaCO3  17.0 17.0 
Monocalcium phosphate  11.0 11.0 
KCI  10.0 10.0 
NaHCO3  15.0 15.0 
NaCI  5.0 5.0 
L‐lysine HCI  1.5 1.5 
Flavouring (Luctarom Advance Cherry Honey)  1.5 1.5 
Total  1000.0 988.8 
1 DS, digestible starch; RS, resistant starch. 
2  Provided  the  following  per  kg  food  (of  the  DS  diet):  retinol:  3.0 mg;  cholecalciferol:  50  µg;  α‐
tocopherol:  25  mg;  menadione:  1.0  mg;  thiamine:  0.75  mg;  riboflavin:  4.0  mg;  niacin:  20  mg; 
pyridoxine: 1.0 mg; cyanocobalamin: 15µg; panthothenic acid: 13 mg; choline chloride: 300 mg; folic 
acid: 2.5 mg; biotin: 0.1 mg; Fe: 80 mg (FeSO4.H2O); Cu: 10 mg (CuSO4.5H2O); Mn: 30 mg (MnO); Zn: 
60 mg (ZnSO4.H2O); Co: 0.20 mg (CoSO4.7H2O); I: 0.75 mg (KI); Se: 0.20 mg (Na2SeO3). 
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Supplemental Table 2. Primer sequences used for qRT‐PCR 
Gene symbol  Primer sequence (Forward)  Primer sequence (Reverse) 
ALPI  CTACACATTGCGTGGAAG  ATGGAGGTATATGGCTTGA 
ANGPTL4  AGATTCAGCAACTCTTCC  AATTCTGGATTCTCAAGTG 
CHGA  AAGAAACAGAGCAGTTATGA  CCTCCTTCAACTCAGTCT 
FFAR1  CTTGTCCTCTGTCACCTG  AGGGAGCTGGTAGTATTG 
FFAR2  CGTGTTCATCGTTCAGTA  GAAGTTCTCATAGCAGGTA 
FFAR3  TGGAGACCTTACGTGTTG  CGAGGATGAGAAGTAGTAGAT 
GCG (glucagon)  CAAGAGGAACAAGAATAACAT  AAGAACTTACATCACTGGTA 
GPR119  TATAGGCAGAAGGAGGTA  AGAGAAGGAGGAGGAATG 
GPR120  TGGGATGTGTCGTTTGTT  CCTTGATGCCTTGGTGAT 
FABP1(L‐FABP)   TGAACTCAACGGTGACATA  ATTCTCTTGCTGATTCTCTTG 
FABP2 (I‐FABP)   AGATAGACCGCAATGAGA  TCCTTCTTGTGTAATTATCAGT 
PYY  AGATATGCTAATACACCGAT  CCAAACCCTTCTCAGATG 
RPLP0  CTTTAGGCATCACCACTA  TGTCTCCAGTCTTAATCAG 
SLC5A8 (SMCT1)  CGCAGATTCCTACTAACC  GATTGTCAGTTCCACCAT 
SLC10A2 (ASBT)   TGCCTCTTAATCTATACCA  GGACACAGGAACAATAAG 
SLC16A1 (MCT1)  CATCAACTACCGACTTCTG  TACTGGTCTCCTCCTCTT 
SLC27A4 (FATP4)  GGTTCTGGGATGATTGTG  TGGTTGAGGAGGTATCTG 
VIL1  TATTATTGGTGTTCGTGCTA  TCTGGAGGAATAGGATACTAA 
Supplemental  Table  3. General  characteristics  of  pigs  fed  the DS  or RS  diet  for  2 wk. Values  are 
presented as means ± SEM, n = 10 pigs per treatment1 
  Diet   
Measurement  DS  RS  P value 
Body weight (kg)  274 ± 6.3  271 ± 5.0  0.68 
Fat depth (mm)  29.0 ± 1.4  29.0 ± 1.1  0.98 
Length small intestine (m)  16.4 ± 1.6  16.9 ± 0.8  0.77 
Length colon (m)  5.8 ± 0.2  5.8 ± 0.2  1.00 
1 DS, digestible starch; RS, resistant starch.
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Supplemental Figure 1.
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Supplemental Figure 1 (continued).
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Supplemental Figure 1 
Relative gene expression of Apical sodium-dependent bile salt transporter, SLC10A2 (A), 
Fatty acid transport protein 4, SLC27A4 (B), Liver-type fatty acid binding protein, FABP1 
(C), Intestine-type fatty acid binding protein, FABP2 (D), Villin 1, VIL1 (E), Intestinal alkaline 
phosphatase, ALPI (F), Chromagranin A, CHGA (G), Free fatty acid receptor 1, FFAR1 
(H), G protein-coupled receptor 120, GPR120 (I), Glucagon, GCG (J), Peptide YY, PYY (K), 
Angiopoietin-like 4, ANGPTL4 (L), Free fatty acid receptor 2, FFAR2 (M), Free fatty acid 
receptor 3, FFAR3 (N), G protein-coupled receptor 119, GPR119 (O), Monocarboxylate 
transporter 1, SLC16A1 (P) and Sodium-coupled monocarboxylate transporter 1, SLC5A8 (Q) 
in mucosal scrapings along the proximal-distal axis of the intestine of adult female pigs, 
as determined by qRT-PCR. Messenger RNA levels were standardized to RPLP0. Values 
are presented as means ± SEM, n = 3 pigs. From left to right, bars represent areas of the 
gastrointestinal tract from proximal to distal. The small intestine was divided into 10 equal 
parts, whereas the caecum and colon were divided into 2 respectively 4 segments of equal 
length. CA, caecum; C, colon; SI, small intestine.
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Supplemental Figure 2.
RDA analysis of DGGE profiling data of samples from small intestine (A), caecum (B) and 
colon (C). Nominal environmental variables DS and RS are represented by triangles. Samples 
are grouped by treatment: RS (□) and DS (●). Each symbol represents 1 pig. Combined both 
axes explain 22.2% of the total variance in the dataset for (A), 23.5% for (B) and 21.9% for 
(C). DS, digestible starch; RS, resistant starch.
A B C
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Supplemental Figure 3.
Glucose (A), insulin (B), TG (C), cholesterol (D), GLP-1 (E) and PYY (F) concentrations in 
plasma of pigs fed the DS or RS diet before the start of the treatment (T0) and on d12 of 
the treatment (T1). n = 10 pigs per treatment; *, ** DS and RS differ, P <0.05 and P <0.01, 
respectively. DS, digestible starch; RS, resistant starch.
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Dietary resistant starch improves mucosal gene expression 
profile and luminal microbiota composition in porcine colon
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Bosch, Jacques Vervoort, Walter J.J. Gerrits, Bas Kemp, Hauke Smidt, Michael 
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Submitted for publication in revised form
54
Chapter 3
Abstract
Dietary resistant starch (RS) favours both colonic and whole-body metabolism and 
health, which has been attributed to its fermentation by microbiota in the colon that 
results in the production of short-chain fatty acids (SCFAs). Although the putative 
beneficial effects of RS have been extensively studied, knowledge on its effects on 
global gene expression in colon is rather limited. The main objective of the current 
study was to identify genes regulated by RS in the proximal colon to infer which 
metabolic and other pathways were modulated, and to link gene expression changes 
to alterations in microbiota composition and SCFA concentrations. Ten 17-wk-old 
male pigs, fitted with a cannula in the proximal colon for repeated collection of 
tissue biopsies and luminal content, were fed a digestible starch (DS) diet, or a diet 
high in RS (34%) for 2 consecutive periods of 14 d in a crossover design. Plasma 
SCFA concentrations were significantly higher with RS consumption compared 
to DS consumption. RS significantly (P <0.05) increased the relative abundance 
of several butyrate-producing microbial groups, including Faecalibacterium 
prausnitzii and Megasphaera elsdenii, and reduced the abundance of potentially 
pathogenic members of the genus Leptospira and the phylum of Proteobacteria. 
Colonic transcriptome profiling revealed that upon RS feeding oxidative metabolic 
pathways, such as beta-oxidation and TCA cycle, were induced, whereas many 
immune response pathways, including adaptive and innate immune system, were 
suppressed. The nuclear receptor PPARG was identified as a potential key upstream 
regulator. Overall, this study provides novel molecular insights on effects of RS in 
colon, and supports the believe that RS has beneficial impact on colonic health.
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Introduction
Dietary resistant starch (RS) is a complex polysaccharide that resists digestion and 
absorption in the small intestine (SI). The effects and potential health benefits of RS 
have been extensively studied (15, 53, 125). In the first place, effects are found in 
the large intestine, i.e. caecum (CA) and colon (C), where RS is highly fermentable 
by microbiota, resulting in the production of short-chain fatty acids (SCFAs). Several 
animal studies have indeed shown that RS increases the caecal and faecal production 
of total SCFAs and the main individual SCFAs acetate, propionate and butyrate (53, 
85, 126). Furthermore, changes in caecal and faecal microbiota composition have 
been demonstrated with RS (111, 112, 126), and it has been reported that RS may 
play a role in the prevention of colorectal cancer (127) and inflammatory bowel 
disease (128).
 Besides its local effects on intestinal function, RS may affect whole-body 
metabolism and health. An increasing amount of literature provides evidence that 
RS improves insulin sensitivity (9, 129) and blood lipid profile (130, 131), reduces 
body fat (82, 83) and food intake (132) and enhances satiety (33, 133).
 A large proportion of these beneficial effects is thought to be mediated 
through the actions of SCFAs (15). In addition to serve as metabolic substrate, both 
locally in the colon and in other tissues (60, 62), it is known that SCFAs can influence 
whole-body metabolism by acting as signalling molecules, e.g. via G protein-coupled 
receptors FFAR2 and FFAR3 that are expressed broadly throughout the body (134, 
135). 
 Genome-wide transcriptional profiling, or transcriptomics, is extensively 
used to study how cells respond to certain stimuli or to diagnose and predict clinical 
outcomes (136, 137). Similarly, there is a major interest in characterizing the genes 
and networks that are regulated by food components, since this contributes to 
our understanding of a healthy diet (72, 73). Remarkably, data on the genome-
wide effects of RS in the intestinal tract is scarce. It has only been reported that 
differential gene expression due to consumption of type 2 RS for 4 wk suggested 
improvement of structure and function of the GI tract in rats compared to a corn 
starch diet with the same energy density (138). In addition, the effect of colonic 
butyrate administration on gene expression profile in distal colonic mucosa has 
been investigated, showing that butyrate regulates fatty acid metabolism, electron 
transport and oxidative stress pathways in healthy humans (139). 
 The aim of this study was to identify genes and corresponding metabolic 
and other processes that are modified by RS in the mucosa of the proximal colon 
(pCO), and to link gene expression changes to alterations in microbiota composition 
and SCFA concentrations. To this end, a crossover study was performed in pigs that 
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were fitted with a permanent cannula in the pCO for repeated collection of luminal 
content and tissue biopsies. The full colonic gene expression profile and luminal 
microbiota composition were obtained by microarray techniques. Pigs were used 
as a model for humans, because the anatomy and physiology of the gastrointestinal 
tract of pigs and the pig genome bear a lot of similarities with those in humans (66, 
93).
Materials and Methods
Experimental design, pigs and housing
Ten Landrace barrows (17 wk of age; initial body weight of 57.9 ±1.61 kg) from 
eight litters were fitted with cannulas and catheters and assigned to two dietary 
treatments in a 2 x 2 cross-over design. Each treatment lasted for 14d, and differed 
with regard to the type of starch in the diet: pregelatinized digestible starch (DS) or 
retrograded resistant starch (RS). Pigs were individually housed in metabolism pens 
of 2 m2, equipped with a feeder. Artificial lights were on from 05:00 h until 19:00 
h and dimmed during the dark period. All experimental protocols describing the 
management, surgical procedures, and animal care were reviewed and approved by 
the Animal Care and Use Committee of Wageningen University and Research Centre 
(Lelystad, the Netherlands).
Diets and feeding
The 2 experimental diets used were identical except for type of starch. The main 
source of starch in the DS diet was pregelatinized potato starch (Paselli WA4, AVEBE), 
which was replaced on dry matter basis in the RS diet by retrograded tapioca starch 
(Actistar, Cargill). According to the supplier, this starch was at least 50% resistant 
to digestion in the SI. Based on physical and chemical characteristics the RS used 
in this study can be classified as RS type 3 (15). Composition of the experimental 
diets is presented in Supplemental Table 1. Diets were fed twice a day at 07:00 
h and 16:00 h as a mash, and mixed with water (ratio water:feed = 2.5:1) in the 
feeders immediately before feeding. The diets were isoenergetic on gross energy 
(GE) basis. The daily feed allowance was adjusted to 2.8 times the energy required 
for maintenance (MEm = 450 kJ/kg0.75 per day) and was based on metabolic body 
weight (kg0.75). Pigs were weighed every week to allow the adjustment of their 
feeding level in accordance to metabolic body weight. All pigs had free access to 
water throughout the study. During the 1-week adaptation period, before surgery, 
pigs were fed a 50:50 mix of the DS and RS diet, and adapted to the feeding pattern 
and individual housing. 
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Surgery
In the second week after arrival, pigs underwent surgery for the placement of a 
cannula in the pCO and a catheter in the carotid artery. See Supplemental Methods 
for details. The pCO was chosen as site of investigation because of the greater 
fermentation and higher SCFA concentrations compared to more distal colonic 
regions (126).
Colon biopsies
Biopsies from the intestinal wall of the pCO were collected 300 min after the 
morning meal on d14 of each dietary treatment. See Supplemental Methods for 
details. 
Digesta collection
Digesta were collected via the gut cannula on d14 of each dietary treatment, both 
30 min before and 300 min after feeding.
 After sampling of digesta and biopsies on d14 of the last treatment period, 
pigs were anesthetized and exsanguinated, after which the abdominal cavity was 
opened. The gastrointestinal tract from stomach to anus was removed from the 
cavity and the length of the SI, CA and CO was determined. The SI was divided into 
10 parts of equal length and the CO into 3 parts. Digesta were collected from 5 areas 
of the gastrointestinal tract: ileum (IL; SI part 7), CA, pCO, middle colon (mCO) and 
distal colon (dCO).
 Collection and storage of the digesta samples, either taken from the cannula 
or at section, for determination of microbiota composition, SCFA concentration, 
and dry matter content was performed as described in the Supplemental Methods. 
SCFA concentrations and dry matter content were determined in the luminal 
content as described before (126).
Blood collection
Blood was drawn from the carotid artery on d14 of each dietary treatment, 300 
min after feeding. Blood was collected in 6 mL Vacutainer EDTA tubes (Becton 
Dickinson) supplemented with protease (Complete, EDTA-free; Roche) and 
dipeptidyl peptidase-4 (Millipore) inhibitors and then placed in ice water. Tubes 
were centrifuged for 10 min at 1300 g at 4°C within 20 min after blood collection. 
Plasma was aliquoted and stored at -80°C.
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RNA isolation and quality control
Total RNA was isolated from CO biopsies using TRIzol reagent (Life Technologies) 
according to the manufacturer’s instructions, followed by RNA Cleanup using the 
RNeasy Micro kit (Qiagen). Concentrations, purity and quality of the RNA samples 
was determined as described in the Supplemental Methods. 
Microarray hybridization and analysis
The pCO biopsies of all 10 pigs, collected on d14 of both dietary treatments, were 
subjected to genome-wide expression profiling. To this end, total RNA (100 ng) 
was used for whole transcript cDNA synthesis using the Ambion WT expression kit 
(Life Technologies) and subsequently labelled using the Affymetrix GeneChip WT 
Terminal Labelling Kit (Affymetrix). Samples were hybridized on Porcine Gene 1.0 ST 
arrays (Affymetrix), washed, stained, and scanned on an Affymetrix GeneChip 3000 
7G scanner. Detailed protocols for array handling can be found in the GeneChip 
WT Terminal Labelling and Hybridization User Manual (Affymetrix; P/N 702808, 
Rev. 4) and are also available on request. Packages from the Bioconductor project 
(140), integrated in an online pipeline (141), were used to analyse the array data. 
Various advanced quality metrics, diagnostic plots, pseudoimages, and classification 
methods were used to determine the quality of the arrays prior statistical analysis 
(142). Array data have been submitted to the Gene Expression Omnibus under 
accession number GSE45554.
 The approximately 600,000 probes on the Porcine Gene 1.0 ST array were 
redefined utilizing current genome information (143). In this study probes were 
reorganized based on the gene definitions as available in the NCBI Sus scrofa 
Entrez Gene database, build 4.1 (Sscrofa10.2 genome assembly)1 as well as the 
gene predictions made by the AUGUSTUST software2. Since the annotation of the 
pig genome is still poor, the functional annotation was improved by mapping the 
AUGUSTUST gene predictions to the human RefSeq database3. Out of 17,118 pig 
gene predictions, 14,505 were found to have a human orthologous gene. Unless 
otherwise stated, the functional interpretation of the transcriptome data was 
performed using the human orthologs. 
 Normalised gene expression estimates were obtained from the raw intensity 
values using the robust multiarray analysis (RMA) pre-processing algorithm available 
in the library ‘AffyPLM’ using default settings (144). Differentially expressed probe 
sets (genes) were identified using linear models, applying moderated t-statistics that 
1 ftp://ftp.ncbi.nih.gov/genomes/MapView/Sus_scrofa/sequence/BUILD.4.1/
2 http://gbi.agrsci.dk/pig/sscrofa10_2_annotation/
3 ssc10.2.RNA.hints.augustus.gff.gffreads.fna.vs.hsa_refseqHsa_2011_10_03.txt.gz
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implemented empirical Bayes regularization of standard errors (library ‘limma’). To 
adjust for both the degree of independence of variances relative to the degree of 
identity and the relationship between variance and signal intensity, the moderated 
t-statistic was extended by a Bayesian hierarchical model to define a intensity-based 
moderated T-statistic (IBMT) (145). Probe sets that satisfied the criterion of P <0.01 
were considered to be significantly regulated.
 Changes in gene expression were related to functional changes using gene 
set enrichment analysis (GSEA) (146). The Enrichment Map plugin for Cytoscape 
was used for visualization and interpretation of the GSEA results (147, 148). See 
Supplemental Methods for details.
 Upstream Regulator Analysis in IPA (Ingenuity Systems) was used to identify 
the cascade of upstream transcriptional regulators that may explain the observed 
gene expression changes in the dataset, and whether they are likely activated or 
inhibited.
 To identify potentially secreted proteins, all significantly regulated genes 
were mapped to determine the corresponding protein IDs and peptide sequences 
via the UniProt database4. The obtained sequences were used as input for ngLOC5 
to predict the subcellular localization of these proteins.
Microbiota analysis
Microbiota composition was determined in the luminal content collected from 
the pCO via the cannula 300 min after feeding on d14 of each dietary treatment, 
essentially as described before (126). Due to technical issues, samples from only 9 
of the 10 pigs could be analysed. Samples were analysed on the second generation 
Pig Intestinal Tract Chip (PITChip), an improved version of the original phylogenetic 
microarray (99) which is comprised of more than 3,200 tiled oligonucleotides 
targeting the 16S rRNA gene sequences of 781 porcine intestinal microbial 
phylotypes. PITChip images were processed using Agilent’s Feature Extraction 
Software version 9.5 and further processed in R (library ‘microbiome’6).
 Univariate testing of differences for individual microbial groups was 
performed using the Mann–Whitney U signed rank test. P values were corrected 
for multiple testing using a false discovery rate (FDR) method (105). Groups that 
satisfied the criterion of P <0.05 were considered to be significantly affected. 
Multivariate analysis was applied for PITChip data interpretation as described in the 
Supplemental Methods.
4 http://www.uniprot.org/
5 http://ngloc.unmc.edu/
6 http://microbiome.github.com/
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SCFA determination by NMR spectroscopy
SCFA concentrations were determined in plasma samples obtained from the carotid 
artery 300 min after feeding on d14 of each dietary treatment as described in the 
Supplemental Methods.
Multivariate correlation analysis 
To get insight into the mutual interactions between the gene expression, microbiota 
composition and plasma SCFA data, these datasets were pair-wise combined using 
the linear multivariate method partial least squares (PLS), taking into account the 
repeated measures (multilevel) structure of the data (149). We used the canonical 
correlation framework of multilevel-PLS since we deliberately did not want to make 
any prior assumption on the relationship between the 2 sets of variables that were 
analysed (150). Analyses were performed in R using the library mixOmics (151).
Standard statistical methods
SCFA concentrations measured in digesta were analysed using a mixed model 
in SAS (version 9.1; SAS Institute). For samples derived from the pCO cannula, 
time and individual pigs were included as repeated measurements. The model 
included period, diet, time, and interaction of diet and time as fixed effects, and 
pig as random effect. For samples taken at section, segment and individual pigs 
were included as repeated measurements. The model included diet, segment, and 
interaction of diet and segment as fixed effects, and pig as random effect. SCFA 
concentrations measured in plasma were analysed using a paired samples t-test in 
IBM SPSS Statistics 19. Differences were considered significant if P <0.05. Results 
were expressed as means ± SEM. 
Results
Anthropometric variables
All pigs remained healthy during the experiment and showed normal growth and 
appetite. Average body weight at the start of the experiment was 57.9 ± 1.6 kg 
and increased with 21.8 ± 1.1 kg during the study period. No significant effect of 
treatment order was found with respect to body weight development (data not 
shown). The average length of the SI and CO, determined at section, were similar 
for both treatment groups (16.1 ± 0.62 m and 3.96 ± 0.18 m respectively).
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Differentially expressed genes in colon
Microarray analysis was performed to identify genes that were differentially 
expressed in pCO by RS compared to DS. When remapping the probes to the Sscrofa 
10.2 genome assembly, the expression of 748 genes was found to be significantly 
changed by RS (P <0.01). Of these genes, 459 were significantly induced, whereas 
289 genes were significantly suppressed by RS (Supplemental Table 2). The top 
induced gene was Intestinal-type alkaline phosphatase-like (LOC100521756), 
showing a 2.9 fold increase on RS (Fig. 1), whereas the most suppressed gene was 
Chitinase 3-like 1 (CHI3L1), with a 3.7 fold decrease on RS (Fig. 1).
Functional implications of differential gene expression
To gain insight into the underlying biological phenomena affected by RS, pig genes 
were mapped to human orthologous and gene set enrichment analysis (GSEA) 
was performed. Results of GSEA were summarized in an enrichment map to 
enhance the functional interpretation of enriched gene sets. Using conservative 
significance thresholds, an enrichment map was generated that consisted of 331 
nodes (gene sets), of which 57 were positively and 274 were negatively enriched 
(Supplemental Fig. 1). These numbers demonstrated that the majority of gene sets 
was suppressed with RS feeding. We observed that gene sets describing processes 
related to tricarboxylic acid (TCA) cycle, lipid metabolism, compound sensing, 
barrier function and metabolism of xenobiotics were significantly enriched in the RS 
group, while gene sets involved in immune response, transcription and translation, 
post-translational modification and intracellular processing were enriched in the DS 
group (Supplemental Fig. 1). 
 Next, expression changes of genes that contributed to the differential 
regulation of the 3 largest clusters of processes, i.e. lipid metabolism, TCA cycle 
and immune response were visualized (Fig. 2). Most importantly, these results 
showed a modest yet consistent regulation of genes involved in the before-
mentioned processes, supporting the robustness of the analysis. In addition, it 
revealed regulation of several key genes, including PDK1 and PDK4; both involved 
in controlling glucose and fatty acid metabolism and homeostasis, ANGPTL4; 
regulating plasma TG levels, as well as NFKB, TLR4, BCL6, ICOS and CR2 that all play 
a role in controlling the adaptive and innate immune response.
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Top induced genes       Individual log2 FC 
Gene Description Gene symbol Entrez ID Mean log2 FC 1 2 3 4 5 6 7 8 9 10 
Intestinal-type alkaline phosphatase-like LOC100521756 100521756 1.55                     
Carbonic anhydrase II CA2 100154873 1.35 
Uncharacterized LOC100621113 LOC100621113 100621113 1.01 
Hydroxysteroid (17-beta) dehydrogenase 2 HSD17B2 100312973 1.00 
Transmembrane 4 L6 family member 20-like LOC100513630 100513630 0.96 
Uncharacterized protein C5orf4 homolog LOC100525263 100525263 0.95 
Solute carrier family 30, member 10 SLC30A10 100623097 0.92 
Angiotensinogen-like LOC100157073 100157073 0.86 
Carbonic anhydrase 12-like LOC100152749 100152749 0.83 
Carcinoembryonic antigen-related cell adhesion molecule 7-like LOC100524810 100524810 0.81 
ATP-binding cassette, sub-family A (ABC1), member 6 ABCA6 100520861 0.79 
Agmatinase, mitochondrial-like LOC100519548 100519548 0.74 
ADAM metallopeptidase domain 23 ADAM23 100518044 0.74 
Claudin 10 CLDN10 100153752 0.73 
Thiopurine S-methyltransferase TPMT 100157630 0.72 
Ubiquitin carboxyl-terminal hydrolase 2-like LOC100520041 100520041 0.72 
Transient receptor potential cation channel subfamily M member 6-like LOC100157775 100157775 0.71 
Transmembrane protein 117 TMEM117 100524623 0.71 
Poly (ADP-ribose) polymerase family, member 15 PARP15 100520273 0.70 
Serine palmitoyltransferase, long chain base subunit 3 SPTLC3 100519280 0.68 
Collagen alpha-6(VI) chain-like LOC100516642 100516642 0.67 
Guanylate cyclase activator 2A (guanylin) GUCA2A 100301560 0.66 
EGF containing fibulin-like extracellular matrix protein 1 EFEMP1 100512046 0.66 
Pancreatic lipase-related protein 2 PNLIPRP2 100462755 0.66 
Olfactory receptor 9K2-like LOC100737562 100737562 0.66                     
Top suppressed genes Individual log2 FC 
Gene Description Gene symbol Entrez ID Mean log2 FC 1 2 3 4 5 6 7 8 9 10 
Chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 396865 -1.88 
C4b-binding protein alpha chain-like LOC100520761 100520761 -1.42 
Secretory leukocyte peptidase inhibitor SLPI 396886 -1.13 
C-type lectin domain family 7, member A CLEC7A 100038025 -0.94 
Immunoresponsive 1 homolog (mouse) IRG1 100524951 -0.93 
Chemokine (C-X-C motif) receptor 4 CXCR4 396659 -0.89 
P2Y purinoceptor 13-like LOC100524766 100524766 -0.86 
BPI fold containing family B, member 2 BPIFB2 100113424 -0.84 
Tryptophan hydroxylase 1 TPH1 100511002 -0.80 
Chromosome 1 open reading frame 162 ortholog C4H1orf162 100627962 -0.78 
SLAM family member 7-like LOC100154053 100154053 -0.78 
Placenta-specific gene 8 protein-like LOC100525175 100525175 -0.78 
Antileukoproteinase-like LOC100512873 100512873 -0.74 
Rho GTPase activating protein 15 ARHGAP15 100520808 -0.74 
Monocarboxylate transporter 7-like LOC100739042 100739042 -0.71 
Lymphoid enhancer-binding factor 1 LEF1 100170126 -0.70 
Transmembrane protein 156-like LOC100525349 100525349 -0.69 
Membrane-spanning 4-domains, subfamily A, member 1 MS4A1 100627952 -0.68 
SLAM family member 6 SLAMF6 100156912 -0.67 
Sorting nexin-10-like LOC100520876 100520876 -0.66 
Acyloxyacyl hydrolase (neutrophil) AOAH 100522290 -0.64 
Clusterin CLU 397025 -0.63 
CD1B antigen PCD1B 100038007 -0.62 
Interleukin 2 receptor, gamma IL2RG 397156 -0.60 
A-kinase anchor protein 5-like LOC100153460 100153460 -0.60                     
Figure 1 
Figure 1 Top 25 induced genes and bottom 25 suppressed genes on the RS diet, 
based on the gene definitions of the NCBI Sus scrofa Entrez Gene database, build 
4.1. Average log2 fold changes of the signal intensity of RS compared with DS were 
determined from the individual response of the 10 pigs, which are expressed as a 
heatmap. The intensity of the red and green colour indicates the degree of induction 
or suppression per pig, respectively.
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COX10 0.23   MLXIPL 0.24   DDOST -0.16   
HMOX2 0.21   ABCD3 0.24   PIK3R2 -0.18   
OGDH 0.18   CYP17A1 0.23   P2RX7 -0.18   
UQCRC1 0.16   MGLL 0.23   PTPN12 -0.19   
UQCRH 0.15   HSD17B8 0.23   FYN -0.19   
PCK2 0.14     SLC35D1 0.23   ABI1 -0.21   
DLST 0.14   PPAP2B 0.23   NFATC2 -0.22   
ACO1 0.13   MBOAT1 0.22   PIK3CD -0.22   
SDHB 0.12   DEGS2 0.22   LYST -0.23   
PCK1 0.97     GPAT2 0.22   LAT -0.23   
PDK4 0.70     ACADM 0.22   SKAP1 -0.24   
SLC16A1 0.61     SLC25A1 0.21   ARHGDIB -0.24   
PC 0.31     ACOT7 0.20   TGFB1 -0.24   
LDHA -0.16     ACOX1 0.20   CD47 -0.25   
C5orf4 1.16   UGDH 0.19   MAP3K1 -0.26   
AGT 0.87   HNF4A 0.19   DEF6 -0.28   
SPTLC3 0.68   PLIN2 0.19   CD5 -0.28   
PNLIPRP2 0.67   SGPP2 0.19   TBX21 -0.29   
CYP27A1 0.63   ACBD4 0.18   CD40 -0.30   
IGF1 0.62   PCCB 0.18   CD83 -0.31   
NR1H4 0.59   KIF1B 0.17   FCRL3 -0.32   
ANGPTL4 0.58   CAB39 0.17   RASGRP2 -0.33   
HPGD 0.56   GPD2 0.16   INPP5D -0.33   
ACSF2 0.50   HADHA 0.15   SH2D3C -0.34   
HMGCS2 0.49   CRAT 0.15   LAT2 -0.34   
GPT 0.45   COL4A3BP 0.15   DOCK2 -0.34   
PLD1 0.42   SPTLC2 0.15   RHOH -0.35   
THRB 0.42   GOT2 0.14   LCK -0.36   
FABP1 0.41   ACADS 0.14   TXK -0.37   
PRDX6 0.41   ADIPOR1 -0.14   JAK3 -0.38   
ACADSB 0.41   MTHFS -0.16   CD3D -0.38   
ECHDC2 0.40   TNFRSF1A -0.17   FCER2 -0.39   
UCP3 0.39   LTA4H -0.19   IL21R -0.40   
PLCE1 0.38   DGKE -0.20   NFKB1 -0.40   
ADH7 0.37   GPX1 -0.24   MAP3K8 -0.40   
FAAH 0.37   LDLR -0.28   KLHL6 -0.42   
SRD5A1 0.37   DEGS1 -0.29   MNDA -0.42   
CYP26B1 0.37   BCAT1 -0.29   HSH2D -0.42   
CES1 0.36   SCPEP1 -0.29   RASGRP1 -0.42   
AGPAT2 0.36   FAR2 -0.29   LCP2 -0.42   
PNPLA2 0.35   FADS1 -0.30   CD2 -0.43   
FA2H 0.35   FADS2 -0.32   BCL6 -0.43   
DGAT2 0.35   DGKA -0.33   IL10 -0.45   
STX3 0.35   ABAT -0.38   PTPN22 -0.46   
ADH5 0.34   SMPDL3A -0.40   PRKCB -0.48   
GLYCTK 0.33   AKR1C1 -0.40   AICDA -0.49   
HMGCL 0.33   HAL -0.42   LCP1 -0.49   
GBA3 0.33   IRG1 -1.07   ITGA4 -0.49   
PPARG 0.33   CAV1 0.38     CD79A -0.52   
SLC25A20 0.32   CREBBP -0.14     PTPRC -0.53   
KDSR 0.32   MUC1 0.37   CD274 -0.55   
GGT5 0.32   FZD5 0.32   CD19 -0.55   
BDH1 0.31   ERBB2 0.23   CD3G -0.57   
EPHX2 0.30   BAD 0.23   TLR4 -0.57   
RBP1 0.30   JUN 0.23   PRKCQ -0.60   
TXNIP 0.30   PTPRH 0.23   CXCR5 -0.68   
TNFRSF21 0.29   JMJD6 0.22   ICOS -0.70   
MGST2 0.29   HDAC5 0.22   LEF1 -0.76   
CERS6 0.29   BMP4 0.19   CLEC7A -0.77   
CYP2J2 0.29   NCK2 0.19   MASP2 -0.21     
CPT1A 0.28   MAPKAP1 0.17   SERPING1 -0.26     
ACAT1 0.28   PIK3R1 0.16   CD55 -0.26     
ACAA2 0.27   PAG1 0.15   C4BPB -0.39     
LIPE 0.27   KLF6 0.15   C2 -0.47     
SGMS2 0.27   STIM1 0.12   CFH -0.47     
AASDH 0.26   ELF1 -0.11   C4B -0.58     
ALDH6A1 0.26   TUBB -0.11   C4BPA -0.62     
PPM1L 0.26   KAT5 -0.13   CLU -0.63     
DGKG 0.26   PAK2 -0.13   CR2 -0.97     
DGAT1 0.25   FOXP1 -0.14   CFB -0.23   
CYP7B1 0.25   PPP3CA -0.14   F5 -0.38   
CIDEC 0.24   CD24 -0.16   PDK1 -0.23         
DECR1 0.24   PTPN6 -0.16   
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Figure 2 Heatmap of significantly regulated genes (P <0.05) present in the positively 
enriched gene sets describing TCA cycle or lipid metabolism, or present in the 
negatively enriched gene sets describing processes involved in adaptive or innate 
immune response. Average and individual log2 fold changes are presented. The 
intensity of the red and green colour indicates the degree of induction or suppression 
per pig, respectively, and ranged from -0.65 (green) to 0.65 (red). Pigs are ranked 
based on their identifier. The vertical colour bars indicate gene set membership; dark 
blue: TCA cycle, light blue: lipid metabolism, olive green: adaptive immune response, 
tan: innate immune response.
Microbiota analysis
RS did not significantly change the microbial diversity as indicated by Shannon’s 
index for diversity (data not shown). Principal response curves analysis showed that 
diet (DS or RS) explained 15.7% of the total variation in microbiota, while period 
and the interaction of period and diet only explained 4.8% and 6.8% respectively 
(data not shown). This indicated that diet was the main factor driving the microbial 
variation. Partial RDA of the PITChip data confirmed that diet had a significant effect 
on microbial variation (P <0.05) (Fig. 3).
 At the phylum level, we observed a significant increase in the relative 
abundance of Bacteroidetes (P = 0.036) (Supplemental Fig. 2A). As a result, we 
found a significantly lower Firmicutes/Bacteroidetes ratio (P = 0.017) in RS-fed pigs 
(10.3 ± 2.0) compared to DS-fed pigs (20.1 ± 3.4) (Supplemental Fig. 2B).
 At the approximate genus level (90% 16S ribosomal RNA similarity 
threshold), the relative abundance of several groups that include known butyrate-
producing bacteria, including those related to Faecalibacterium prausnitzii and 
Megasphaera elsdenii, was increased upon RS feeding compared to DS feeding 
(P <0.05) (Table 1). Other groups that increased in relative abundance comprised 
Prevotella melaninogenica-like, uncultured Prevotella, Enterococcus-like, Dialister-
like, Mitsuokella multacida-like and Clostridium ramosum-like bacteria. On the other 
hand, Eggerthella-like, uncultured Bacteroidetes, Turicibacter-like, Clostridium 
perfringens-like, Anaerovorax-like, Peptoniphilus-like, uncultured Clostridia XIVa, 
uncultured Planctomycetacia, as well as a range of potentially pathogenic microbial 
groups, including Leptospira, and several facultative bacterial groups within the 
Proteobacteria, including Sphingomonas-like, uncultured Betaproteobacteria, 
Actinobacillus indolicus-like, Aeromonas, Alishewanel-like, Halomonas-like, 
Pasteurella-like, Pseudomonas-like, Psychrobacter-like, Ruminobacter amylophilus-
like, Vibrio-like, Xanthomonas-like, were found to be decreased on the RS diet (P 
<0.05) (Table 1).
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Figure 3 Biplot of partial RDA results, representing the principal component analysis 
of the microbiota composition as measured by the mean hybridization signals for 151 
genus-level phylogenetic groups in the luminal content of proximal colon of pigs fed 
the DS or RS diet for 2 wk. Samples are grouped by diet. Each symbol represents 1 pig, 
with numbers indicating pig identifiers. The average of the nominal environmental 
variables DS and RS are represented by triangles. DS, digestible starch; RS, resistant 
starch.
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Table 1 Phylogenetic groups in the luminal content of proximal colon of pigs fed DS or RS diet for 2 
wk, which were significantly affected by diet according to univariate analysis of PITChip data. 
Phylogenetic group  P value  FDR1 
ARC2 
Effect3 (RS‐DS) 
DS  RS 
Actinobacteria           
   Actinobacteria           
      Eggerthella et rel.  0.008   0.079   0.109 ± 0.050  0.033 ± 0.043  ‐ 
      Microbacterium et rel.  0.055   0.223   0.586 ± 0.100  0.709 ± 0.193  + 
Bacteroidetes           
   Bacteroidetes           
      Parabacteroides distasonis et rel.  0.055   0.223   0.411 ± 0.278  0.622 ± 0.278  + 
      Prevotella melaninogenica et rel.  0.012   0.088   0.056 ± 0.055  3.079 ± 3.194  + 
      Uncultured Bacteroidetes  0.039   0.203   0.605 ± 0.934  0.080 ± 0.241  ‐ 
      Uncultured Prevotella  0.008   0.079   0.836 ± 0.531  2.501 ± 1.679  + 
Firmicutes           
   Bacilli           
      Enterococcus et rel.  0.039   0.203   2.480 ± 0.576  3.025 ± 0.657  + 
      Lactobacillus amylovorus et rel.  0.055   0.223   1.094 ± 0.963  0.400 ± 0.458  ‐ 
      Lactobacillus salivarius et rel.  0.055   0.223   0.926 ± 0.356  1.267 ± 0.426  + 
      Turicibacter et rel.  0.004   0.079   0.197 ± 0.069  0.062 ± 0.036  ‐ 
   Clostridium cluster I           
      Clostridium perfringens et rel.  0.008  0.079  2.398 ± 1.763  0.403 ± 0.810  ‐ 
   Clostridium cluster IV           
      Faecalibacterium prausnitzii et rel.  0.020   0.123   0.969 ± 0.398  1.925 ± 1.142  + 
      Uncultured Clostridia IV  0.055   0.223   2.404 ± 0.863  1.697 ± 1.005  ‐ 
   Clostridium cluster IX           
      Dialister et rel.  0.004   0.079   0.453 ± 0.248  0.852 ± 0.328  + 
      Megasphaera elsdenii et rel.  0.008   0.079   0.850 ± 0.210  1.386 ± 0.600  + 
      Mitsuokella multacida et rel.  0.008   0.079   1.084 ± 0.301  1.776 ± 0.743  + 
   Clostridium cluster XI           
      Anaerovorax et rel.  0.004  0.079  1.811 ± 0.681  0.495 ± 0.973  ‐ 
   Clostridium cluster XIII           
      Peptoniphilus et rel.  0.008  0.079  0.601 ± 0.350  0.176 ± 0.364  ‐ 
   Clostridium cluster XIVa           
      Uncultured Clostridia XIVa  0.039  0.203  2.412 ± 0.828  1.657 ± 0.928  ‐ 
   Clostridium cluster XVIII           
      Clostridium ramosum et rel.  0.008  0.079  0.213 ± 0.057  0.296 ± 0.101  + 
Planctomycetes           
   Planctomycetacia           
      Uncultured Planctomycetacia  0.012  0.088  0.159 ± 0.114  0.037 ± 0.048  ‐ 
Proteobacteria           
   Alphaproteobacteria           
      Rhizobium et rel.  0.055   0.223   0.552 ± 0.085  0.382 ± 0.153  ‐ 
      Sphingomonas et rel.  0.027   0.165   0.214 ± 0.203  0.059 ± 0.154  ‐ 
   Betaproteobacteria           
      Uncultured Betaproteobacteria  0.012  0.088  0.329 ± 0.046  0.246 ± 0.066  ‐ 
   Gammaproteobacteria           
      Actinobacillus indolicus et rel.  0.008   0.079   0.332 ± 0.058  0.227 ± 0.079  ‐ 
      Aeromonas  0.020   0.123   0.671 ± 0.147  0.389 ± 0.268  ‐ 
      Alishewanel et rel.  0.020   0.123   0.472 ± 0.093  0.255 ± 0.176  ‐ 
      Escherichia coli et rel.  0.055   0.223   0.397 ± 0.190  0.166 ± 0.196  ‐ 
      Halomonas et rel.  0.004   0.079   0.747 ± 0.204  0.448 ± 0.225  ‐ 
      Pasteurella et rel.  0.012   0.088   0.145 ± 0.041  0.093 ± 0.037  ‐ 
      Pseudomonas et rel.  0.008   0.079   0.697 ± 0.253  0.279 ± 0.340  ‐ 
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Figure 4 Acetate, propionate and butyrate concentrations in peripheral plasma of 
pigs fed the DS or the RS diet for 2 wk. Samples were collected 300 min after feeding. 
Values are means ± SEM, n = 10 for DS-fed pigs and n = 9 for RS-fed pigs. ** indicates 
P <0.01. DS, digestible starch; RS, resistant starch. 
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Table 1 Phylogenetic groups in the luminal content of proximal colon of pigs fed DS or RS diet for 2 
wk, which were significantly affected by diet according to univariate analysis of PITChip data. 
Phylogenetic group  P value  FDR1 
ARC2 
Effect3 (RS‐DS) 
DS  RS 
Actinobacteria           
   Actinobacteria           
      Eggerthella et rel.  0.008   0.079   0.109 ± 0.050  0.033 ± 0.043  ‐ 
      Microbacterium et rel.  0.055   0.223   0.586 ± 0.100  0.709 ± 0.193  + 
Bacteroidetes           
   Bacteroidetes           
      Parabacteroides distasonis et rel.  0.055   0.223   0.411 ± 0.278  0.622 ± 0.278  + 
      Prevotella melaninogenica et rel.  0.012   0.088   0.056 ± 0.055  3.079 ± 3.194  + 
      Uncultured Bacteroidetes  0.039   0.203   0.605 ± 0.934  0.080 ± 0.241  ‐ 
      Uncultured Prevotella  0.008   0.079   0.836 ± 0.531  2.501 ± 1.679  + 
Firmicutes           
   Bacilli           
      Enterococcus et rel.  0.039   0.203   2.480 ± 0.576  3.025 ± 0.657  + 
      Lactobacillus amylovorus et rel.  0.055   0.223   1.094 ± 0.963  0.400 ± 0.458  ‐ 
      Lactobacillus salivarius et rel.  0.055   0.223   0.926 ± 0.356  1.267 ± 0.426  + 
      Turicibacter et rel.  0.004   0.079   0.197 ± 0.069  0.062 ± 0.036  ‐ 
   Clostridium cluster I           
      Clostridium perfringens et rel.  0.008  0.079  2.398 ± 1.763  0.403 ± 0.810  ‐ 
   Clostridium cluster IV           
      Faecalibacterium prausnitzii et rel.  0.020   0.123   0.969 ± 0.398  1.925 ± 1.142  + 
      Uncultured Clostridia IV  0.055   0.223   2.404 ± 0.863  1.697 ± 1.005  ‐ 
   Clostridium cluster IX           
      Dialister et rel.  0.004   0.079   0.453 ± 0.248  0.852 ± 0.328  + 
      Megasphaera elsdenii et rel.  0.008   0.079   0.850 ± 0.210  1.386 ± 0.600  + 
      Mitsuokella multacida et rel.  0.008   0.079   1.084 ± 0.301  1.776 ± 0.743  + 
   Clostridium cluster XI           
      Anaerovorax et rel.  0.004  0.079  1.811 ± 0.681  0.495 ± 0.973  ‐ 
   Clostridium cluster XIII           
      Peptoniphilus et rel.  0.008  0.079  0.601 ± 0.350  0.176 ± 0.364  ‐ 
   Clostridium cluster XIVa           
      Uncultured Clostridia XIVa  0.039  0.203  2.412 ± 0.828  1.657 ± 0.928  ‐ 
   Clostridium cluster XVIII           
      Clostridium ramosum et rel.  0.008  0.079  0.213 ± 0.057  0.296 ± 0.101  + 
Planctomycetes           
   Planctomycetacia           
      Uncultured Planctomycetacia  0.012  0.088  0.159 ± 0.114  0.037 ± 0.048  ‐ 
Proteobacteria           
   Alphaproteobacteria           
      Rhizobium et rel.  0.055   0.223   0.552 ± 0.085  0.382 ± 0.153  ‐ 
      Sphingomonas et rel.  0.027   0.165   0.214 ± 0.203  0.059 ± 0.154  ‐ 
   Betaproteobacteria           
      Uncultured Betaproteobacteria  0.012  0.088  0.329 ± 0.046  0.246 ± 0.066  ‐ 
   Gammaproteobacteria           
      Actinobacillus indolicus et rel.  0.008   0.079   0.332 ± 0.058  0.227 ± 0.079  ‐ 
      Aeromonas  0.020   0.123   0.671 ± 0.147  0.389 ± 0.268  ‐ 
      Alishewanel et rel.  0.020   0.123   0.472 ± 0.093  0.255 ± 0.176  ‐ 
      Escherichia coli et rel.  0.055   0.223   0.397 ± 0.190  0.166 ± 0.196  ‐ 
      Halomonas et rel.  0.004   0.079   0.747 ± 0.204  0.448 ± 0.225  ‐ 
      Pasteurella et rel.  0.012   0.088   0.145 ± 0.041  0.093 ± 0.037  ‐ 
      Pseudomonas et rel.  0.008   0.079   0.697 ± 0.253  0.279 ± 0.340  ‐ 
      Psychrobacter et rel.  0.008   0.079   0.629 ± 0.126  0.408 ± 0.173  ‐ 
      Ruminobacter amylophilus et rel.  0.039   0.203   0.211 ± 0.022  0.153 ± 0.057  ‐ 
      Thiocapsa et rel.  0.055   0.223   0.675 ± 0.163  0.450 ± 0.202  ‐ 
      Vibrio et rel.  0.008   0.079   0.690 ± 0.149  0.438 ± 0.207  ‐ 
      Xanthomonas et rel.  0.020   0.123   0.852 ± 0.063  0.682 ± 0.140  ‐ 
Spirochaetes           
   Spirochaetes           
      Leptospira  0.012  0.088  0.717 ± 0.172  0.402 ± 0.208  ‐ 
1 FDR: false discovery rate. 
2 ARC: average relative contribution (%) of a microbial group. Values represented means ± SEM, n = 9 
per treatment. 
3 ”+” or “‐” indicates whether the average relative contribution of the microbial group was increased 
or decreased by the RS treatment. 
SCFA concentrations
Total SCFA concentration in the luminal content of pCO, collected 30 min before and 
300 min after feeding, was not affected by dietary treatment (Supplemental Fig. 
3A). However, the percentage of branched-chain fatty acids (BCFAs), i.e. isobutyrate 
and isovalerate, of total SCFAs was significantly lower in pigs fed RS (Supplemental 
Fig. 3B). Total SCFA concentration in the luminal content of CA and dCO obtained 
at sacrifice was significantly higher with RS consumption (Supplemental Fig. 4A). In 
pCO, mCO and dCO, significantly lower percentages of BCFAs were observed with RS 
consumption (Supplemental Fig. 4B). 
 Acetate, propionate, and butyrate concentrations determined in peripheral 
plasma collected 300 min after feeding were significantly higher with RS consumption 
compared to DS consumption (Fig. 4).
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Correlation analysis
The expression of the 618 significantly regulated genes (AUGUSTUST annotation) 
was integrated with the relative abundance of the 37 significantly changed microbial 
groups using multivariate correlation analysis. A network was generated that 
revealed gene-microbiota combinations that were strongly correlated (correlation 
coefficient >0.9). This network contained 123 genes and 17 microbial groups, with 
each gene correlating with 1 up to 14 microbial groups (Fig. 5A). Most genes (i.e. 
96) were significantly correlated with Vibrio-like bacteria, of which 75 genes were 
negatively correlated including the SCFA transporter SLC16A1, PPARG and the 
PPARG target gene GPT.
 In addition, we determined which of the 618 genes correlated with 
concentrations of acetate, propionate and butyrate measured in peripheral plasma 
300 min after feeding. The resulting network showed that 26 genes were correlated 
(correlation coefficient >0.9) with acetate and 48 genes were correlated with 
propionate and/or butyrate (Fig. 5B).
 Correlation analysis of the 37 microbial groups with plasma acetate, 
propionate and butyrate (correlation coefficient >0.8) revealed 20 highly correlating 
microbial groups (Fig. 5C). Whereas the majority of correlations included negative 
correlations of microbial groups reduced in the presence of RS, we also observed 
positive correlations with known acid producing bacteria, including Megasphaera 
elsdenii, a known producer of acetate, propionate and butyrate, as well as 
Mitsuokella multacida, which has been shown to predominantly produce lactate, 
succinate and smaller amounts of acetate from carbohydrate fermentation. The 
latter compounds are in turn used as substrates by producers of propionate and 
butyrate (116).
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Figure 5 Correlation networks of genes correlating with microbial groups with 
correlation coefficient >0.9 (A), genes correlating with plasma acetate, propionate 
and butyrate concentrations with correlation coefficient >0.9 (B), and microbial 
groups correlating with plasma acetate, propionate and butyrate concentrations with 
correlation coefficient >0.8 (C). Genes are indicated as white hexagons, microbial 
groups as green circles, and SCFAs as grey triangles. Blue and red lines respectively 
represent negative and positive correlations.
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Table 2 Upstream regulators, determined by Ingenuity Systems Pathway Analysis Software. 
Upstream Regulator  Molecular Type Predicted activation state Activation z‐score1  P‐value of overlap2
PPARG  Ligand‐dependent nuclear receptor Activated 3.069  3.10 10‐4
ERG  Transcription regulator  Activated 2.828  1.33 10‐2
XBP1  Transcription regulator  Inhibited ‐2.041  3.96 10‐2
PPARG,  Peroxisome  proliferator‐activated  receptor  gamma;  ERG,  V‐ets  erythroblastosis  virus  E26 
oncogene homolog (avian); XBP1, X‐box binding protein 1. 
1 Activation z‐score predicts the activation state of the upstream regulator, using the gene expression 
pattern of its downstream genes in the dataset and takes into account the consistency of target gene 
activation. Upstream regulators with z‐score ≥ 2 were considered to be activated, if z‐score ≤ ‐2 the 
upstream regulator was considered to be inhibited. 
2 The overlap P‐value measures the significance of overlap between the dataset genes and the genes 
reported to be regulated by the transcriptional activator. 
 
Table 3 PPARG target genes, determined by Ingenuity Systems Pathway Analysis Software. 
1 Column  indicates the predicted activation state of PPARG (either Activated or Inhibited), based on 
the direction of the gene expression change in the uploaded dataset.  
2 Average log2 fold change of the signal intensity of RS compared to DS. 
3  Column  indicates  whether  literature  findings  support  the  prediction.  ‘Down’  and  ‘up’  indicate 
whether  literature supports a down‐ or an up‐regulation of the target gene by PPARG, respectively. 
‘Regulates’  indicates  that  there  is  insufficient support  from  literature  that  the  target gene  is either 
up‐ or down‐regulated by PPARG.
 
Name  Gene symbol 
Prediction of activation 
state1 
Mean log2 FC2 
Literature 
Findings3 
Transforming growth factor, beta receptor 1  TGFBR1 Activated ‐0.25 Down
Chemokine (C‐X‐C motif) ligand 14  CXCL14 Activated ‐0.26 Down
Carbonic anhydrase II  CA2 Activated 1.36 Up
Angiopoietin‐like 4  ANGPTL4 Activated 0.58 Up
3‐hydroxy‐3‐methylglutaryl‐CoA synthase 2 (mitochondrial)  HMGCS2 Activated 0.49 Up
Uncoupling protein 3 (mitochondrial, proton carrier)  UCP3 Activated 0.39 Up
Caveolin 1, caveolae protein, 22kDa  CAV1 Activated 0.38 Up
Vascular endothelial growth factor A  VEGFA Activated 0.37 Up
Peroxisome proliferator‐activated receptor gamma  PPARG Activated 0.33 Up
Solute carrier family 25 member 20  SLC25A20 Activated 0.32 Up
3‐hydroxybutyrate dehydrogenase, type 1 BDH1 Activated 0.31 Up
Lipase, hormone‐sensitive  LIPE Activated 0.27 Up
Diacylglycerol O‐acyltransferase 1  DGAT1 Activated 0.25 Up
Monoglyceride lipase  MGLL Activated 0.23 Up
Acyl‐CoA dehydrogenase, C‐4 to C‐12 straight chain  ACADM Activated 0.22 Up
Phosphodiesterase 3B, cGMP‐inhibited  PDE3B Inhibited ‐0.45 Up
Serpin peptidase inhibitor, clade A, member 1  SERPINA1 Inhibited ‐0.60 Up
Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT ‐ 0.87 Regulates
Insulin‐like growth factor 1 (somatomedin C)  IGF1 ‐ 0.62 Regulates
Glutamic‐pyruvate transaminase (alanine aminotransferase) GPT ‐ 0.45 Regulates
Protein tyrosine phosphatase, receptor type, F  PTPRF ‐ 0.27 Regulates
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Upstream regulators
The underlying mechanisms by which RS modulated gene expression changes 
are not well understood. We therefore aimed to identify potential upstream 
transcriptional regulators that could explain the observed shift in gene expression 
profile. Results of this analysis predicted the transcription factors PPARG and ERG 
to be significantly activated on RS, while XBP1 was predicted to be inhibited (Table 
2). Because the highest z-score (3.069) was found for PPARG, we had a closer look 
at the downstream PPARG target genes. Out of 21 PPARG target genes regulated by 
RS, 15 genes had an expression change consistent with activation of PPARG (Table 
3). Since TGFBR1 and CXCL14 are known to be down-regulated by PPARG and we 
indeed observed reduced expression of these target genes, this suggests that PPARG 
was activated by RS. The other 13 target genes were induced in our dataset, which 
corresponds with observations from literature, suggesting that PPARG is activated 
by RS.
Potentially secreted proteins
The transcriptome data were mined to identify potentially secreted proteins that may 
mediate effects of RS in liver or other tissues and organs. From the 655 significantly 
regulated genes in our dataset, we identified 849 unique encoding proteins for 
which the predicted locations were determined. The number of proteins is larger 
than the number of genes due to alternatively splicing of the mRNA molecules of 
the regulated gens. Fifty-three proteins were predicted to be located extracellular, 
and therefore secreted, with a probability above 0.20 (Supplemental Table 3). Of 
these proteins, 31 were encoded by genes induced on RS and 22 proteins were 
encoded by suppressed genes. Among the potentially secreted proteins that, based 
on the transcriptome data, are expected to increase on RS were IGF1, AGT, VEGFA 
and ANGPTL4. These proteins are all derived from PPARG target genes. The proteins 
that are expected to go down on RS include 2 more proteins derived from PPARG 
target genes, namely SERPINA1 and CXCL14.
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Discussion
In the present study, we examined the effects of 2-wk-consumption of a diet high 
in RS on the mucosal transcriptome and luminal microbiota composition and SCFA 
concentrations in proximal colon of pigs. Our results showed that compared to a DS 
diet, the RS diet shifted colonic gene expression profile of the host from immune 
regulation towards metabolic regulation and reduced the abundance of several 
potentially pathogenic bacteria in the colonic lumen. In addition, plasma SCFA 
concentrations increased on the RS diet. The nuclear receptor PPARG was identified 
as a potential key upstream regulator.
Microbiota composition
Evidence suggesting that gut microbiota are highly important in the regulation of 
energy homeostasis and fat storage is accumulating (38, 39). Supporting this view, the 
Firmicutes/Bacteroidetes ratio has been linked to adiposity in humans, since obese 
individuals were found to have fewer Bacteroidetes compared to lean controls. In 
addition, the relative abundance of Bacteroidetes increased while the abundance 
of Firmicutes decreased with weight loss in obese subjects (42). Because we found a 
significantly lower Firmicutes/Bacteroidetes ratio in RS-fed pigs compared to DS-fed 
pigs, the microbial profile might have shifted towards a more healthy phenotype 
in RS-fed pigs. Although the relative abundance of Firmicutes slightly, albeit not 
significantly, decreased (Supplementary Fig. 2), we observed a significant increase 
in the relative abundance of several microbial groups previously shown to produce 
butyrate, including Faecalibacterium prausnitzii and Megasphaera elsdenii (116, 
152, 153). Other microbial populations stimulated by RS included fermenting 
microorganisms such as members of the Parabacteroides, Prevotella, Mitsuokella 
multacida, and lactic acid bacteria, that produce organic acids such as acetate, 
lactate and succinate that are in turn used as main substrates for the production of 
propionate and butyrate (116).
Fermentation products
In contrast with our previous study in pigs consuming the same RS diet (126), in 
the current study no significant difference in SCFA concentration was observed in 
the pCO digesta 300 min after feeding. However, the changed percentage of BCFAs 
in colonic digesta confirms the applied dietary contrast. These branched-chain 
products are formed by amino acid fermenting microbial species that metabolize 
undigested and endogenous proteins, peptides, and amino acids (54), particularly 
when carbohydrates as preferential energy source are absent. The lower percentage 
of BCFAs reflects the use of RS as energy source by microbiota whereas in the DS 
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diet the microbiota used proteinaceous energy sources due to the digestion and 
fermentation of starch in the upper gastrointestinal tract and the cecum. Moreover, 
plasma SCFA concentrations are known to be a more reliable measure of colonic SCFA 
production (154). As expected, we observed increased plasma SCFA concentrations 
upon RS feeding.
Functional implications colon
Genome-wide expression profiling is an unbiased approach for identifying genes 
regulated by RS. Our microarray analysis resulted in a dataset with the expression 
levels of 17,118 unique genes measured in 20 colonic samples from 10 pigs on 
2 dietary conditions (DS and RS). From these data we extracted the significantly 
regulated genes and the main processes that are expected to change based on the 
gene expression profile.
 In RS-fed pigs, we observed an increased expression of genes involved in the 
TCA cycle, the pathway responsible for generating energy through the oxidization 
of acetyl-CoA. We previously showed that RS increases SCFA concentrations in the 
colonic lumen (126). These SCFAs are subsequently taken up by the colonocytes, 
where mainly butyrate serves as an energy source for these cells as a precursor 
to the TCA cycle (155). Therefore, the increased energy generation in colonocytes 
upon RS feeding was in line with our expectations.
 In addition, genes involved in lipid metabolism were found to be induced 
by RS. More specifically, GSEA revealed increased uptake and release of fatty acids, 
fatty acid beta-oxidation and triglyceride (TG) synthesis. We hypothesize that these 
processes are a consequence of increased SCFA production, having a direct link with 
energy metabolism resulting in increased energy harvest from the diet.
 Gene expression profiling also showed that RS suppressed genes involved in 
both the innate and the adaptive immune response, which indicates that the CO of 
RS-fed pigs is less exposed to potential pathogens as was confirmed by microbiota 
analysis of luminal content, where especially members of the Proteobacteria were 
found reduced in relative abundance in the RS group. This observation, combined 
with a less pro-inflammatory state, might thus indicate a healthier condition of RS-
fed pigs as compared to DS. This observation is in line with previous studies on 
RS in relation to immune regulation, showing amelioration of inflammatory bowel 
disease upon RS feeding (156).
 Microbiota are known to play a crucial role in the immune system. Therefore, 
it is likely that the changed microbiota composition we observed on RS directly 
reflects changes in expression level of genes involved in immunity. Furthermore, 
immune signalling can affect microbiota composition, as shown by altered gut 
microbiota in mice lacking toll-like receptor 5, an essential protein for pathogen 
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recognition and activation of innate immunity (157).
 In addition to the microbiota, we hypothesize that PPARG, a ligand-activated 
transcription factor found to be significantly activated by RS, plays a role in the 
suppressed immune response. This is in line with a recent report that showed that 
SCFA, and especially butyrate, are agonists for PPARG (158). PPARG is also known 
to be involved in the prevention of inflammatory bowel disease in mice (159), pigs 
(160), and humans (161). Moreover, PPARG activation suppresses the activity of NF-
κB, thereby blocking pro-inflammatory gene transcription (162).
Functional implications whole-body metabolism
To determine how colonic gene expression changes affect inter-organ crosstalk, we 
identified potentially secreted proteins. Among these proteins were angiopoietin-
like 4 (ANGPTL4) and apolipoprotein D (APOD), which both play an important role 
in lipid metabolism. ANGPTL4 provides a link between microbiota and SCFAs in CO 
on one hand and adiposity on the other hand. Studies have suggested that there 
is a relationship between microbiota composition and ANGPTL4, as observed by 
strong suppression of ANGPTL4 after conventionalization of germ free mice (40, 41). 
Furthermore, microbiota are able to induce ANGPTL4 production in colonocytes 
via production of SCFAs and subsequent activation of PPARG (158). Because we 
found ANGPTL4 to be a potentially secreted protein, we hypothesize that ANGPTL4 
is secreted from the colonocytes into the circulation, where it inhibits lipoprotein 
lipase (LPL), an enzyme that hydrolyses TGs in lipoproteins into free fatty acids for 
uptake by tissues (124). Therefore, SCFAs may inhibit fat storage by stimulating 
ANGPTL4 release.
 Based on the direction of the expression of its encoding gene, we expect 
APOD to be decreased with RS consumption. Elevated APOD production was found 
to significantly reduce plasma TG levels in mice, due to enhanced LPL activity and 
improved catabolism of TG-rich particles (163). Plasma TG levels measured in the 
pigs from our experiment were significantly higher after RS consumption (164). 
Assuming that APOD decreases and ANGPTL4 increases on RS as suggested by 
the transcriptome data, we expect to find a decrease in LPL activity, resulting in 
increased plasma TG levels. 
 Based on our data, TG uptake by adipose tissue is expected to be inhibited 
by RS, indicating that long-term RS consumption might decrease adiposity. However, 
the final destination of the circulating TGs is yet unknown.
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Conclusion 
We demonstrated that compared to an iso-caloric DS diet, a diet high in RS favoured 
the growth of microbial populations producing organic acids, and inhibited a range 
of potentially pathogenic microbial groups. We also showed that RS provoked major 
changes in colonic gene expression, that represent induction of oxidative metabolic 
pathways, and suppression of immune response pathways. Our results provide 
novel molecular insights on effects of RS in colon, that emphasize the resilience of 
the colon and support the believe that RS has beneficial impact on colonic health. 
Because pigs are known to be a good model for humans, our study outcomes are 
highly relevant to human health.
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Supplemental Methods
Surgery 
After an overnight fast, all pigs were sedated with intramuscular Ketamine 10 mg/kg 
(Ketamine; Alfasan) and Midazolam 0.75 mg/kg (Dormicum; Roche) and anaesthesia 
was intravenously induced with the anodyne Sufentanil 1 µg/kg (Sufenta; Janssen-
Cilag). Pigs were intubated and anaesthesia was maintained by inhalation of 2% 
Sevoflurane (Abbott) combined with 40% oxygen and nitrous oxide. A Sufentanil 
infusion was maintained at 1 µg/kg.hour.
 Pigs were surgically fitted with a simple T-cannula in the pCO 1.45 ±0.16 
m distal from the ileocaecal sphincter, as was confirmed at section. The cannula 
was inserted in the intestinal lumen, exteriorized through a hole, fastened to the 
exterior part and closed with a stopper (165). In addition, pigs were fitted with 
a permanent blood vessel catheter (Tygon, Norton) as described previously (166). 
The catheter for blood sampling was placed in the carotid artery, fixed firmly at the 
site of insertion, tunnelled subcutaneously to the back of the pig and exteriorized 
between the shoulder blades. The catheters were filled and sealed off with saline 
containing heparin and penicillin (Procpen) and kept in a backpack which was glued 
to the skin.
 The first 3 d after surgery, pigs were fed a restricted amount of the 50:50 
mix of the DS and RS diet, i.e. 25%, 50% and 75% of their daily feed allowance on d 
1, 2 and 3 respectively, to allow a gradual recovery and to avoid problems with the 
gut cannula. Pigs were habituated to digesta collection from the cannula and blood 
sampling in the first week after surgery. After 4 to 6 d of postsurgical recovery, pigs 
were gradually switched to one of two dietary treatments (DS and RS).  
Colon biopsies
Pigs were acutely sedated by i.v. injection with propofol (Alfasan). The stopper 
was unscrewed from the cannula and digesta was removed to expose the mucosal 
wall of the pCO. An endoscope (OES Colonofiberscope, Olympus CF type ITIOL/1, 
Olympus Optical Co; LTD) was inserted via the permanent cannula into the lumen 
of the pCO, the intestinal wall was illuminated (OES Halogen light source with flash, 
Model CLE-F10, Olympus Optical Co; LTD) and visualized on a monitor (Endovision 
538; Karl Storz). Biopsies were taken by an endoscopic biopsy forceps (Olympus FB-
28U-1, 2 mm, 225 cm, Olympus Optical Co; LTD) and collected in screw cap tubes, 
after which they were immediately frozen in liquid nitrogen and stored at -80°C 
until further analysis.
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Digesta collection
To determine microbiota composition, digesta were collected in 1.5 mL Eppendorf 
tubes, after which the tubes were immediately frozen in liquid nitrogen and stored 
at -80°C until further analyses. In addition, digesta was collected in pre-weighed 
2 mL Eppendorf tubes with 0.75 mL H
3
PO
4
 for determining SCFA concentrations. 
These tubes were weighed again, thoroughly mixed on a vortex and stored at -20°C 
until further analysis. For measuring dry matter content, digesta were collected in 
empty pre-weighed Eppendorf tubes and stored at -20°C until further analysis.
RNA quality control
Concentrations and purity of RNA samples were determined on a NanoDrop ND-
1000 spectrophotometer (Isogen Life Science). RNA quality was verified on an 
Agilent 2100 Bioanalyzer (Agilent Technologies) by using 6000 Nano Chips (Agilent 
Technologies) according to the manufacturer’s instructions. RNA was judged as 
suitable for array hybridization only if samples exhibited intact bands corresponding 
to the 18S and 28S ribosomal RNA subunits, and displayed no chromosomal peaks 
or RNA degradation products (RNA Integrity Number >8.0).
GSEA analysis
GSEA has the advantage that it is unbiased, because no gene selection step is 
used, and a score is computed based on all genes in a gene set. Briefly, genes were 
ranked based on the paired IBMT-statistic and subsequently analysed for over- or 
underrepresentation in predefined gene sets derived from Gene Ontology, KEGG, 
National Cancer Institute, PFAM, Biocarta, Reactome and WikiPathways pathway 
databases. Only gene sets consisting of more than 15 and fewer than 500 genes 
were taken into account. Statistical significance of GSEA results was determined 
using 1,000 permutations. 
SCFA determination by NMR spectroscopy
Plasma samples were diluted 1:1 in a 75 mM phosphate buffer (pH 7.4) and filtered 
using Nanosep centrifugal devices with Omega Membrane (Pall Corporation). The 
molecular weight cut-off of the filter was 10K. Subsequently, 200 µL of the eluate 
was transferred to a 3 mm NMR tube (Bruker match system). Samples were stored at 
-20 ⁰C until analysis using NMR spectroscopy. Before NMR measurements, samples 
were slowly warmed up to room temperature and measured at 310 K (calibrated 
temperature) in an Avance III NMR spectrometer operated at 600.13 MHz. After 
transfer of each sample into the magnet, the sample was equilibrated at 310 K for 
5 min. Subsequently automated locking, automated shimming and automated 90 
degree pulse angle determination was performed. 1H NMR NOESY datasets were 
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acquired for each sample. In addition, each dataset was automatically processed 
and aligned using the alanine signal (upfield resonance of the alanine doublet signal) 
at 1.49 ppm. From the aligned spectra, integrals for resonances of the metabolites 
of interest were selected and quantified. Concentrations of metabolites were 
calculated based on the number of hydrogens for each metabolite selected.
Multivariate analysis microbiota
To relate changes in total bacterial community composition to diet (DS or RS), 
period, and the interaction of period and diet, redundancy analysis (RDA) and 
Principal response curves were used as implemented in the CANOCO 5 software 
package (Biometris). RDA is the canonical form of principle component analysis 
and is a multivariate linear regression method where several response parameters 
are related to the same set of environmental variables. The signal intensities for 
151 genus-level phylogenetic groups of PITChip were used as responsive variables. 
Partial RDA was employed to analyse the effect of diet on microbiota. RDA was 
performed by centering the species and samples, using freely exchangeable whole-
plot Permutations.
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Supplemental Tables and Figures
Supplemental Table 1. Ingredient and nutrient composition of the experimental diets. 
   DS RS
Ingredient composition (g/kg)   
Pregelatinized purified potato starch1   350.0 0.0
Retrograded tapioca starch2  0.0 342.6
Soy oil  29.2 29.5
Wheat  200.0 202.3
Beet pulp (sugar<100 g/kg) 50.0 50.6
Barley  150.0 151.7
Wheat gluten meal  60.0 60.7
Potato protein3  100.0 101.1
Premix4  10.0 10.1
CaCO3  13.5 13.7
Ca(H2PO4)2   11.0 11.1
NaCl  3.0 3.0
L‐lysine HCl  2.2 2.2
L‐tryptophan  0.2 0.2
MgO (80%)  0.4 0.4
NaHCO3  14.0 14.2
KCl  3.0 3.0
TiO2  2.0 2.0
Flavor5  1.5 1.5
Nutrient (g/kg dry matter)
Dry matter (g/kg)  894.5 910.0
Organic matter  941.4 941.9
Crude protein (N x 6.25)  190.9 194.3
Crude fat  16.1 28.6
Starch  524.7 477.1
Sugar  13.1 69.4
TiO2  1.6 1.6
Energy content (MJ/kg) 
GE  16.48 16.78
DS, digestible starch diet; RS, resistant starch diet. 
1
PaselliTM WA4, Avebe Food, Veendam, the Netherlands.  
2
C*Actistar 11700, Cargill, Amsterdam, the Netherlands. 
3
Protostar, Avebe Food, Veendam, the Netherlands. 
4Provided  the  following per kg of  feed: vitamin A: 7500  IU; vitamin D3: 1500  IU; vitamin E: 60 mg; 
vitamin K3: 1.0 mg; vitamin B1: 1.0 mg; vitamin B2: 4.0 mg; vitamin B6: 1.0 mg; vitamin B12: 20 µg; 
niacin: 20 mg; calcium‐D pantothenate: 10.5 mg; choline chloride: 100 mg; folic acid: 0.4 mg; Fe: 120 
mg (FeSO4.H2O); Cu: 15 mg (CuSO4.5H2O); Mn: 60 mg (MnO); Zn: 75 mg (ZnSO4.H2O);  I: 4.0 mg (KI); 
Se: 0.30 mg (Na2SeO3); anti‐oxidant: 75 mg. 
5
Luctarom Advance Cherry Honey, Lucta S.A., Barcelona, Spain. 
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Supplemental Table 2. An overview of all significantly regulated genes (P <0.01) will become 
available online.
Supplemental Figure 1.
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Supplemental Figure 1 (continued).
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Supplemental Figure 1 (continued).
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Enrichment map indicating positively and negatively enriched gene sets. Nodes represent 
functional gene sets, and edges between nodes their similarity. Black nodes indicate 
increased and white nodes indicate suppressed gene sets in the RS group compared with 
the DS group. Node size represents the gene set size, and edge thickness represent degree 
of overlap between 2 connected gene sets. Clusters were manually circled and labelled to 
highlight the prevalent biological functions among related gene sets.
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Supplemental Figure 2.
The abundance of the phyla Bacteroidetes and Firmicutes (A) and the ratio Firmicutes/
Bacteroidetes (B) in pigs fed DS or RS for 2 wk, as determined by PITChip. Data are presented 
as means ± SEM, n = 9 per treatment. * indicates P <0.05. DS, digestible starch; RS, resistant 
starch.
Supplemental Figure 3.
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Supplemental Figure 2 
Total SCFAs (A) and percentage of BCFAs from total SCFAs (B) measured in luminal content 
from proximal colon, collected 30 min before feeding (-30) and 300 min after feeding in 
pigs fed the DS and the RS diet. Data are presented as means ± SEM, n = 10 per treatment. 
** indicates P <0.01. BCFAs, branched-chain fatty acids; DS, digestible starch; RS, resistant 
starch.
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Supplemental Figure 4.
Total SCFAs (A) and percentage of BCFAs from total SCFAs (B) measured in luminal content 
from different segments of the gastrointestinal tract in pigs fed the DS or the RS diet. Data 
are presented as means ± SEM, n = 5 per treatment. * indicates P <0.05, ** indicates P <0.01. 
BCFAs, branched-chain fatty acids; DS, digestible starch; RS, resistant starch; ileum, IL; 
caecum, CA; proximal colon, pCO; middle colon, mCO; distal colon, dCO.
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Supplemental Table 3. Potentially secreted proteins. 
Name  Gene symbol  Entrez ID  Mean log2 FC1  Protein ID  Prob
2 
Insulin‐like growth factor 1 (somatomedin C)  IGF1   3479  0.62  Q5U743  0.78 
Bone morphogenetic protein 4  BMP4   652  0.19  P12644  0.63 
Pancreatic lipase‐related protein 2  PNLIPRP2   5408  0.67  P54317  0.62 
Wingless‐type MMTV integration site family, member 2B  WNT2B   7482  0.44  Q93097  0.61 
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3C  SEMA3C   10512  0.36  Q99985  0.60 
Dermatopontin  DPT   1805  0.58  Q07507  0.60 
Bone morphogenetic protein 2  BMP2   650  0.33  P12643  0.57 
Resistin like beta  RETNLB   84666  0.64  Q9BQ08  0.57 
Proline/arginine‐rich end leucine‐rich repeat protein  PRELP   5549  0.58  P51888  0.57 
Bone morphogenetic protein 5  BMP5   653  0.41  P22003  0.57 
Tubulointerstitial nephritis antigen  TINAG   27283  0.52  Q9UJW2  0.54 
Angiotensinogen (serpin peptidase inhibitor, clade A, member 8)  AGT   183  0.87  B2R5S1  0.54 
Gastric intrinsic factor (vitamin B synthesis)  GIF   2694  0.49  P27352  0.54 
ADAM metallopeptidase domain 23  ADAM23   8745  0.76  O75077  0.53 
Vascular endothelial growth factor A  VEGFA   7422  0.37  P15692  0.52 
Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase  CILP  8483  0.56  O75339  0.51 
EGF containing fibulin‐like extracellular matrix protein 1  EFEMP1   2202  0.67  Q12805  0.47 
Guanylate cyclase activator 2A (guanylin)  GUCA2A   2980  0.66  Q02747  0.44 
Signal peptide, CUB domain, EGF‐like 1  SCUBE1   80274  0.34  A0JP65  0.43 
Peptidase domain containing associated with muscle regeneration 1  PAMR1   25891  0.33  Q6UXH9  0.42 
Guanylate cyclase activator 2B (uroguanylin)  GUCA2B   2981  1.02  Q16661  0.42 
Protocadherin‐related 15  PCDH15   65217  0.40  A2A3E3  0.42 
Transmembrane protease, serine 2  TMPRSS2   7113  0.35  O15393  0.37 
Collagen, type VI, alpha 6  COL6A6   131873  0.85  A6NMZ7  0.33 
Lysophosphatidic acid receptor 2  LPAR2  9170  0.31  Q9HBW0  0.31 
Collagen, type XIV, alpha 1  COL14A1   7373  0.45  Q05707  0.31 
Transmembrane protease, serine 4  TMPRSS4   56649  0.48  B7Z8C5  0.30 
EPH receptor A3  EPHA3  2042  0.52  P29320  0.29 
Angiopoietin‐like 4  ANGPTL4   51129  0.58  Q9BY76  0.27 
Thrombospondin 3  THBS3   7059  0.48  B4DQ20  0.22 
Slit homolog 3 (Drosophila)  SLIT3   6586  0.41  O75094  0.20 
Complement component 2  C2   717  ‐0.47  E9PFN7  0.66 
Granulin  GRN   2896  ‐0.19  P28799  0.61 
Complement component 4B (Chido blood group)  C4B   721  ‐0.58  P0C0L5  0.60 
Complement factor H  CFH   3075  ‐0.47  F8WDX4  0.59 
Serpin peptidase inhibitor, clade A, member 1  SERPINA1   5265  ‐0.60  P01009  0.58 
Peptidase inhibitor 3, skin‐derived  PI3   5266  ‐0.49  P19957  0.57 
Lymphocyte antigen 96  LY96  23643  ‐0.58  Q9Y6Y9  0.57 
Apolipoprotein D  APOD   347  ‐0.43  P05090  0.56 
Complement component 4 binding protein, alpha  C4BPA   722  ‐0.62  P04003  0.53 
Complement component 4 binding protein, beta  C4BPB   725  ‐0.39  P20851  0.53 
Acyloxyacyl hydrolase (neutrophil)  AOAH   313  ‐0.63  P28039  0.50 
Clusterin  CLU   1191  ‐0.63  P10909  0.49 
Chromogranin B (secretogranin 1)  CHGB   1114  ‐0.55  P05060  0.46 
EMI domain containing 1  EMID1   129080  ‐0.40  Q96A84  0.43 
Olfactomedin 4  OLFM4   10562  ‐0.22  Q6UX06  0.42 
Poliovirus receptor‐related 4  PVRL4   81607  ‐0.75  Q96NY8  0.41 
Chemokine (C‐X‐C motif) ligand 14  CXCL14   9547  ‐0.26  O95715  0.36 
Polymeric immunoglobulin receptor  PIGR   5284  ‐0.30  P01833  0.35 
Bactericidal/permeability‐increasing protein  BPI   671  ‐0.39  P17213  0.34 
Serine peptidase inhibitor, Kazal type 4  SPINK4   27290  ‐0.34  O60575  0.33 
Cathepsin K  CTSK  1513  ‐0.25  P43235  0.25 
ADAM metallopeptidase domain 17  ADAM17  6868  ‐0.22  P78536  0.23 
1 Average log2 fold changes of the signal intensity of RS compared with DS. 
2  Probability  that  the  listed  protein  is  present  extracellularly  (secreted),  as  determined  by  ngLOC. 
Only proteins with a probability above 0.20 are listed.
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Abstract
Acetate, propionate and butyrate are the main short-chain fatty acids (SCFAs) 
produced in the colon as a result of microbial fermentation of dietary fibres, and are 
believed to exert major health benefits. The composition of the microbiome is altered 
by dietary fat, which is believed to impact SCFA production. Currently it is unknown 
whether host gene expression responses to SCFAs are modulated by dietary fat 
content. The study aim was to compare changes in colonic gene expression profiles 
after acetate, propionate and butyrate infusions between a low fat and high fat diet, 
with focus on metabolic genes. Male C57BL/6J mice were fed a semi-synthetic low 
or high fat diet starting 2 wk before the SCFA treatment period. During treatment, 
mice received a rectal infusion of either an acetate, propionate, butyrate, or a saline 
(control) solution for 6 consecutive days, after which colon was subjected to gene 
expression profiling. Unsupervised visualization of the dataset was performed using 
Independent Principal Component Analysis. For each SCFA, similarities of effects 
on a low fat and a high fat diet were assessed using Rank-rank Hypergeometric 
Overlap. In addition, differentially expressed genes were identified, and gene set 
enrichment analysis was performed to determine functional implications of the 
regulated genes. Taking into account the complete dataset, we observed that more 
variation in gene expression profiles was explained by dietary fat content than by 
SCFA treatment. Gene expression responses to acetate and butyrate were similar 
on the low fat and high fat diet, but were reversed for propionate. Functionally, 
expression changes reflected differential modulation of several metabolic and 
immune processes; genes involved in oxidative phosphorylation, lipid catabolism, 
lipoprotein metabolism and cholesterol transport were suppressed by acetate and 
butyrate treatment, whereas propionate treatment resulted in changes in fatty 
acid and sterol biosynthesis, and in amino acid and carbohydrate metabolism. In 
conclusion, dietary fat content impacts the colonic gene expression response to 
propionate, and to a lesser extent to acetate and butyrate. Each SCFA modifies the 
expression of distinct, partially overlapping sets of genes. Knowledge on dietary fat 
content is essential when studying effects of SCFAs on metabolism.
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Introduction
The gut microbiota is highly important for metabolic homeostasis and health, as 
it was found to play a crucial role in the regulation of energy homeostasis and fat 
storage (38, 39). The first evidence supporting this statement was derived from 
studies in germ-free mice, showing that conventionally raised mice have 42% more 
total body fat compared to germ-free mice, and conventionalization of germ-free 
mice resulted in a 57% increase in total body fat (40). Furthermore, germ-free mice 
were found to be protected from the development of obesity after consuming a high 
fat diet (41). The relationship between microbiota composition and fat storage has 
also been studied in humans, indicating that obese people have fewer Bacteroidetes 
compared to lean controls (42). In these obese subjects, the relative abundance of 
Bacteroidetes increased while the abundance of Firmicutes decreased with weight 
loss (42). 
 A Western-type diet typically contains high amounts of fat, and dietary fat 
content was shown to have a major impact on microbiota composition in the colon 
(43, 48). For instance, mice consuming a high fat diet displayed reduced numbers 
of Bacteroidetes and increased numbers of Firmicutes and Proteobacteria (48). 
Besides changing the microbiota composition, a high fat diet was also previously 
shown to alter small intestinal gene expression profile compared to a low fat diet 
(167).
 Various studies have shown that modification of dietary patterns can have 
substantial impact on the development of obesity and the metabolic syndrome 
(6, 80). In the prevention of these metabolic abnormalities, dietary fibre is an 
extensively studied food component for its potential role in the management of 
food intake and body weight (81). The consumption of fibres was shown to prevent 
the accumulation of fat mass (82, 83), to increase insulin sensitivity (9, 84) and to 
enhance satiety (12, 14). Several types of dietary fibre, including resistant starch, 
pectin and inulin, are highly fermentable by the microbiota in the colon, resulting in 
the production of short-chain fatty acids (SCFAs). An increasing amount of evidence 
suggests that the health benefits observed with dietary fibre consumption are 
partly due to the action of these SCFAs (53). The three main SCFAs produced in the 
colon are acetate, propionate and butyrate, and each SCFA has distinct biological 
properties and can affect metabolism and health in a specific way. Butyrate is almost 
entirely utilized by colonocytes as their preferred energy substrate and therefore 
only a small proportion reaches the systemic circulation (168, 169). Butyrate 
was found to play an important role in the prevention and inhibition of colon 
carcinogenesis, the protection against mucosal oxidative stress, strengthening of 
the colonic defence barrier and it was found to have anti-inflammatory properties 
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(55). Acetate and propionate are less efficiently used by the colon and can serve as 
anabolic substrates in tissues other than colon (61, 62, 87). 
 Potential health benefits of dietary and bioactive compounds can be 
studied by measuring their effects on colonic gene expression profiles (73, 170). 
Regarding SCFAs it has been observed that colonic administration of butyrate 
enhances the maintenance of homeostasis in healthy humans, by regulating fatty 
acid metabolism, electron transport and oxidative stress pathways (139). However, 
the effects of acetate nor propionate, nor the potential modulating effect of dietary 
fat content has been investigated.
 In the current study we therefore aimed to determine the effect of dietary 
fat content on changes in gene expression profile in colon after colonic acetate, 
propionate and butyrate administration. The experiment was performed in mice 
that were fed either a low fat or a high fat diet before and during SCFA treatment. 
Mice were treated with SCFAs received by rectal infusion on 6 consecutive days, 
after which the colonic epithelial cells were isolated to measure gene expression 
profiles.
 This is the first experiment in which the effect of colonic SCFA administration 
on a low fat or a high fat diet background was studied using a comprehensive 
gene expression profiling approach. We demonstrate that fat content had a major 
impact on gene expression response to SCFAs in colon. In addition, we show which 
functional implications are involved in the discriminating effects of the background 
diets.
Materials and Methods
Ethics statement
The institutional and national guidelines for the care and use of animals were 
followed and the experiment was approved by the Local Committee for Care and 
Use of Laboratory Animals at Wageningen University.
Animals and diets
Male C57BL/6J mice were purchased from Charles River Laboratories at 8 wk of age. 
Mice were housed individually in a light- and temperature-controlled animal facility, 
with light on from 23:00 h to 11:00 h. Mice had free access to water and food, and 
24h food intake was monitored in every cage. Mice received standard laboratory 
chow (RMH-B, Arie Blok) during the first 2 wk after arrival. Subsequently, mice were 
switched to semi-synthetic diets, either containing 10 en% of fat (low fat diet; LFD; n 
= 24) or 45 en% of fat (high fat diet; HFD; n = 24). Diets were based on Research Diets 
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formulas D12450B/D12451, with adaptations regarding type of fat (palm oil instead 
of lard) and carbohydrates to mimic the fatty acid and carbohydrate composition of 
the average human diet in Western societies. Diets were prepared by Research Diet 
Services. The complete composition of the diets is shown in Table 1. 
Table 1 Composition of the experimental diets. 
  LFD HFD 
  g%  kcal% g% kcal%
Protein  19  20 24 20
Carbohydrate  67  70 41 35
Fat  4  10 24 45
Total    100 100
kcal/g  3.85  4.73  
Ingredient  g  kcal g kcal
Casein, lactic  200  800 200 800
L‐Cystine  3  12 3 12
Corn starch  427.2  1,709 72.8 291
Maltodextrin  100  400 100 400
Sucrose  172.8  691 172.8 691
Cellulose, BW200 
Soybean oil 
50 
25 
0
225 
50
25 
0 
225 
Palm oil  20  180 177.5 1,598
Mineral mix S10026*  10  0 10 0 
Dicalcium phosphate 
Calcium carbonate 
13 
5.5 
0
0 
13
5.5 
0 
0 
Potassium citrate, 1 H2O  16.5  0 16.5 0 
Vitamin mix V10001#  10  40 10 40
Choline bitartrate  2  0 2 0 
Total  1,055  4,057 858.1 4,057
LFD, low fat diet; HFD, high fat diet. *Mineral mix S10026 contains the following (g/kg mineral mix): 
41.9 magnesium oxide, 257.6 magnesium sulfate•7H2O, 259 sodium chloride, 1.925 chromium 
KSO4•12H2O, 1.05 cupric carbonate, 0.035 potassium iodate, 21 ferric citrate, 12.25 manganous 
carbonate, 0.035 sodium selenite, 5.6 zinc carbonate, 0.20 sodium fluoride, 0.30 ammonium 
molybdate•4H2O, 399.105 sucrose. 
#Vitamin mix V10001 contains the following (g/kg vitamin mix): 
0.80 retinyl palmitate, 1.0 cholecalciferol, 10 all‐rac‐a‐tocopheryl acetate, 0.08 menadione 
sodiumbisulfite, 2.0 biotin (1.0%), 1.0 cyancocobalamin (0.1%), 0.20 folic acid, 3.0 nicotinic acid, 1.6 
calcium pantothenate, 0.70 pyridoxine‐HCl, 0.60 riboflavin, 0.60 thiamin‐HCl, and 978.42 sucrose. 
SCFA infusions
After 2 wk on either the LFD or HFD, the 6-day treatment period started. Mice were 
assigned to one of 4 treatment groups: Control, Acetate, Propionate or Butyrate. 
On 6 consecutive days, the mice were mildly sedated with a mixture of isofluorane 
(1.5%), nitrous oxide (70%) and oxygen (30%) 2 h before the start of the dark phase, 
where after they received a rectal infusion of the test solutions. At time of infusion, 
mice were kept under sedation. Mice received an 80 µL saline solution (Control; n 
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= 6 per diet group), or an 80 µL saline solution containing 100 mM sodium acetate 
(Acetate; n = 6), 100 mM sodium propionate (Propionate; n = 6) or 100 mM sodium 
butyrate (Butyrate; n = 6). All solutions had a pH of 6.5 and were isotonic. The 
solutions were administered by inserting a gel loading tip 3 cm into the rectum and 
slowly pushing the solution out of the tip. 
Sample collection
Four hours after the rectal infusion on day 6, colon samples were collected. To 
reduce the inter-individual variation in physiological state at time of tissue collection, 
mice were provided a restricted amount of their habitual food (approximately 20% 
of their average daily intake of LFD or HFD) 2 h before tissue removal. Mice were 
anaesthetized with isoflurane, where after the colon was excised and the length 
was measured. The adhering fat around the colon was carefully removed, and 
the colon was cut open longitudinally. The intestinal content was removed and 
the tissue was rinsed with phosphate buffered saline. Subsequently, the epithelial 
lining of the colon was scraped. These scrapings were collected in 1.5 mL Eppendorf 
tubes, which were immediately snap frozen in liquid nitrogen and stored at -80°C 
for subsequent RNA isolation.
RNA isolation and quality control
Total RNA was isolated from colon samples using TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions, followed by RNA Cleanup using 
the RNeasy Micro kit (Qiagen). Concentrations and purity of RNA samples were 
determined on a NanoDrop ND-1000 spectrophotometer (Isogen Life Science). RNA 
quality was verified on an Agilent 2100 Bioanalyzer (Agilent Technologies) using 
6000 Nano Chips according to the manufacturer’s instructions. RNA was judged as 
suitable for array hybridization only if samples exhibited intact bands corresponding 
to the 18S and 28S ribosomal RNA subunits, and displayed no chromosomal peaks 
or RNA degradation products (RNA Integrity Number >8.0).
Microarray hybridization 
Samples were subjected to genome-wide expression profiling using Affymetrix 
Mouse Gene 1.1 ST arrays (Affymetrix). Total RNA (100 ng) was used for whole 
transcript cDNA synthesis using the Ambion WT expression kit (Life Technologies) 
and subsequently labelled using the Affymetrix GeneChip WT Terminal Labeling 
Kit (Affymetrix). Samples were hybridized, washed, stained and scanned on an 
Affymetrix GeneTitan instrument. Detailed protocols for array handling can be found 
in the GeneChip WT Terminal Labeling and Hybridization User Manual (Affymetrix; 
P/N 702808, Rev. 4) and are also available on request. 
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Microarray analysis
Packages from the Bioconductor project (140), integrated in an online pipeline (141), 
were used to analyse the array data. Various advanced quality metrics, diagnostic 
plots, pseudoimages, and classification methods were used to determine the 
quality of the arrays prior statistical analysis (142, 171). One colon sample, derived 
from a mouse on the LFD in the Acetate group, was excluded from analyses because 
the array was of insufficient quality. The 828,268 probes on the Mouse Gene 1.1 ST 
array were redefined utilizing current genome information from the Entrez Gene 
database (custom CDF v16) (143). Array data have been submitted to the Gene 
Expression Omnibus, a database repository for gene expression data hosted at the 
NCBI, under accession number GSE48856.
 Normalized gene expression estimates were obtained from the raw intensity 
values using the Robust Multi-array Average (RMA) preprocessing algorithm 
available in the library ‘AffyPLM’ using default settings (144).
 The Mouse Gene 1.1 ST array probes the expression of 21,225 unique genes. 
Differentially expressed genes (probe sets) were identified using linear models, 
applying moderated t-statistics that implemented empirical Bayes regularization 
of standard errors (library ‘limma’). The moderated t-test statistic has the same 
interpretation as an ordinary t-test statistic, except that the standard errors have 
been moderated across genes, i.e. shrunk to a common value, using a Bayesian 
model (172). To adjust for both the degree of independence of variances relative to 
the degree of identity and the relationship between variance and signal intensity, 
the moderated t-statistic was extended by a Bayesian hierarchical model to define 
an intensity-based moderated T-statistic (IBMT) (145). IBMT improves the efficiency 
of the Empirical Bayes moderated t-statistics and thereby achieves greater power 
while correctly estimating the true proportion of false positives. Probe sets that 
satisfied the criterion of P <0.01 were considered to be significantly regulated. 
 Unsupervised visualization of the full dataset was performed using 
Independent Principal Component Analysis (IPCA), a variant of the classical tool 
PCA that better reflects the internal structure of the data generated of noisy omics 
experiments (173).
 Similarity of the effects of each SCFA on the LFD and HFD was assessed 
using the Rank-rank Hypergeometric Overlap (RRHO) algorithm (174). RRHO is a 
threshold-free method which visualizes the overlap between 2 ranked lists of 
differentially expressed genes. In brief, genes differentially expressed between SCFA 
infusion and the control treatment were ranked according to their IBMT t-statistic. 
The hypergeometric P value of overlap was calculated to determine the significance 
of overlapping genes between 2 datasets which is visualized in a matrix. On the 
x-axis of the matrix, genes were ranked by their degree of differential regulation 
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(top up to bottom down) between SCFA infusion on the LFD and the control infusion 
on the LFD. On the y-axis genes were ranked based on their expression change with 
SCFA treatment on the HFD compared to control.
Analysis of functional implications
Changes in gene expression were related to functional changes using gene set 
enrichment analysis (GSEA) (146). GSEA has the advantage that it is unbiased, 
because no gene selection step is used, and a score is computed based on all 
genes in a gene set. Briefly, genes were ranked based on the IBMT-statistic and 
subsequently analysed for over- or underrepresentation in predefined gene sets 
derived from Gene Ontology, KEGG, National Cancer Institute, PFAM, Biocarta, 
Reactome and WikiPathways pathway databases. Only gene sets consisting of more 
than 15 and fewer than 500 genes were taken into account. Statistical significance 
of GSEA results was determined using 1,000 permutations. The Enrichment Map 
plugin for Cytoscape was used for visualization and interpretation of the GSEA 
results (147, 148).
 To identify the cascade of upstream transcriptional regulators that may 
explain the observed gene expression changes in the dataset, Upstream Regulator 
Analysis was performed using Ingenuity Pathway Analysis (IPA; Ingenuity Systems).
Statistics
Results on food intake and body weight were expressed as means ± SEM, regarding 
P <0.05 as statistically significant.
Results
Food intake and body weight development
At the start of the 2-wk intervention on the LFD and HFD, mice were stratified into 2 
groups based on body weight, that averaged 22.7 g in both groups. Mice fed the HFD 
consumed the same amount of food as mice receiving the LFD (3.11 ± 0.08 versus 
3.09 ± 0.04 g per day, respectively). However, since the HFD contained more energy 
per gram, the caloric intake was significantly higher in mice fed the HFD compared 
to mice fed the LFD (14.8 ± 0.36 versus 11.9 ± 0.14 kcal per day, respectively; P 
<0.0001). During the treatment period, caloric intake of mice on the HFD remained 
significantly higher compared to mice fed the LFD (Table 2). SCFA treatment did not 
significantly affect caloric intake within both diet groups.
 After the 2-wk intervention, body weight of mice fed the HFD was 
significantly higher compared to mice fed the LFD (26.6 ± 0.31 versus 23.9 ± 0.24 
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g respectively; P <0.0001), which is in line with the observed difference in caloric 
intake between the 2 diet groups. During the SCFA treatment period, body weight 
change was similar with all SCFA treatments (data not shown).
Table 2 Daily food intake during the SCFA treatment period in mice fed the LFD or the HFD. 
    Daily food intake (g) Daily food intake (kcal) 
LFD  Control  3.03 ± 0.076 11.67 ± 0.294 
  Acetate  2.98 ± 0.118 11.48 ± 0.453 
  Propionate  3.08 ± 0.114 11.84 ± 0.439 
  Butyrate  2.89 ± 0.076 11.14 ± 0.293 
  Average all treatments  3.00 ± 0.049 11.54 ± 0.188 
HFD  Control  2.71 ± 0.095 12.80 ± 0.450 
  Acetate  2.70 ± 0.097 12.77 ± 0.457 
  Propionate  2.57 ± 0.084 12.17 ± 0.400 
  Butyrate  2.48 ± 0.100 11.73 ± 0.474 
  Average all treatments  2.61 ± 0.047** 12.37 ± 0.224** 
Values are means ± SEM, n = 6 per diet group, ** indicates a significant difference between average 
daily food intake in mice fed the LFD compared to mice fed HFD (P <0.01). LFD, low fat diet; HFD, high 
fat diet. 
Dietary fat drives variation in SCFA-induced gene expression changes
After the SCFA treatment period, gene expression in colonic scrapings was profiled on 
microarrays. IPCA revealed that most variation in the dataset was due to fat content 
of the diet, since  on the first dimension LFD and HFD samples clustered together 
(Fig. 1). The IPCA plot did not show a clear clustering based on SCFA treatment, 
indicating that dietary fat content was the major factor driving differences in gene 
expression profiles. 
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Figure 1 IPCA plot colonic gene 
expression profile. Independent 
principle component analysis 
(IPCA) was used to plot the 
variation of normalized gene 
expression among the samples. 
The first 2 dimensions, explaining 
the highest variation, are shown. 
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Characterization of overlap between LFD and HFD
To characterize the similarity of the transcriptional responses to SCFA treatment 
on the LFD and HFD, RRHO analysis was applied. As indicated by the RRHO P value 
heatmaps, the response to acetate or butyrate was rather similar on both diets (Fig. 
2A and 2C respectively). For acetate we noticed in the RRHO heatmap a significant 
(yellow-red) area across the bottom left to top right diagonal of the map (Fig. 2A). 
This showed that the gene ranking in both lists was similar, indicating that the genes 
regulated by acetate on either the LFD or HFD were the same, even in case of a 
different extent of regulation. For butyrate treatment a comparable RRHO heatmap 
was observed, although the significance area was more pronounced in the top-right 
area (Fig. 2C), which suggested a higher similarity between the LFD and the HFD 
for genes suppressed by butyrate than for genes induced by butyrate. In contrast, 
for propionate treatment a completely different RRHO heatmap was observed (Fig. 
2B). A significant (blue-purple) area was observed mainly in the upper left quarter 
of the heatmap that further extended to bottom right of the diagonal. Since RRHO 
conventions state a strong negative signal should be interpreted as a strong positive 
trend in the opposite sense (174), these results showed that genes induced by 
propionate on the LFD were suppressed on the HFD. For the inversely regulated 
genes (i.e. suppressed on the LFD and increased on the HFD) this effect was less 
pronounced. In summary, the global, cutoff-free RRHO analysis indicated that 
dietary fat content mostly impacted the regulation of propionate-responsive genes, 
and to a lesser extent genes regulated by acetate and butyrate.
 Next we used a significance cut-off (P <0.01) to determine the number 
of genes regulated by acetate, propionate or butyrate treatment as compared to 
the control infusion. Because we were interested in the modulatory role of dietary 
fat, Venn diagrams were created to compare regulation on LFD and HFD. Acetate 
treatment resulted in the differential expression of 151 genes in mice fed the LFD, 
and 138 genes were changed in mice fed the HFD (Fig. 2D). Two genes were regulated 
on both the LFD and the HFD (Cnih2 and Zfp367). Propionate treatment modified 
the expression of 214 genes in the LFD group, whereas almost twice as many genes, 
i.e. 440, were changed in mice fed the HFD (Fig. 2E). Of the 29 overlapping genes, 
25 were changed in opposite direction when comparing HFD with LFD, which is 
in line with the result of RRHO analysis. Among the 12 genes that were induced 
in the LFD group and suppressed in the HFD group were genes involved in energy 
homeostasis (Echs1, Gcdh, Hibadh, Ndufs7 and Nmnat1). Vice versa, among the 13 
genes that were suppressed by propionate in the LFD group and induced in the HFD 
group were small nuclear RNAs (snRNAs; Rnu12 and Rnu3a) and small nucleolar 
RNAs (snoRNAs; Snora31, Snora7a and Snord35b). Butyrate treatment resulted in 
250 regulated genes on the LFD, and 267 genes on the HFD, with 8 genes (Apoa2, 
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Apoc2, Cd19, Cd22, Cd72, Fcer2a, Gpx4 and Rnu3a) being regulated on both diets 
(Fig. 2F). In addition, Venn diagrams showed that both on the LFD and HFD, the 
number of overlapping genes between SCFA treatments was limited (Supplemental 
Fig. 1).
 Taken together, these results showed that the effects of the SCFAs on 
gene expression were dependent on dietary fat, and that each SCFA modifies the 
expression of a distinct, partially overlapping set of genes.
LFD HFD
136149 2
LFD HFD
2214 29 440
A 
LFD HFD
2242 8 259
C B 
D E F 
Figure 2 
Figure 2 Effects of dietary fat on colonic gene expression. Heatmaps of Rank–rank 
Hypergeometric Overlap (RRHO) analysis of the effect of 6-day acetate (A), propionate 
(B) and butyrate (C) infusion on colonic gene expression, and Venn diagrams showing 
the number of significantly regulated genes (P <0.01) in the colon of mice after 6 d 
of rectal infusion of acetate (D), propionate (E) or butyrate (F). For RRHO analysis 
the full dataset was used to determine the overlap between the transcriptional 
responses on the LFD and the HFD after SCFA infusion. The plots indicate the pattern 
of overlap between the LFD and the HFD background. Differentially regulated genes 
for each SCFA infusion on HFD versus LFD background were ranked based on IBMT t 
value and plotted along the axis, with the X-axis representing the LFD and the Y-axis 
representing the HFD. Colour represents the degree of hypergeometric distribution 
(Benjamini and Yekutieli-corrected signed log10 transformed P value of overlap). 
Each Venn diagram shows the number of regulated genes on a LFD background, on 
a HFD background and the number of genes regulated on both dietary backgrounds. 
Effects of SCFA infusion were compared with effects after saline infusion in mice fed 
the same background diet (LFD or HFD).
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Functional implications of gene expression changes
GSEA was performed to determine which biological processes were affected by the 
SCFA treatments. Results on the LFD and HFD were jointly visualized in enrichment 
maps (Supplemental Fig. 2). 
 Acetate infusion changed gene sets in the same direction in the LFD and the 
HFD group (Supplemental Fig. 2A). Immune response (e.g. lymphocyte activation, 
cytokine production, positive regulation of immune response and antigen processing 
and presentation) was induced by acetate and among the suppressed processes 
were cell cycle (e.g. mitosis and KEGG: DNA Replication), lipid metabolism (e.g. 
cholesterol transport, lipoprotein metabolic process, lipid homeostasis and 
acylglycerol catabolic process), and oxidative phosphorylation (e.g. mitochondrial 
respiratory chain). 
 With propionate treatment, the direction of gene set enrichment was 
highly dependent on the fat content of the diet (Supplemental Fig. 2B). Processes 
increased on the LFD and suppressed on the HFD include DNA replication, DNA 
repair, WiP: Mm_Fatty_Acid_Biosynthesis, amino acid metabolism (e.g. WiP: 
Mm_Tryptophan_metabolism, KEGG: Histidine metabolism, and KEGG: Valine, 
leucine, and isoleucine degradation) and carbohydrate metabolism (REACT: Glucose 
metabolism and REACT: Metabolism of carbohydrates). Translation (e.g. REACT: 
Translation and KEGG: Ribosome) and oxidoreductase activity (e.g. heme-copper 
terminal oxidase activity) were suppressed in the LFD and induced in the HFD 
group. In addition, immune-related processes (e.g. lymphocyte activation, cytokine 
binding and B cell receptor signaling pathway) were increased by propionate with 
both diets. 
 Similarly, in both diet groups butyrate treatment resulted in induction of 
the immune response (e.g. positive regulation of immune system process, T cell 
activation, B cell activation and antigen processing and presentation). Furthermore, 
mRNA processing and chromatin modification were increased by butyrate, whereas 
lipid metabolism (e.g. lipid homeostasis, regulation of cholesterol transport and 
triglyceride-rich lipoprotein particle) and oxidative phosphorylation (e.g. KEGG: 
Oxidative phosphorylation and REACT: Respiratory electron transport) were 
suppressed by butyrate (Supplemental Fig. 2C). 
Metabolic implications
After studying all biological processes changed by SCFA treatment, we focused on 
the metabolic processes altered by the different treatments (Fig. 3A). In general, 
oxidative phosphorylation, digestive processes (e.g. digestion, digestive system 
process and intestinal absorption), and lipid-related processes were suppressed by 
acetate and butyrate treatment. Regarding the lipid-related processes, on both dietary 
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backgrounds acetate and butyrate inhibit lipid catabolism (e.g. neutral lipid catabolic 
process and acylglycerol catabolic process), lipoprotein metabolism (e.g. protein-
lipid complex remodeling and triglyceride-rich lipoprotein particle) and cholesterol 
transport. Propionate treatment resulted in increased fatty acid biosynthesis on the 
LFD background, while suppressing this process on a HFD background. On the HFD, 
propionate also decreased sterol biosynthesis. Furthermore, propionate was shown 
to affect amino acid metabolism and carbohydrate metabolism, with an induction 
on the LFD and suppression in the HFD group.
 Subsequently we determined which of the genes present in the enriched 
metabolic gene sets were robustly regulated (P <0.01). In total 121 genes were 
changed in at least one treatment condition. These genes were clustered on 
expression rations, and this revealed 2 main clusters that separated according to 
LFD and HFD (data not shown). Within these diet clusters, acetate and butyrate 
were most similar to each other and differed from propionate. To further compare 
the metabolic genes responsive to SCFAs independent of the dietary background, 
overlap analysis was performed for genes robustly regulated by each SCFA on either 
the LFD or the HFD (Fig. 3B). Overlap between all 3 SCFAs was found for 2 genes 
(Fabp1 and Slc2a2) which were suppressed with SCFAs on the LFD. In addition, 11 
genes were commonly regulated by acetate and butyrate on the LFD. Acetate and 
propionate shared only one gene (Bckdhb) and propionate and butyrate commonly 
regulated 9 genes. Overall, the 23 commonly regulated genes are mainly involved 
in lipid transport (Apoa4, Apoa1, Apoc3, Apoc2, Npc1l1, Mttp, Plb1, Mogat2 and 
Rbp2), glucose homeostasis (G6pc and Slc2a2) and, in particular with propionate 
and butyrate treatment, in the generation of energy, i.e. mitochondrial metabolism 
(Idh3b, Acaa2, Echdc2, Hibadh, H2-Ke6, Ndufs7, Uqcr10 and Cox6a1). No overlapping 
genes between SCFAs were found on the HFD. 
 Besides metabolic genes commonly regulated by SCFAs, we identified 
metabolic genes specifically regulated by one SCFA (highlighted in Fig. 3B). The 
highest proportion of specifically regulated genes was found for propionate. 
These genes were only changed on the HFD and were mainly involved in fatty 
acid metabolism (Acaa1b and Acot7), mitochondrial metabolism (Cox4i1, Ndufa7, 
Atp6v1d, Atp6v1a, Atp6v0d1, Cyc1, Slc25a1 and Slc25a11) and amino acid 
metabolism (Maob, Lap3, Aldh9a1, Got1 and Tdh). Similarly, on the LFD propionate 
specifically regulated genes involved in fatty acid metabolism (Acsl1 and Acot2) and 
amino acid metabolism (Hnmt, Bhmt, Aldh7a1 and Alas2). However, whereas the 
majority of genes changed with propionate on the HFD were suppressed (25 vs. 9 
genes induced), most genes were induced (9 vs. 2 genes suppressed) in the LFD 
group. Four of the propionate-specific genes were commonly regulated in opposite 
direction depending on the fat content of the diet (Gcdh, Echs1, Cyb5r3 and Nmnat). 
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 Taken together, although we observed more overlap of effects of SCFAs 
infused on the LFD, a more divergent set of genes was induced by SCFAs when 
infused on the HFD. These results support an important role of dietary fat content 
in determining the transcriptional response to SCFA infusion.
 Next we aimed to identify upstream regulators that potentially could 
explain the observed shift in gene expression profile for each SCFA treatment (Table 
3). On the LFD, acetate and butyrate treatment were predicted to significantly 
inhibit HNF4A, whereas propionate might activate the proinflammatory cytokine 
TNF. For butyrate on a HFD, many regulators were expected to change. A number of 
regulators involved in immunity, such as the transcription regulator CEBPB and the 
cytokines CSF2 and IL6, were predicted to be activated.
Control Acetate Propionate Butyrate 
Process HFD vs LFD LFD HFD LFD HFD LFD HFD 
Lipid metabolism               
TG metabolism   down           
Lipid catabolism   down down     down down 
Lipid biosynthesis down     up down     
Membrane lipid biosynthesis           up   
Lipid transport           down   
Mitochondrial LCFA beta oxidation     up         
Lipoprotein metabolism   down down     down   
Cholesterol biosynthesis down       down     
Cholesterol transport   down down     down down 
                
Amino acid metabolism               
Amino acid metabolism       up down     
Tryptophan metabolism       up down     
Histidine metabolism       up down     
Phenylalanine metabolism         down     
Lysine degradation       up down up   
BCAA degradation       up down up   
                
Carbohydrate metabolism               
Carbohydrate metabolism       up down     
Glycolysis and gluconeogenesis         down     
Glucose metabolism       up down     
                
Energy metabolism               
Oxidative phosphorylation down down down     down down 
NAD metabolism       up down     
Propanoate metabolism       up down     
Beta-alanine metabolism         down     
                
Digestion               
Digestive process   down down     down down 
Intestinal absorption down             
Fat digestion and absorption down down down     down down 
Vitamin digestion and absorption   down down     down down 
                
Others               
Monoamine transport   up           
Glutathione metabolism       up down up   
Exopeptidase activity         down     
Aminopeptidase activity         down     
Collagen metabolic process             up 
PPAR signaling pathway down             
                
Figure 3A 
A
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Control Acetate Propionate Butyrate 
Process HFD vs LFD LFD HFD LFD HFD LFD HFD 
Lipid metabolism               
TG metabolism   down           
Lipid catabolism   down down     down down 
Lipid biosynthesis down     up down     
Membrane lipid biosynthesis           up   
Lipid transport           down   
Mitochondrial LCFA beta oxidation     up         
Lipoprotein metabolism   down down     down   
Cholesterol biosynthesis down       down     
Cholesterol transport   down down     down down 
                
Amino acid metabolism               
Amino acid metabolism       up down     
Tryptophan metabolism       up down     
Histidine metabolism       up down     
Phenylalanine metabolism         down     
Lysine degradation       up down up   
BCAA degradation       up down up   
                
Carbohydrate metabolism               
Carbohydrate metabolism       up down     
Glycolysis and gluconeogenesis         down     
Glucose metabolism       up down     
                
Energy metabolism               
Oxidative phosphorylation down down down     down down 
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Acetate Propionate Butyrate 
Gene  Entrez ID LFD HFD LFD HFD LFD HFD Gene description 
Slc2a2 20526           solute carrier family 2 (facilitated glucose transporter), member 2 
Fabp1 14080           fatty acid binding protein 1, liver 
Apoc3 11814           apolipoprotein C-III 
G6pc 14377           glucose-6-phosphatase, catalytic 
Nos2 18126           nitric oxide synthase 2, inducible 
Plb1 665270           phospholipase B1 
Npc1L1 237636           NPC1-like 1 
Mttp 17777           microsomal triglyceride transfer protein 
Anpep 16790           alanyl (membrane) aminopeptidase 
Apoa4 11808           apolipoprotein A-IV 
Apoa1 11806           apolipoprotein A-I 
Zdhhc15 108672           zinc finger, DHHC domain containing 15 
Slc22a16 70840           solute carrier family 22 (organic cation transporter), member 16 
Cwh43 231293           cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) 
Ptplb 70757           protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b 
Mgst1 56615           microsomal glutathione S-transferase 1 
Cpt2 12896           carnitine palmitoyltransferase 2 
Atp6v1g2 66237           ATPase, H+ transporting, lysosomal V1 subunit G2 
Oxt 18429           oxytocin 
Farsb 23874           phenylalanyl-tRNA synthetase, beta subunit 
Scp2 20280           sterol carrier protein 2, liver 
Kdm1a 99982           lysine (K)-specific demethylase 1A 
Cox4I1 12857           cytochrome c oxidase subunit IV isoform 1 
Ndufa7 66416           NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a) 
Sirt3 64384           sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. cerevisiae) 
Atp8b3 67331           ATPase, class I, type 8B, member 3 
Dgkd 227333           diacylglycerol kinase, delta 
Cpxm2 55987           carboxypeptidase X 2 (M14 family) 
Apoe 11816           apolipoprotein E 
Acaa1B 235674           acetyl-Coenzyme A acyltransferase 1B 
Cybb 13058           cytochrome b-245, beta polypeptide 
Aldh1a3 56847           aldehyde dehydrogenase family 1, subfamily A3 
Mmp2 17390           matrix metallopeptidase 2 
Gstm1 14862           glutathione S-transferase, mu 1 
Pink1 68943           PTEN induced putative kinase 1 
Gstz1 14874           glutathione transferase zeta 1 (maleylacetoacetate isomerase) 
Hpd 15445           4-hydroxyphenylpyruvic acid dioxygenase 
Ftcd 14317           formiminotransferase cyclodeaminase 
Hnmt 140483           histamine N-methyltransferase 
Bhmt 12116           betaine-homocysteine methyltransferase 
Idh3b 170718           isocitrate dehydrogenase 3 (NAD+) beta 
Hadh 15107           hydroxyacyl-Coenzyme A dehydrogenase 
Sod1 20655           superoxide dismutase 1, soluble 
Aldh7a1 110695           aldehyde dehydrogenase family 7, member A1 
Creg1 433375           cellular repressor of E1A-stimulated genes 1 
Acaa2 52538           acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
Pycr1 209027           pyrroline-5-carboxylate reductase 1 
Idh1 15926           isocitrate dehydrogenase 1 (NADP+), soluble 
Echdc2 52430           enoyl Coenzyme A hydratase domain containing 2 
Sox9 20682           SRY-box containing gene 9 
Ghr 14600           growth hormone receptor 
Dpp7 83768           dipeptidylpeptidase 7 
Acsl1 14081           acyl-CoA synthetase long-chain family member 1 
Gcdh 270076           glutaryl-Coenzyme A dehydrogenase 
Aldh9a1 56752           aldehyde dehydrogenase 9, subfamily A1 
Ppp2Ca 19052           protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 
Echs1 93747           enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 
Cyb5r3 109754           cytochrome b5 reductase 3 
Slc25a11 67863           solute carrier family 25 (mitochondrial carrier oxoglutarate carrier), member 11 
Hibadh 58875           3-hydroxyisobutyrate dehydrogenase 
H2-Ke6 14979           H2-K region expressed gene 6 
Ndufs7 75406           NADH dehydrogenase (ubiquinone) Fe-S protein 7 
Lhpp 76429           phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
Atp6v1d 73834           ATPase, H+ transporting, lysosomal V1 subunit D 
Ppt1 19063           palmitoyl-protein thioesterase 1 
Ctsl 13039           cathepsin L 
Pgcp 54381           plasma glutamate carboxypeptidase 
Kynu 70789           kynureninase (L-kynurenine hydrolase) 
Tlr9 81897           toll-like receptor 9 
Kmo 98256           kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
F2R 14062           coagulation factor II (thrombin) receptor 
Aspdh 68352           aspartate dehydrogenase domain containing 
Ugt2b1 71773           UDP glucuronosyltransferase 2 family, polypeptide B1 
Acot2 171210           acyl-CoA thioesterase 2 
Cyp1a1 13076           cytochrome P450, family 1, subfamily a, polypeptide 1 
Ndufa5 68202           NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 
Apob 238055           apolipoprotein B 
Rdh7 54150           retinol dehydrogenase 7 
Treh 58866           trehalase (brush-border membrane glycoprotein) 
Suox 211389           sulfite oxidase 
Taldo1 21351           transaldolase 1 
Uqcr10 66152           ubiquinol-cytochrome c reductase, complex III subunit X 
Alas2 11656           aminolevulinic acid synthase 2, erythroid 
Akr1d1 208665           aldo-keto reductase family 1, member D1 
Spr 20751           sepiapterin reductase 
Pah 18478           phenylalanine hydroxylase 
Pfkfb4 270198           6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
Baat 12012           bile acid-Coenzyme A: amino acid N-acyltransferase 
Apoa2 11807           apolipoprotein A-II 
Cox6a1 12861           cytochrome c oxidase, subunit VI a, polypeptide 1 
Gpx7 67305           glutathione peroxidase 7 
Nos1 18125           nitric oxide synthase 1, neuronal 
Atp6v1a 11964           ATPase, H+ transporting, lysosomal V1 subunit A 
Cyc1 66445           cytochrome c-1 
Itgav 16410           integrin alpha V 
Lap3 66988           leucine aminopeptidase 3 
Pemt 18618           phosphatidylethanolamine N-methyltransferase 
Atp6v0d1 11972           ATPase, H+ transporting, lysosomal V0 subunit D1 
Tpi1 21991           triosephosphate isomerase 1 
Slc25a1 13358           solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1 
Acot7 70025           acyl-CoA thioesterase 7 
Ace2 70008           angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
Mogat2 233549           monoacylglycerol O-acyltransferase 2 
Enpep 13809           glutamyl aminopeptidase 
Ggt1 14598           gamma-glutamyltransferase 1 
Rbp2 19660           retinol binding protein 2, cellular 
Adh6a 69117           alcohol dehydrogenase 6A (class V) 
Apoc2 11813           apolipoprotein C-II 
Oxct2b 353371           3-oxoacid CoA transferase 2B 
Rdh9 103142           retinol dehydrogenase 9 
Ggh 14590           gamma-glutamyl hydrolase 
Eno3 13808           enolase 3, beta muscle 
Gstm7 68312           glutathione S-transferase, mu 7 
Hsd11b2 15484           hydroxysteroid 11-beta dehydrogenase 2 
Nmnat1 66454           nicotinamide nucleotide adenylyltransferase 1 
Got1 14718           glutamate oxaloacetate transaminase 1, soluble 
Bckdhb 12040           branched chain ketoacid dehydrogenase E1, beta polypeptide 
Tdh 58865           L-threonine dehydrogenase 
Bmp2 12156           bone morphogenetic protein 2 
Maob 109731           monoamine oxidase B 
Abcg5 27409             ATP-binding cassette, sub-family G (WHITE), member 5 
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Acetate Propionate Butyrate 
Gene  Entrez ID LFD HFD LFD HFD LFD HFD Gene description 
Slc2a2 20526           solute carrier family 2 (facilitated glucose transporter), member 2 
Fabp1 14080           fatty acid binding protein 1, liver 
Apoc3 11814           apolipoprotein C-III 
G6pc 14377           glucose-6-phosphatase, catalytic 
Nos2 18126           nitric oxide synthase 2, inducible 
Plb1 665270           phospholipase B1 
Npc1L1 237636           NPC1-like 1 
Mttp 17777           microsomal triglyceride transfer protein 
Anpep 16790           alanyl (membrane) aminopeptidase 
Apoa4 11808           apolipoprotein A-IV 
Apoa1 11806           apolipoprotein A-I 
Zdhhc15 108672           zinc finger, DHHC domain containing 15 
Slc22a16 70840           solute carrier family 22 (organic cation transporter), member 16 
Cwh43 231293           cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) 
Ptplb 70757           protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b 
Mgst1 56615           microsomal glutathione S-transferase 1 
Cpt2 12896           carnitine palmitoyltransferase 2 
Atp6v1g2 66237           ATPase, H+ transporting, lysosomal V1 subunit G2 
Oxt 18429           oxytocin 
Farsb 23874           phenylalanyl-tRNA synthetase, beta subunit 
Scp2 20280           sterol carrier protein 2, liver 
Kdm1a 99982           lysine (K)-specific demethylase 1A 
Cox4I1 12857           cytochrome c oxidase subunit IV isoform 1 
Ndufa7 66416           NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a) 
Sirt3 64384           sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. cerevisiae) 
Atp8b3 67331           ATPase, class I, type 8B, member 3 
Dgkd 227333           diacylglycerol kinase, delta 
Cpxm2 55987           carboxypeptidase X 2 (M14 family) 
Apoe 11816           apolipoprotein E 
Acaa1B 235674           acetyl-Coenzyme A acyltransferase 1B 
Cybb 13058           cytochrome b-245, beta polypeptide 
Aldh1a3 56847           aldehyde dehydrogenase family 1, subfamily A3 
Mmp2 17390           matrix metallopeptidase 2 
Gstm1 14862           glutathione S-transferase, mu 1 
Pink1 68943           PTEN induced putative kinase 1 
Gstz1 14874           glutathione transferase zeta 1 (maleylacetoacetate isomerase) 
Hpd 15445           4-hydroxyphenylpyruvic acid dioxygenase 
Ftcd 14317           formiminotransferase cyclodeaminase 
Hnmt 140483           histamine N-methyltransferase 
Bhmt 12116           betaine-homocysteine methyltransferase 
Idh3b 170718           isocitrate dehydrogenase 3 (NAD+) beta 
Hadh 15107           hydroxyacyl-Coenzyme A dehydrogenase 
Sod1 20655           superoxide dismutase 1, soluble 
Aldh7a1 110695           aldehyde dehydrogenase family 7, member A1 
Creg1 433375           cellular repressor of E1A-stimulated genes 1 
Acaa2 52538           acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
Pycr1 209027           pyrroline-5-carboxylate reductase 1 
Idh1 15926           isocitrate dehydrogenase 1 (NADP+), soluble 
Echdc2 52430           enoyl Coenzyme A hydratase domain containing 2 
Sox9 20682           SRY-box containing gene 9 
Ghr 14600           growth hormone receptor 
Dpp7 83768           dipeptidylpeptidase 7 
Acsl1 14081           acyl-CoA synthetase long-chain family member 1 
Gcdh 270076           glutaryl-Coenzyme A dehydrogenase 
Aldh9a1 56752           aldehyde dehydrogenase 9, subfamily A1 
Ppp2Ca 19052           protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 
Echs1 93747           enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 
Cyb5r3 109754           cytochrome b5 reductase 3 
Slc25a11 67863           solute carrier family 25 (mitochondrial carrier oxoglutarate carrier), member 11 
Hibadh 58875           3-hydroxyisobutyrate dehydrogenase 
H2-Ke6 14979           H2-K region expressed gene 6 
Ndufs7 75406           NADH dehydrogenase (ubiquinone) Fe-S protein 7 
Lhpp 76429           phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
Atp6v1d 73834           ATPase, H+ transporting, lysosomal V1 subunit D 
Ppt1 19063           palmitoyl-protein thioesterase 1 
Ctsl 13039           cathepsin L 
Pgcp 54381           plasma glutamate carboxypeptidase 
Kynu 70789           kynureninase (L-kynurenine hydrolase) 
Tlr9 81897           toll-like receptor 9 
Kmo 98256           kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
F2R 14062           coagulation factor II (thrombin) receptor 
Aspdh 68352           aspartate dehydrogenase domain containing 
Ugt2b1 71773           UDP glucuronosyltransferase 2 family, polypeptide B1 
Acot2 171210           acyl-CoA thioesterase 2 
Cyp1a1 13076           cytochrome P450, family 1, subfamily a, polypeptide 1 
Ndufa5 68202           NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 
Apob 238055           apolipoprotein B 
Rdh7 54150           retinol dehydrogenase 7 
Treh 58866           trehalase (brush-border membrane glycoprotein) 
Suox 211389           sulfite oxidase 
Taldo1 21351           transaldolase 1 
Uqcr10 66152           ubiquinol-cytochrome c reductase, complex III subunit X 
Alas2 11656           aminolevulinic acid synthase 2, erythroid 
Akr1d1 208665           aldo-keto reductase family 1, member D1 
Spr 20751           sepiapterin reductase 
Pah 18478           phenylalanine hydroxylase 
Pfkfb4 270198           6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
Baat 12012           bile acid-Coenzyme A: amino acid N-acyltransferase 
Apoa2 11807           apolipoprotein A-II 
Cox6a1 12861           cytochrome c oxidase, subunit VI a, polypeptide 1 
Gpx7 67305           glutathione peroxidase 7 
Nos1 18125           nitric oxide synthase 1, neuronal 
Atp6v1a 11964           ATPase, H+ transporting, lysosomal V1 subunit A 
Cyc1 66445           cytochrome c-1 
Itgav 16410           integrin alpha V 
Lap3 66988           leucine aminopeptidase 3 
Pemt 18618           phosphatidylethanolamine N-methyltransferase 
Atp6v0d1 11972           ATPase, H+ transporting, lysosomal V0 subunit D1 
Tpi1 21991           triosephosphate isomerase 1 
Slc25a1 13358           solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1 
Acot7 70025           acyl-CoA thioesterase 7 
Ace2 70008           angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
Mogat2 233549           monoacylglycerol O-acyltransferase 2 
Enpep 13809           glutamyl aminopeptidase 
Ggt1 14598           gamma-glutamyltransferase 1 
Rbp2 19660           retinol binding protein 2, cellular 
Adh6a 69117           alcohol dehydrogenase 6A (class V) 
Apoc2 11813           apolipoprotein C-II 
Oxct2b 353371           3-oxoacid CoA transferase 2B 
Rdh9 103142           retinol dehydrogenase 9 
Ggh 14590           gamma-glutamyl hydrolase 
Eno3 13808           enolase 3, beta muscle 
Gstm7 68312           glutathione S-transferase, mu 7 
Hsd11b2 15484           hydroxysteroid 11-beta dehydrogenase 2 
Nmnat1 66454           nicotinamide nucleotide adenylyltransferase 1 
Got1 14718           glutamate oxaloacetate transaminase 1, soluble 
Bckdhb 12040           branched chain ketoacid dehydrogenase E1, beta polypeptide 
Tdh 58865           L-threonine dehydrogenase 
Bmp2 12156           bone morphogenetic protein 2 
Maob 109731           monoamine oxidase B 
Abcg5 27409             ATP-binding cassette, sub-family G (WHITE), member 5 
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Acetate Propionate Butyrate 
Gene  Entrez ID LFD HFD LFD HFD LFD HFD Gene description 
Slc2a2 20526           solute carrier family 2 (facilitated glucose transporter), member 2 
Fabp1 14080           fatty acid binding protein 1, liver 
Apoc3 11814           apolipoprotein C-III 
G6pc 14377           glucose-6-phosphatase, catalytic 
Nos2 18126           nitric oxide synthase 2, inducible 
Plb1 665270           phospholipase B1 
Npc1L1 237636           NPC1-like 1 
Mttp 17777           microsomal triglyceride transfer protein 
Anpep 16790           alanyl (membrane) aminopeptidase 
Apoa4 11808           apolipoprotein A-IV 
Apoa1 11806           apolipoprotein A-I 
Zdhhc15 108672           zinc finger, DHHC domain containing 15 
Slc22a16 70840           solute carrier family 22 (organic cation transporter), member 16 
Cwh43 231293           cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) 
Ptplb 70757           protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b 
Mgst1 56615           microsomal glutathione S-transferase 1 
Cpt2 12896           carnitine palmitoyltransferase 2 
Atp6v1g2 66237           ATPase, H+ transporting, lysosomal V1 subunit G2 
Oxt 18429           oxytocin 
Farsb 23874           phenylalanyl-tRNA synthetase, beta subunit 
Scp2 20280           sterol carrier protein 2, liver 
Kdm1a 99982           lysine (K)-specific demethylase 1A 
Cox4I1 12857           cytochrome c oxidase subunit IV isoform 1 
Ndufa7 66416           NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a) 
Sirt3 64384           sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. cerevisiae) 
Atp8b3 67331           ATPase, class I, type 8B, member 3 
Dgkd 227333           diacylglycerol kinase, delta 
Cpxm2 55987           carboxypeptidase X 2 (M14 family) 
Apoe 11816           apolipoprotein E 
Acaa1B 235674           acetyl-Coenzyme A acyltransferase 1B 
Cybb 13058           cytochrome b-245, beta polypeptide 
Aldh1a3 56847           aldehyde dehydrogenase family 1, subfamily A3 
Mmp2 17390           matrix metallopeptidase 2 
Gstm1 14862           glutathione S-transferase, mu 1 
Pink1 68943           PTEN induced putative kinase 1 
Gstz1 14874           glutathione transferase zeta 1 (maleylacetoacetate isomerase) 
Hpd 15445           4-hydroxyphenylpyruvic acid dioxygenase 
Ftcd 14317           formiminotransferase cyclodeaminase 
Hnmt 140483           histamine N-methyltransferase 
Bhmt 12116           betaine-homocysteine methyltransferase 
Idh3b 170718           isocitrate dehydrogenase 3 (NAD+) beta 
Hadh 15107           hydroxyacyl-Coenzyme A dehydrogenase 
Sod1 20655           superoxide dismutase 1, soluble 
Aldh7a1 110695           aldehyde dehydrogenase family 7, member A1 
Creg1 433375           cellular repressor of E1A-stimulated genes 1 
Acaa2 52538           acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
Pycr1 209027           pyrroline-5-carboxylate reductase 1 
Idh1 15926           isocitrate dehydrogenase 1 (NADP+), soluble 
Echdc2 52430           enoyl Coenzyme A hydratase domain containing 2 
Sox9 20682           SRY-box containing gene 9 
Ghr 14600           growth hormone receptor 
Dpp7 83768           dipeptidylpeptidase 7 
Acsl1 14081           acyl-CoA synthetase long-chain family member 1 
Gcdh 270076           glutaryl-Coenzyme A dehydrogenase 
Aldh9a1 56752           aldehyde dehydrogenase 9, subfamily A1 
Ppp2Ca 19052           protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 
Echs1 93747           enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 
Cyb5r3 109754           cytochrome b5 reductase 3 
Slc25a11 67863           solute carrier family 25 (mitochondrial carrier oxoglutarate carrier), member 11 
Hibadh 58875           3-hydroxyisobutyrate dehydrogenase 
H2-Ke6 14979           H2-K region expressed gene 6 
Ndufs7 75406           NADH dehydrogenase (ubiquinone) Fe-S protein 7 
Lhpp 76429           phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
Atp6v1d 73834           ATPase, H+ transporting, lysosomal V1 subunit D 
Ppt1 19063           palmitoyl-protein thioesterase 1 
Ctsl 13039           cathepsin L 
Pgcp 54381           plasma glutamate carboxypeptidase 
Kynu 70789           kynureninase (L-kynurenine hydrolase) 
Tlr9 81897           toll-like receptor 9 
Kmo 98256           kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
F2R 14062           coagulation factor II (thrombin) receptor 
Aspdh 68352           aspartate dehydrogenase domain containing 
Ugt2b1 71773           UDP glucuronosyltransferase 2 family, polypeptide B1 
Acot2 171210           acyl-CoA thioesterase 2 
Cyp1a1 13076           cytochrome P450, family 1, subfamily a, polypeptide 1 
Ndufa5 68202 NADH dehyd ogenase (ub quinone) 1 alpha subcomplex, 5 
Apob 238055 apolipoprotein B 
Rdh7 54150 retinol dehydrogenase 7 
Treh 58866 trehalase (bru h-bord r membrane glycoprotein) 
Suox 21 389 sulf te oxidase 
Taldo1 21351 transaldolase 1 
Uq r10 66152 ubiquinol-cytochrome c reductase, complex III subunit X 
Alas2 1656 aminolevulinic acid synthase 2, erythroid 
kr1d1 208665 do-keto reductase family 1, member D1 
S r 20751 sepia te in reductase 
Pah 8478 phenylalanine hydroxylase 
Pfkfb4 270198 6-phosphofructo-2-kin se/fructose-2,6-biphosphatase 4 
Baat 12012 bile acid-Co nzy e A: amino a id N-acyltransferase
Apoa2 11807 apolipoprotein A-II 
Cox6a1 12861 cytochrome c oxidase, subunit VI a, p ypeptid  1
Gpx7 6730 glutathione peroxidase 7 
Nos1 8125 nitric oxide syn hase 1, n uronal 
a 11964 A 
Cyc1 66 45 cytochrome c-1 
Itgav 16410 int grin lpha V 
La 3 669 8 leucine aminopeptidase 3 
Pe t 18618 phosphatidylethanolamine N-methyltransferase 
Atp6v0d1 1972 ATPase, H+ transporting, lysosomal V0 subunit D1 
Tpi1 21991 triosephosphate isomerase 1 
lc25a1 13 58 olute carri r fa ily 25 (mitochondrial carrier, c trate transp rter), member 1 
cot7 70025 acyl-CoA thioesterase 7
Ace2 70008 angiotensin I co verting enzyme (peptidyl-dipeptidase A) 2 
Mogat2 233549 mon acylglycerol O-acyltransferase 2 
Enp p 3 09 glutamyl aminopeptidase 
Ggt1 14 98 gamma-gluta yltransferase 1 
Rbp2 9660 re inol binding protein 2, cellular 
dh6a 6911 co ol dehydrogenase 6A (class V) 
Apoc  1813 apolipoprotein C-II 
Oxct2b 353371 3-oxoacid CoA transferase 2B 
Rdh9 103142 retinol dehydrogenase 9 
gh 590 amma-glutamyl hydrolase 
Eno3 3808 enolase 3, beta muscle 
Gstm7 68 2 glutathione S-transferase, mu 7 
sd11b2 5484 ydroxysteroid 11-beta d hydrogenase 2 
Nmnat1 66454 nicotinamide nucl otide adenylyltransferase 1 
Got1 4718 glutamate oxaloacetate transaminase 1, soluble 
Bckdhb 2040 branched chain ketoacid dehydrogenase E1, beta polypeptide 
Tdh 5886 L-thre nine dehydrogena e 
Bmp2 2156 bone morphogenetic protein 2 
Maob 109731 monoamine oxidase B 
bcg5 27409   ATP-binding cassette, sub-family G (WHITE), member 5 
Figure 3 Metabolic process s ch nged in colon of mice after 6 days of SCFA treatment. 
A. Overview of the metabolic processes changed in colon as observed with gene 
set enrichment analysis (GSEA). Each process name represents a cluster of gene 
sets describing similar pr cesse . P sitive or negative enrichment of the gene sets 
according to conservative criteria (P <0.001, False Discovery Rate <0.05, and Jaccard 
+ Overlap Combined 0.375) is indicated with ‘up’ and ‘down’ respectively. 
B. List of all significantly regulate  genes (P <0.01) present in the gene sets describing 
the metabolic processes in Fig. 3A. Relative expression of genes is indicated for SCFA 
vs. control treatment, with d indicating an increase and green indicating a decrease 
in expression. The Venn d gram shows the number of genes regulated by each 
SCFA. The colour of each g e me on the list corresponds to the area of the Venn 
diagram the gene belongs to.  
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Table 3 Potential upstream regulators in colon of mice after 6 days of SCFA treatment. 
Upstream regulators were determined by Ingenuity Systems Pathway Analysis Software. 
1 Average fold changes of the signal intensity after SCFA infusion compared with saline infusion in 
mice fed the same background diet (LFD or HFD).  
2 Activation z‐score predicts the activation state of the upstream regulator, using the gene expression 
pattern of its downstream genes. Upstream regulators with z‐score ≥ 2 are considered to be 
significantly activated, if z‐score ≤ ‐2 the upstream regulator is significantly inhibited. 
  Upstream Regulator  Average Fold Change1  Molecule Type  Activation z‐score2 
LFD         
Acetate  HNF4A  ‐1.03  transcription regulator  ‐2.60 
  KDM5B  1.03  transcription regulator  2.00 
  NUPR1  1.16  transcription regulator  2.00 
  TP53  1.14  transcription regulator  2.93 
Propionate  PAX5  1.53  transcription regulator  2.17 
  NFE2L2  ‐1.02  transcription regulator  2.24 
  TNF  1.19  cytokine  2.43 
Butyrate  HNF4A  1.05  transcription regulator  ‐2.45 
  PKD1  1.04  ion channel  ‐2.00 
  ZBTB20  1.13  other  2.00 
  MAPK1  1.04  kinase  2.24 
HFD         
Acetate  SRF  ‐1.07  transcription regulator  ‐2.34 
  MKL1  ‐1.02  transcription regulator  ‐2.22 
  TNF  1.00  cytokine  2.23 
Propionate  TP53  ‐1.05  transcription regulator  ‐2.12 
  BNIP3L  1.08  other  2.00 
Butyrate  Alpha catenin    group  ‐3.26 
  Estrogen receptor    group  ‐2.45 
  HOXA10  ‐1.07  transcription regulator  ‐2.00 
  CEBPB  ‐1.00  transcription regulator  2.00 
  HBB  ‐1.29  transporter  2.00 
  HBD    transporter  2.00 
  LTBR  ‐1.01  transmembrane receptor  2.00 
  TCR    complex  2.00 
  PRL  1.07  cytokine  2.02 
  CSF2  1.06  cytokine  2.18 
  Cg    complex  2.20 
  TGFB1  1.25  growth factor  2.26 
  IL6  1.01  cytokine  2.49 
  CEBPA  1.02  transcription regulator  2.60 
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SCFA infusion reverses effects of high fat feeding
A stemmed heatmap was created to determine whether the genes significantly 
regulated (P <0.01) by the HFD after control infusion were also significantly regulated 
by SCFA infusion. As observed from the colour coding of the regulated genes, SCFA 
infusion on a LFD background tended to have the same effects on gene expression 
as the control infusion on a HFD background (Fig. 4A). However, SCFA infusion on 
the HFD changed gene expression in opposite direction compared with the control 
infusion on the HFD, indicating that SCFAs in combination with a HFD might shift 
gene expression profile towards the control, LFD situation.
 When using a fold change cut-off of 1.5, the expression of 47 genes was 
increased on the HFD compared to the LFD with the control treatment. Of these 
genes, 8 were suppressed with at least one SCFA treatment on the HFD, including 
Cnn1, Klb, Tagln, Col8a1 and 4 genes encoding for transporters (Scnn1g, Slc24a3, 
Scnn1b and Best2) (Fig. 4B). In addition, with the control treatment the expression 
of 73 genes was decreased with the HFD compared to the LFD (Fig. 4C). Seven 
of these genes (Glo1, Psma3, Mir18, Ang4, Snord35b, Retnlb and Snora75) were 
induced with propionate and one gene (Apol9b) was induced with acetate on the 
HFD.
 These results indicate that SCFAs on a HFD background might reverse the 
gene expression changes induced by HFD feeding without SCFA infusion.
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Figure 4 Effects SCFA infusion in combination with HFD. A. Heat diagram showing 
the co-regulation of genes under HFD conditions (Control) in comparison to SCFA 
infusions under LFD and HFD conditions. Significantly regulated genes (P <0.01) are 
shown and only genes regulated with HFD compared to LFD (Control) were included 
in the analysis. B. Bar chart showing the effect of SCFAs on genes highly induced (P 
<0.01 and fold change >1.5) with HFD compared to LFD; values are given as log2 of 
the relative expression. Effects of SCFAs are only plotted if effects are significant (P 
<0.01), with ns indicating non-significant effects. C. Bar chart showing the effect of 
SCFAs on genes highly suppressed (P <0.01 and fold change <-1.5) with HFD compared 
to LFD; values are given as log2 of the relative expression. Effects of SCFAs are only 
plotted if effects are significant (P <0.01), with ns indicating non-significant effects.
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Discussion 
To our knowledge, this is the first experiment in which the impact of fat content in 
the diet on gene expression changes induced by colonic SCFAs was investigated. We 
showed that dietary fat is an important factor determining the metabolic implications 
of SCFA administration. Although a HFD combined with colonic SCFA treatment 
has not been studied before, experiments have been conducted to determine the 
effect of diets both high in fibres and fat. A mouse study reported that fermentable 
fibre decreased energy intake, body weight gain and fat mass when added to a high 
fat diet (175). A similar effect was observed in pigs fed diets differing in fat level 
(5% or 17.5%) and fibre type (fermentable or non-fermentable fibre) (176). The 
fermentable fibre inulin resulted in an attenuation of the body weight development 
and fat mass accumulation induced by high fat feeding, suggesting a strong interplay 
between dietary fat and fibre type. We speculate this interaction might be, at least 
partially, attributed to an increased SCFA production resulting from fermentation 
of fibres by bacteria in the colon, as we showed here on gene expression level that 
SCFAs reverse the changes induced by HFD feeding. 
 It was previously shown that the colonic microbiota composition is affected 
by dietary fat content (43). Although our experiment did not allow the measurement 
of microbiota composition, we assume the 2-wk run-in period on either a low or 
high fat diet might have resulted in a stable change in microbiota composition, as 
has been reported (46, 177, 178). Therefore, it is very likely that part of the colonic 
gene expression changes observed on the HFD background are the result of changed 
microbial composition. Interestingly, a number of studies showed that animals fed a 
HFD have lower intestinal concentrations of acetate, propionate and butyrate than 
animals on a LFD (176, 179). It appears that HFD feeding reduces the fermentation 
capacity of the microbiota compared with a LFD, which might be explained by the 
lower amount of carbohydrates in the HFD compared to LFD (179). In our study, the 
amount of colonic SCFAs that was infused was kept constant both in mice fed the 
LFD and in mice fed the HFD. 
Functional implications
In general, the main metabolites produced by the microbiota are SCFAs which 
induce a wide array of gene expression changes. In particular these changes relate 
to metabolic and immune-related processes, but SCFAs are also suggested to have 
regulatory functions.
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Metabolic impact of SCFAs in colon
Acetate, propionate and butyrate have very distinct properties and are known 
to affect health and metabolism in a specific way. To have a closer look at the 
metabolic effects of each individual SCFA, we administered the SCFAs separately in 
this experiment. 
 Acetate is known to serve as a substrate for cholesterol synthesis and 
lipogenesis (60), and the gene expression changes suggest this also occurs in colon. 
 Propionate is known for its potential to reduce cholesterol levels in blood 
(180, 181). This effect is supported by the current study, as colonic gene expression 
changes indicate that propionate suppresses cholesterol biosynthesis on the HFD 
background. Furthermore, propionate was shown to affect amino acid metabolism, 
which might be explained by the fact that propionate can be metabolized by the 
TCA cycle, thereby contributing to the generation of TCA-derived amino acids (182).
 Butyrate is generally believed to be the preferred energy substrate for 
colonocytes (60). Indeed, butyrate was shown to have a very high impact on 
oxidative phosphorylation. In addition, butyrate has been reported to restore 
energy homeostasis and prevent autophagy which mainly can be attributed to its 
metabolic effects (155).
 Effects of acetate and butyrate on the expression of genes involved in lipid 
and lipoprotein metabolism were highly comparable, whereas propionate induced 
very distinct changes in gene expression profile. It is known that both acetate and 
butyrate enter the TCA cycle as acetyl-CoA, whereas propionate enters as succinyl-
CoA (182). This pattern of SCFA utilization might explain the similar effects of acetate 
and butyrate on gene expression level.
 In general, the metabolic implications of lipoprotein and lipid metabolic 
processes are not well described for colonic tissue. Dietary fat is assumed to 
be taken up by the small intestine and effects on colonic tissue remain unclear. 
However, the changes on gene expression level suggest a role for colonic tissue in 
lipid metabolism.
Immune response 
The consumption of dietary fibres was previously shown to attenuate the 
development of inflammatory bowel disease and irritable bowel syndrome (183). 
It has been hypothesized that this beneficial effect can mainly be attributed to the 
production of SCFAs as a result of fermentation of the fibres by colonic bacteria 
(184). With acetate, propionate and butyrate treatment, we observed an increase 
in immune response, both on a LFD and a HFD background. The upstream regulator 
analysis suggests that these processes can in part be attributed to the transcription 
factor CEBPB and the cytokines CSF2, IL6 and TNF. 
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 SCFAs were previously found to regulate immune-related processes via 
the chemoattractant receptor GPR43 (45). Besides the regulation of inflammatory 
responses by Gpr43, metabolic implications of Gpr43 were demonstrated by Kimura 
et al. (179). In this study, adipose tissue specific transgenic Gpr43 mice remained 
lean, whereas GPR43 -/- mice exhibited obesity. The effects were seemingly 
mediated by microbial metabolites, i.e. SCFAs. In addition to our observation that 
SCFAs regulate genes involved in both immunity and metabolism, dietary fibre was 
also shown to modulate immune-related processes and metabolism in opposite 
direction (185). The effects of SCFAs on gene expression therefore point to GPR43-
activated signalling. However, it remains unclear to what extend this signalling 
results in the suppression of genes involved in lipid-related process in colonic tissue.
Regulatory role SCFAs via non-coding RNAs
We observed that several non-coding RNAs were regulated by SCFA infusion. 
In the top 50 of genes induced by propionate treatment in mice fed the HFD, 
25 small nucleolar RNAs (snoRNAs) were present. snoRNAs are non-coding RNA 
molecules of about 60-300 nucleotides, which form a new class of RNA species 
putatively involved in the regulation of gene expression. A recent study provided 
evidence for a role of snoRNAs in palmitate-induced oxidative stress, as shown by 
resistance to lipotoxic and oxidative stress in vitro and prevention of propagation 
of oxidative stress in vivo as a result of loss of snoRNAs U32a, U33 and U35a (186). 
The HFD used in our study contained high amounts of palm oil. However, in mice 
receiving the control infusion we did not observe any snoRNAs induced with HFD 
consumption. Therefore, it appears that snoRNAs are particularly induced on the 
HFD in combination with propionate treatment. Since studies on the effect of 
propionate on snoRNAs have not been performed, we could only speculate which 
specific characteristic of propionate caused this effect. Furthermore, it has been 
observed that butyrate regulates non-coding RNAs, among others snoRNAs (187). 
 Altogether, we believe that the observed changes in the expression 
of snoRNAs are a highly relevant finding for the function of SCFAs as regulatory 
molecules. In future research, the impact of snoRNAs on metabolism should be 
further elucidated.
Conclusion
We showed that dietary fat content has a major impact on gene expression response 
to SCFAs in colon, an important metabolic organ. Based on the study outcomes, we 
conclude that standardization of the fat content in the background diet is essential 
for studying effects of colonic SCFAs, because there appears to be a close interplay 
between dietary fat and colonic SCFAs. The HFD used in this experiment, containing 
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45 en% of fat, closely represents the human diet and therefore results obtained 
from mice consuming the HFD might best reflect what would happen in humans. 
More research is required to further elucidate how diet composition, in particular 
the amount of fat and dietary fibre, can improve human health.
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Supplemental Tables and Figures
Supplemental Figure 1.
Supplemental Figure 2.
Venn diagrams of significantly regulated genes in colon. Each Venn diagram shows the 
number of significantly regulated genes (P <0.01) in the colon of mice fed the LFD (A) or the 
HFD (B) after 6 days of rectal infusion of acetate, propionate and butyrate. Effects of SCFA 
infusion were compared with effects after saline infusion in mice fed the same background 
diet (LFD or HFD).
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Supplemental Figure 2 (continued).
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upplemental Figure 2 (continued).
Enrichment maps indicating positively and negatively enriched gene sets. Enrichment maps 
were created to visualize gene expression changes in colon after acetate (A), propionate 
(B) and butyrate (C) treatment. Nodes represent functional gene sets, and edges between 
nodes represent their similarity. The inner part of each node indicates the effect on a 
LFD background; the outer part of each node indicates the effect on a HFD background. 
Black indicates induction and white indicates suppression of gene sets with SCFA infusion 
compared with saline infusion. A grey colour indicates that the gene set was not enriched. 
Node size represents the gene set size, and edge thickness represents the degree of overlap 
between 2 connected gene sets. The significance thresholds used were P <0.001, False 
Discovery Rate <0.05 and Jaccard + Overlap Combined 0.375. Clusters were manually circled 
and labelled to highlight the prevalent biological functions among related gene sets.
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Abstract
Resistant starch (RS) has been suggested to prolong satiety in adult pigs. The 
present study investigated the RS-induced changes in behaviour, satiety-related 
hormones and metabolites in catheterised growing pigs to explore the possible 
underlying mechanisms for RS-induced satiety. In a cross-over design with two 14d 
periods, 10 pigs (approximately 58 kg) were assigned to two dietary treatments 
comprising diets containing either 35% of pregelatinized potato starch (PS) or 
34% of retrograded tapioca starch (RS). Diets were isoenergetic on gross energy 
basis. Pigs were fed at 2.8 × maintenance. The postprandial plasma response of 
satiety-related hormones and metabolites was measured at the end of each period 
using frequent blood sampling. Faecal and urinary energy losses were measured. 
Behaviour was scored from video recordings using instantaneous scan sampling for 
24 h. Energy digestibility and metabolisability were ~6% lower in the RS compared 
with the PS diet (P <0.001), and metabolizable energy (ME) intake was ~3% lower 
in RS-fed than in PS-fed pigs (P <0.001). RS-fed pigs showed less feeder-directed (P 
=0.001) and drinking (P =0.10) behaviours than PS-fed pigs, and higher peripheral 
short-chain fatty acid (SCFA) levels (P <0.001) throughout the day. Postprandial 
glucose and insulin responses were lower in RS-fed than in PS-fed pigs (P <0.001). 
Triglyceride (TG) levels were higher in RS-fed than in PS-fed pigs (P <0.01), and 
nonesterified fatty acids (NEFAs) levels did not differ between diets (P =0.90). 
Glucagon-like peptide-1 (GLP-1) levels were lower in RS-fed than in PS-fed pigs (P 
<0.001), and peptide tyrosine tyrosine (PYY) levels did not differ between diets (P 
=0.90). Blood serotonin levels were lower (P <0.001), whereas monoamine oxidase 
activity (P <0.05) and tryptophan (P <0.01) levels were higher in RS-fed than in 
PS-fed pigs. Despite a lower ME intake, RS seemed to enhance satiety based on 
behavioural observations. Possible underlying mechanisms for RS-induced satiety 
include increased 24 h plasma SCFA levels, and decreased postprandial glucose and 
insulin responses. GLP-1 and PYY seemed not to play a role in RS-induced satiety. 
Low blood serotonin levels suggested a difference in intestinal serotonin release 
between treatments. The role of intestinal serotonin on motility and transit, and 
immunity in relation to RS requires additional research. It is unknown if higher 
plasma tryptophan levels led to higher brain serotonin levels in RS-fed pigs, which 
could support the reduced feeder-directed behaviours after the RS diet. Increased 
postprandial plasma TG levels corresponded with increased SCFA levels, but it is 
unclear if TGs may have signalled satiety in RS-fed pigs.
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Implications
In this study, resistant starch seemed to enhance satiety, to increase 24 h short-
chain fatty acid and TG concentrations, to reduce postprandial glucose, insulin, and 
serotonin, but not to affect some putative hormonal regulators of satiety such as 
GLP-1 and PYY. Increased knowledge about the underlying mechanisms by which 
resistant starch induces satiety could facilitate a deliberate and effective application 
of resistant starch in animal and human diets. Resistant starch may potentially be 
used for improving welfare in restrictedly-fed sows, which may experience hunger. 
Moreover, resistant starch may be used for reducing energy intake and body weight 
gain in humans.
Introduction
Resistant starch (RS) escapes enzymatic digestion in the small intestine and is 
largely fermented in the caecum and colon into short-chain fatty acids (SCFAs) 
(188). Behavioural studies in pigs suggest that RS prolongs the duration of satiety 
(17, 133, 189). For adult pigs, RS appeared to be more satiating than other types 
of fermentable fibre, likely due to its slow rate of fermentation, which may impact 
feelings of satiety (133).
 In humans, however, studies on the satiating properties of RS have yielded 
inconsistent results (12, 125), which could be related to the difficulty to standardize 
external factors affecting satiety regulation (age, body weight, gender, food intake) 
and the time required for microbial adaptation to fermentable fibre. Therefore, pigs, 
which are also omnivorous colonic fermenters (53) are increasingly used as models 
for human digestive function. Moreover, the fat content of a meal influences satiety 
regulation, as consumption of high fat diets reduces plasma glucose levels (125). 
Most RS diets used in human studies had a low fat content (0-5%) or were not 
matched for fat content, which may influence satiating effects of RS (125).
 Putative mechanisms for the satiating effects of RS are related to the 
increased microbial production of SCFAs. First, increased intestinal absorption of 
SCFAs may prolong postprandial energy supply to the body (188, 190), which may 
cover energy requirements particularly after intestinal absorption of glucose is 
completed, and thereby, prolong satiety (190). It has been shown that exchange 
of enzymatically digestible starch by RS in the diet, indeed, resulted in stabilized 
postprandial levels of glucose and insulin, which prolongs satiety likely by 
preventing drops in glucose levels below basal levels (94, 190). Second, SCFAs may 
stimulate the release of the satiety-related hormones peptide tyrosine tyrosine 
118
Chapter 5
(PYY) and glucagon-like peptide-1 (GLP-1) from entero-endocrine cells (138). Both 
hormones affect satiety via an effect in the brain (either through the circulation or 
through vagal afferent signals, or both) and via the ‘ileal brake’ (25). Finally, SCFAs 
may stimulate the release of serotonin (5-hydroxytryptamine, 5-HT) in the colon 
through activation of free fatty acid 2 receptors expressed in 5-HT-containing cells, 
which affects colonic motility and overall transit time of digesta, thus contributing 
to satiety regulation, independently of PYY and GLP-1 (25). 
 Postprandial changes in metabolic and hormonal profiles and physical 
activity induced by RS are not well characterized over time, and are important to 
study the mechanisms by which RS promotes long-term satiety. Therefore, the 
present study aimed to assess the time-course of RS-induced changes in general 
physical activity and behaviour (as an indicator of hunger/satiety), satiety-related 
hormones and metabolites in growing pigs, and relate those to feeding behaviour 
and meal size during an ad libitum meal. In addition, satiating effects of RS were 
evaluated in the presence of extra dietary fat. 
Materials and methods 
 
Animals and housing
Ten Landrace barrows (initial body weight: 58 ± 1.6 kg; age: 4 months) from 8 litters 
(1-2 pigs per litter) were assigned to 2 dietary treatments in a 2 × 2 crossover design 
with 2 identical 14d experimental periods. Treatments differed in the type of starch 
in the diet: pregelatinized potato starch (PS) or retrograded tapioca starch (RS). 
Pigs were individually housed in metabolism pens (2 × 1 m) within a temperature 
controlled room (20 ± 2°C). Lights were on from 05:00 h until 19:00 h and dimmed 
during the night. Pens were equipped with a feeder and cleaned daily. A metal 
tray and funnel system beneath a rubberized metal-grid floor (0.5 cm oval holes) 
allowed urine collection with minimal faecal contamination. The Animal Care and 
Use Committee of Wageningen University and Research Centre (Lelystad, The 
Netherlands) approved the experiment.
Diets, feeding and surgery
The two experimental diets contained either 35% PS (PaselliTM WA4, Avebe 
Food) or 34% RS (C*Actistar 11700, Cargill), and were designed to meet nutrient 
requirements according to the Dutch feed evaluation system for pigs (191). Diets 
were formulated to provide equal amounts of gross energy (GE) (~17 MJ GE/kg 
diet). Table 1 shows the ingredient and analysed chemical composition of the diets. 
Diets were produced as a single batch of a basal diet to which starch sources were 
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added. Diets were flavoured to mask differences in palatability, and TiO
2
 was added 
as an indigestible marker. Two isocaloric high-fat (HF) diets were formulated with 
wheat and barley starch being exchanged for 20% soy oil resulting in a HF-PS and 
a HF-RS diet (Table 1). Diets were fed as mash, and mixed with water (water:feed 
= 2.5:1) in the feeders just before feeding. Pigs were fed at 07:00 h and 16:00 h at 
2.8 × the energy requirements for maintenance (MEm = 450 kJ/kg0.75 per day). The 
amount of feed was adjusted daily according to the metabolic body weight (kg0.75) 
of the pigs and an anticipated daily gain of about 500 g. Water was continuously 
available.
 During 1-week habituation, pigs were fed a 50:50 mix of the PS and RS diets, 
and adapted to individual housing and feeding regime. Furthermore, each of the two 
HF diets was fed twice to prevent feed neophobia during the experiment. After the 
habituation period, pigs were provided with two permanent blood vessel catheters 
in the carotid artery for blood sampling and in the jugular vein for back-up in case of 
a malfunctioning arterial catheter (see (166) for details). In the week after surgery, 
pigs were habituated to blood sampling. After 4 to 6 days of postsurgical recovery, 
pigs were gradually switched to the experimental diets. In each experimental period 
(d1 to d14), pigs were daily fed a restricted meal of the PS and RS diets, with the 
exception of the morning meal on d8, when a restricted meal of the HF-PS and HF-
RS diets was provided, and the morning meal on d10, when an ad libitum meal of 
the PS and RS diets was provided.
Table 1 Ingredient and analysed chemical composition of experimental diets. 
  Experimental diet 
  PS  RS  HF‐PS  HF‐RS 
Ingredient composition (g/kg)   
Pregelatinized purified potato starch1   350.0  0.0  452.0  0.0 
Retrograded tapioca starch2  0.0  342.6  0.0  444.0 
Soy oil  29.2  29.5  198.2  201.2 
Wheat  200.0  202.3  0.0  0.0 
Beet pulp (sugar<100 g/kg)  50.0  50.6  64.6  65.5 
Barley  150.0  151.7  0.0  0.0 
Wheat gluten meal  60.0  60.7  77.5  78.6 
Potato protein3  100.0  101.1  129.1  131.0 
Premix4  10.0  10.1  12.9  13.1 
CaCO3  13.5  13.7  17.4  17.7 
Ca(H2PO4)2   11.0  11.1  14.2  14.4 
NaCl  3.0  3.0  3.9  3.9 
L‐lysine HCL  2.2  2.2  2.8  2.9 
L‐tryptophan  0.2  0.2  0.3  0.3 
MgO (80%)  0.4  0.4  0.5  0.5 
NaHCO3  14.0  14.2  18.1  18.3 
KCl  3.0  3.0  3.9  3.9 
TiO2  2.0  2.0  2.6  2.6 
Flavour5  1.5  1.5  1.9  2.0 
Chemical composition (g/kg dry matter)   
Dry matter (g/kg as is)  894.5  910.0  924.3  952.1 
Organic matter  941.4  941.9  937.4  936.9 
Crude protein (N × 6.25)  190.9  194.3  186.2  188.7 
Crude fat  16.1  28.6  197.0  201.0 
Starch  524.7  477.1  411.1  337.5 
Sugar  13.1  69.4  6.0  70.7 
Ti  1.6  1.6  ‐  ‐ 
Energy content (MJ/kg)   
GE   16.48  16.78  ‐  ‐ 
PS=pregelatinized  potato  starch  diet;  RS=retrograded  tapioca  starch  diet;  HF‐PS=high‐fat 
pregelatinized potato starch diet; HF‐RS=high‐fat retrograded tapioca starch diet. 
1PaselliTM WA4, Avebe Food, Veendam, The Netherlands. 
2C*Actistar 11700, Cargill, Amsterdam, The Netherlands. 
3Protostar, Avebe Food, Veendam, The Netherlands. 
4Provided  the  following per kg of  feed: vitamin A: 7500  IU; vitamin D3: 1500  IU; vitamin E: 60 mg; 
vitamin K3: 1.0 mg; vitamin B1: 1.0 mg; vitamin B2: 4.0 mg; vitamin B6: 1.0 mg; vitamin B12: 20  μg; 
niacin: 20 mg; calcium‐D pantothenate: 10.5 mg; choline chloride: 100 mg; folic acid: 0.4 mg; Fe: 120 
mg (FeSO4.H2O); Cu: 15 mg (CuSO4.5H2O); Mn: 60 mg (MnO); Zn: 75 mg (ZnSO4.H2O);  I: 4.0 mg (KI); 
Se: 0.30 mg (Na2SeO3); anti‐oxidant: 75 mg. 
5Luctarom Advance Cherry Honey, Lucta S.A., Barcelona, Spain.
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Measurements and sample collection
Body weight was measured weekly. Faeces (for GE and Ti analyses) and urine (for 
GE analysis) were collected quantitatively per pig during the last 2 and 3 days, 
respectively, of each experimental period. Faecal samples were collected directly 
from the pen floor twice daily and urine samples were collected daily from the total 
urine output of each pig, and stored at -20°C until analysis. In each period, satiating 
effects of the diets were assessed when pigs were fed a restricted morning meal of 
the HF-PS and HF-RS diets (d8), an ad libitum morning meal (d10) and a restricted 
morning meal (d14), both of the PS and RS diets. An additional ad libitum meal of 
a 50:50 mix of the PS and RS diets was provided 7 h after the HF morning meals. 
During the ad libitum meals (d8 and d10), feeding behaviour and voluntary feed 
intake were measured.
 Blood samples (6 mL) were collected in EDTA tubes with protease and 
dipeptidyl peptidase-IV inhibitors before (at -30 and 0 min) and after (at 20, 40, 60, 
90, 120, 180, 240 and 300 min) the restricted meal of the PS and RS diets on d14, 
Table 1 Ingredient and analysed chemical composition of experimental diets. 
  Experimental diet 
  PS  RS  HF‐PS  HF‐RS 
Ingredient composition (g/kg)   
Pregelatinized purified potato starch1   350.0  0.0  452.0  0.0 
Retrograded tapioca starch2  0.0  342.6  0.0  444.0 
Soy oil  29.2  29.5  198.2  201.2 
Wheat  200.0  202.3  0.0  0.0 
Beet pulp (sugar<100 g/kg)  50.0  50.6  64.6  65.5 
Barley  150.0  151.7  0.0  0.0 
Wheat gluten meal  60.0  60.7  77.5  78.6 
Potato protein3  100.0  101.1  129.1  131.0 
Premix4  10.0  10.1  12.9  13.1 
CaCO3  13.5  13.7  17.4  17.7 
Ca(H2PO4)2   11.0  11.1  14.2  14.4 
NaCl  3.0  3.0  3.9  3.9 
L‐lysine HCL  2.2  2.2  2.8  2.9 
L‐tryptophan  0.2  0.2  0.3  0.3 
MgO (80%)  0.4  0.4  0.5  0.5 
NaHCO3  14.0  14.2  18.1  18.3 
KCl  3.0  3.0  3.9  3.9 
TiO2  2.0  2.0  2.6  2.6 
Flavour5  1.5  1.5  1.9  2.0 
Chemical composition (g/kg dry matter)   
Dry matter (g/kg as is)  894.5  910.0  924.3  952.1 
Organic matter  941.4  941.9  937.4  936.9 
Crude protein (N × 6.25)  190.9  194.3  186.2  188.7 
Crude fat  16.1  28.6  197.0  201.0 
Starch  524.7  477.1  411.1  337.5 
Sugar  13.1  69.4  6.0  70.7 
Ti  1.6  1.6  ‐  ‐ 
Energy content (MJ/kg)   
GE   16.48  16.78  ‐  ‐ 
PS=pregelatinized  potato  starch  diet;  RS=retrograded  tapioca  starch  diet;  HF‐PS=high‐fat 
pregelatinized potato starch diet; HF‐RS=high‐fat retrograded tapioca starch diet. 
1PaselliTM WA4, Avebe Food, Veendam, The Netherlands. 
2C*Actistar 11700, Cargill, Amsterdam, The Netherlands. 
3Protostar, Avebe Food, Veendam, The Netherlands. 
4Provided  the  following per kg of  feed: vitamin A: 7500  IU; vitamin D3: 1500  IU; vitamin E: 60 mg; 
vitamin K3: 1.0 mg; vitamin B1: 1.0 mg; vitamin B2: 4.0 mg; vitamin B6: 1.0 mg; vitamin B12: 20  μg; 
niacin: 20 mg; calcium‐D pantothenate: 10.5 mg; choline chloride: 100 mg; folic acid: 0.4 mg; Fe: 120 
mg (FeSO4.H2O); Cu: 15 mg (CuSO4.5H2O); Mn: 60 mg (MnO); Zn: 75 mg (ZnSO4.H2O);  I: 4.0 mg (KI); 
Se: 0.30 mg (Na2SeO3); anti‐oxidant: 75 mg. 
5Luctarom Advance Cherry Honey, Lucta S.A., Barcelona, Spain.
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placed in ice water and centrifuged at 1300 g for 10 min at 4°C within 20 min after 
collection. Plasma was stored at -80°C until analysis. Extra blood samples (9 mL) 
were collected in EDTA tubes before (at -30 min) and after (at 20 and 300 min) the 
restricted meal on d14. For measuring 5-HT levels, tubes with blood were placed 
in ice water and centrifuged at 160  for 10 min at room temperature to obtain 
platelet-rich plasma (PRP). The extracted PRP (1 mL) was centrifuged at 13000 g for 
15 min at room temperature to obtain platelet pellets. The washed (with 1 mL of 
0.9% NaCl solution, followed by centrifugation at 13000 g for 5 min) pellets were 
stored at -80°C until analysis. For measuring monoamine oxidase (MAO) activity, 
blood samples (1.2 mL) were stored at -80°C until analysis.
Chemical analyses and calculations 
Diets were analysed for dry matter, ash, starch, sugar, crude protein, crude fat, GE 
and Ti as previously described (26), see Supplemental Material for details. Blood 
plasma was analysed for glucose, insulin, TGs, NEFAs, active GLP-1, active PYY, 
tryptophan (Trp), large neutral amino acids (LNAA) and SCFAs. Blood platelet pellets 
were analysed for 5-HT, and whole blood for MAO activity (see Supplemental 
Material for details). Apparent faecal energy digestibility coefficient was calculated 
as previously described (26) and the digestible energy (DE) content of the diet as 
its GE content multiplied by this coefficient. The metabolizable energy (ME) content 
was calculated as GE intake minus energy lost in faeces and urine.
Behavioural observations
On d12 of each experimental period, the pigs’ postures and behaviours were 
scored from video recordings using 10 min-instantaneous scan sampling for 24 h 
and expressed as percentages of observation time. Postures were standing and 
walking, kneeling and sitting, lateral lying, and ventral lying (133). Behavioural 
oral activities were explorative behaviour (rooting or nosing floor or pen fixtures), 
chewing (repetitively chewing of pen fixtures or sham chewing) (189), feeder-
directed behaviour (eating, and sniffing, licking or touching the feeder with the 
snout), drinking, and other (all other behavioural activities).
 Furthermore, pigs were observed continuously for 1 h during the ad libitum 
meal of a 50:50 mix of the PS and RS diets 7 h after the HF-PS and HF-RS diets 
(d8) and during the ad libitum meal of the PS and RS diets (d10). Behaviours and 
postures scored were the same as described above, except that eating was scored 
separately, and used to determine the duration of the first bout of eating. The 
Observer software package (Noldus Information Technology B.V.) was used for all 
behavioural recordings. 
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Statistical analyses
Data were analysed using a mixed model in SAS (version 9.1; SAS Institute) with 
values in time and treatment of individual pigs taken as repeated measurements. 
For feed intake and body weight data, the model included period and diet as fixed 
effects and pig as random effect. For the behaviours (d8, d10 and d12), plasma 
hormones and metabolites (d14) the model included period, diet, (sampling or 
observation) time, and interaction of diet and time as fixed effects, and pig and pig 
(diet) as random effects. Sequence of treatments effect was removed from the final 
model if not significant (P >0.10). Data are presented as least-square means ± SEM.
Results
Catheters functioned well during the experiment and were accurately placed 
as confirmed after section. None of the diets offered was refused during the 
experiment. All pigs remained healthy, and had a normal growth throughout the 
experiment. Pigs’ body weight at the start (57.9 ± 1.6 kg) and end (79.7 ± 2.0 kg) of 
the experiment did not differ between diets.
Diets and feed intake
Energy digestibility (DE:GE) and metabolisability (ME:GE) were approximately 6% 
lower (P <0.001, Table 2), and ME intake was approximately 27 kJ//kg0.75 per day 
(~3%) lower in the RS compared with the PS diet (P <0.001, Table 2). When a mixture 
of the PS and RS diets was provided ad libitum 7 h after providing a restricted meal 
of either HF-PS and HF-RS diets in the morning of d8, pigs consumed 70.3 and 58.9 
g/kg0.75 (SEM = 5.1), respectively, corresponding to a difference in ME intake of 165 
kJ/kg0.75 (P =0.12, Table 2). When the PS and RS diets were fed ad libitum in the 
morning of d10, feed intake was about twice the normal meal size: 70.3 and 68.8 
g/kg0.75 (SEM=5.0) in PS- and RS-fed pigs, respectively, with no difference between 
diets (P =0.83). ME intake of the ad libitum meal was 69 kJ/kg0.75 lower in RS-fed than 
in PS-fed pigs (P =0.52, Table 2). There was an effect of the sequence of treatments 
on the size of the ad libitum meal consumed on d8 and d10. Pigs receiving the 
PS-RS sequence ate 23 and 15 g/kg0.75 less compared with pigs receiving the RS-PS 
sequence (P <0.05 and P =0.07 on d8 and d10, respectively). This corresponded to a 
difference in ME intake of 332 kJ/kg0.75 and 214 kJ/kg0.75 (P <0.05 and P =0.08 on d8 
and d10, respectively).
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Physical activity (24 h)
Behaviours on d12 were affected by time of the day (all P <0.001; Table 3), except 
for drinking behaviour. Generally, pigs showed a daily activity pattern characterized 
by peaks of activity around feeding in the morning (between 07:00 h and 09:00 
h) and in the afternoon (between 16:00 h and 18:00 h), interspersed by resting 
periods. Lying did not differ between diets (P =0.30). RS-fed pigs spent more time 
lying ventrally (45% vs. 37%) and less time lying laterally (44% vs. 51%, SEM=2) than 
PS-fed pigs (both P <0.05, Table 3). PS-fed pigs performed more feeder-directed 
behaviours (5% vs. 3%, SEM=1, P =0.001), and tended to spend more time drinking 
(1.3% vs. 0.6%, SEM=0.3, P =0.10) than RS-fed pigs (Table 3).
Table 2 Digestible and metabolizable energy intake (in kJ//kg0.75 per day, unless indicated otherwise) 
in growing pigs  fed an ad  libitum meal of a 50:50 mix of  the pregelatinized potato starch  (PS) and 
retrograded  tapioca starch  (RS) diets at 7 h after a  restricted high  fat  (HF) meal of either PS or RS 
(d8), an ad  libitum morning meal (d10), and a restricted morning meal (d14), both of the PS and RS 
diets1. 
  Diet    Effects2 
  PS RS s.e.3  D  S 
Day 8 (kJ/kg0.75 per meal)4           
    ME intake  1015.3 850.2 73.8  ns  * 
Day 10 (kJ/kg0.75 per meal)       
    ME intake  1039.0 970.1 72.9  ns  # 
Day 14       
    GE intake  1095.3 1137.3 4.0  ***  ns 
    DE intake  988.9 963.1 3.5  ***  ns 
    ME intake  982.3 955.6 3.5  ***  ns 
    DE:GE, %  90.1 84.5 0.3  ***  ns 
    ME:GE, %  89.6 84.0 0.3  ***  ns 
DE=digestible energy; GE=gross energy; ME=metabolizable energy. 
1Throughout the experiment, pigs were daily fed a restricted meal of the PS and RS diets, with the 
exception of the morning meals on d8 and d10. 
2Statistical significance of effects of diet (D), and sequence of treatment (S) is indicated: #P <0.10, *P 
<0.05, **P <0.01, ***P <0.001, ns=non‐significant. Period (P) did not influence energy intake. 
3Pooled standard error of the least‐square means. 
4Pigs were fed a HF meal containing PS or RS in the morning of d8, and ME intake corresponds to the 
consumption of a 50:50 mix of the PS and RS diets 7 h after each HF meal. 
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Behaviour during ad libitum meals
During the ad libitum meal of the PS and RS diets (d10), all behaviours were affected 
by time (all P <0.001). Generally, activity of the pigs decreased after the first 15 min 
of the meal. The duration of the first bout of eating was shorter (P <0.01) in RS-fed 
(452 s) than in PS-fed pigs (957 s, SEM=109). RS-fed pigs spent more time on non-
feeder directed explorative behaviour (77 s vs. 42 s, SEM=13, P <0.05), and less 
time on feeder-directed behaviour, including eating, than PS-fed pigs (74 s vs. 130 
s, SEM=11, P <0.01). RS-fed pigs (63 s) spent less time eating than PS-fed pigs (116 
s, SEM=9, P <0.001), and this effect tended to be most pronounced during the first 
30 min of the meal (diet × time interaction, P =0.06). During the ad libitum meal 
of a 50:50 mix of the PS and RS diets provided 7 h after the HF-PS and HF-RS diets 
(d8), all behaviours were affected by time (all P <0.001), but were unaffected by diet 
(data not shown).
Blood parameters
Plasma SCFA, glucose, insulin, TG, NEFA, GLP-1 and PYY levels around ingestion of 
the restricted PS and RS meals on d14 are presented in Figures 1-4. 5-HT, MAO, 
Trp, LNAA and Trp:LNAA ratio are given in Table 4. Plasma SCFA levels were higher 
in RS-fed than in PS-fed pigs (all P <0.001). Basal glucose and insulin levels did not 
Table 3 Daily physical activity  (in % of observation  time) of growing pigs  fed a restricted meal of a 
diet containing either pregelatinized potato starch (PS) or retrograded tapioca starch (RS), based on 
video observations using 10 min‐instantaneous scan sampling. 
Behaviour  Diet    Effects1 
  PS RS  s.e.2  D  T 
Posture         
    Lying  88.0 90.0  1.0  ns  *** 
        Ventrally  37.0 45.0  2.0  *  *** 
        Laterally  51.0 44.0  2.0  *  *** 
    Standing and walking  9.0 8.0  1.0  ns  *** 
    Kneeling and sitting  3.0 3.0  1.0  ns  *** 
Behavioural oral activities  23.0 19.0  2.0  ns  *** 
    Explorative behaviour  10.0 10.0  2.0  ns  *** 
    Chewing  7.0 6.0  2.0  ns  *** 
    Feeder‐directed behaviour  5.0 3.0  1.0  **  *** 
    Drinking  1.3 0.6  0.3  #  ns 
1Statistical significance of effects of diet (D) and observation time (T) is indicated: #P <0.10, *P <0.05, 
**P <0.01, ***P <0.001, ns=non‐significant. Interaction between diet and time (D × T) and period (P) 
did not influence daily physical activity.  
2Pooled standard error of the least‐square means. 
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differ between diets. When pigs were fed the restricted meal, plasma glucose levels 
were affected by diet (P <0.001), sampling time (P <0.001) and their interaction (P 
<0.01), with lower levels in RS-fed than in PS-fed pigs, particularly at 20, 40, 60, 
120 and 240 min postprandial. The peak in glucose levels at approximately 20 min 
postprandial was lower in RS-fed than in PS-fed pigs (P <0.01). Plasma insulin levels 
were affected by diet (P <0.001), sampling time (P <0.001) and their interaction (P 
<0.001), with lower levels in RS-fed than in PS-fed pigs, particularly at 20, 40 and 
60 min postprandial. The peak in insulin at approximately 40 min postprandial was 
lower in RS-fed than in PS-fed pigs (P <0.01). Plasma TG levels were higher in RS-
fed pigs than in PS-fed pigs (P <0.01). TG levels differed between sampling times 
(P <0.001), with higher levels at 90 min postprandial than at 0 min. Plasma NEFA 
levels were unaffected by diet (P =0.90), but were affected by sampling time (P 
<0.05), with higher levels at 90, 120, 180 and 240 min than at 40 min postprandial. 
Plasma GLP-1 levels were lower in RS-fed than in PS-fed pigs (P <0.001). GLP-1 levels 
differed between sampling times (P <0.001), with higher levels at 60 min than at 90, 
120 and 180 min postprandial. Plasma PYY levels were unaffected by diet (P =0.90), 
but tended to be affected by sampling time (P =0.06), with higher levels at -30 min 
than at 120 min postprandial.
 Platelet 5-HT was affected by sampling time (P <0.05) with higher levels 
at -30 min than at 20 min postprandial, and tended to be lower in RS-fed pigs (P 
=0.08). Blood 5-HT levels were lower (P <0.001) and MAO activity was higher in RS-
fed than in PS-fed pigs (P <0.05). Plasma Trp levels were affected by diet (P <0.01), 
sampling time (P <0.001) and there was a trend for the effect of their interaction (P 
=0.07). Trp levels were higher in RS-fed than in PS-fed pigs, particularly at 300 min 
postprandial. Plasma LNAA levels and Trp:LNAA ratio tended to be higher in RS-fed 
than in PS-fed pigs (P =0.08 and P =0.07, respectively). LNAA levels were affected 
by sampling time (P <0.001), with higher levels at 300 min postprandial than at 
-30 min. The Trp:LNAA ratio was affected by sampling time (P =0.001), with higher 
levels at -30 min than at 20 and 300 min postprandial.
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Figure 1 
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Figure 1 Plasma concentrations of SCFAs: acetate (A), propionate (B) and butyrate 
(C), in peripheral blood collected before (-30 min), during (0 min) and after (20 to 
300 min) feeding growing pigs a restricted meal of the pregelatinized potato starch 
(PS) diet (●) and retrograded tapioca starch (RS) diet (○) in the morning of d14. 
Statistical significance of effects of diet (D), sampling time (T), their interaction (D × 
T), and period (P) is indicated: #P <0.10, *P <0.05, **P <0.01, ***P <0.001, ns=non-
significant.
A
B
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Figure 2 Plasma concentrations of glucose (A) and insulin (B) in peripheral blood 
collected before (-30 min), during (0 min) and after (20 to 300 min) feeding growing 
pigs a restricted meal of the pregelatinized potato starch (PS) diet (●) and retrograded 
tapioca starch (RS) diet (○) in the morning of d14. Statistical significance of effects of 
diet (D), sampling time (T), their interaction (D × T), and period (P) is indicated: 
#P <0.10, *P <0.05, **P <0.01, ***P <0.001, ns=non-significant.
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Figure 3 
Figure 3 Plasma concentrations of TGs (A) and NEFAs (B) in peripheral blood collected 
before (-30 min), during (0 min) and after (20 to 300 min) feeding growing pigs a 
restricted meal of the pregelatinized potato starch (PS) diet (●) and retrograded 
tapioca starch (RS) diet (○) in the morning of d14. Statistical significance of effects of 
diet (D), sampling time (T), their interaction (D × T), and period (P) is indicated: 
#P <0.10, *P <0.05, **P <0.01, ***P <0.001, ns=non-significant.
A
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Figure 4 Plasma concentrations of GLP-1 (A) and PYY (B) in peripheral blood collected 
before (-30 min), during (0 min) and after (20 to 300 min) feeding growing pigs a 
restricted meal of the pregelatinized potato starch (PS) diet (●) and retrograded 
tapioca starch (RS) diet (○) in the morning of d14. Statistical significance of effects of 
diet (D), sampling time (T), their interaction (D × T), and period (P) is indicated: 
#P <0.10, *P <0.05, **P <0.01, ***P <0.001, ns=non-significant.
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Table 4 Platelet serotonin (platelet 5‐HT, in µmol/109 platelets), whole blood serotonin (blood 5‐HT, 
in  µmol/L), monoamine  oxidase  activity  (MAO,  in  µmol/L/h),  tryptophan  (Trp,  in mmol/L),  large 
neutral amino acids (LNAA, in mmol/L), and Trp:LNAA ratio in peripheral blood of growing pigs fed a 
restricted meal of a diet containing either pregelatinized potato  starch  (PS) or  retrograded  tapioca 
starch (RS). 
   Diet    Effects1 
   PS RS s.e.
2  D  T  D × T  P 
Average over sampling times         
Platelet 5‐HT  0.024 0.021 0.002 #  *  ns  *** 
Blood 5‐HT  6.46 5.03 0.46 ***  ns  ns  ns 
MAO activity  82.94 89.34 7.70 *  ns  ns  ns 
Trp  0.060 0.068 0.002 **  ***  #  ns 
LNAA  1.22 1.32 0.05 #  ***  ns  ns 
Trp:LNAA  0.050 0.053 0.002 #  **  ns  ns 
30 min before the meal         
Platelet 5‐HT  0.026 0.023 0.003 ns  ‐  ‐  ** 
Blood 5‐HT  5.95 4.91 0.58 #  ‐  ‐  # 
MAO activity  84.78 85.93 8.29 ns  ‐  ‐  ns 
Trp  0.043 0.046 0.003 #  ‐  ‐  ns 
LNAA  0.80 0.79 0.08 ns  ‐  ‐  ns 
Trp:LNAA  0.054 0.059 0.002 ns  ‐  ‐  ns 
20 min after the meal         
Platelet 5‐HT  0.021 0.018 0.003 ns  ‐  ‐  ** 
Blood 5‐HT  6.86 5.18 0.58 *  ‐  ‐  ns 
MAO activity  79.81 91.78 8.29 *  ‐  ‐  ns 
Trp  0.070 0.074 0.003 ns  ‐  ‐  ns 
LNAA  1.46 1.50 0.08 ns  ‐  ‐  ns 
Trp:LNAA  0.048 0.050 0.002 ns  ‐  ‐  ns 
300 min after the meal         
Platelet 5‐HT  0.023 0.020 0.003 ns  ‐  ‐  * 
Blood 5‐HT  6.56 5.01 0.58 **  ‐  ‐  ns 
MAO activity  84.23 90.31 8.29 ns  ‐  ‐  ns 
Trp  0.067 0.084 0.003 *  ‐  ‐  ns 
LNAA  1.39 1.66 0.08 #  ‐  ‐  ns 
Trp:LNAA  0.049 0.051 0.002 ns  ‐  ‐  ns 
1Significance  of  effects  of  diet  (D),  sampling  time  (T),  their  interaction  (D  ×  T),  and  period  (P)  is 
indicated: #P <0.10, *P <0.05, **P <0.01, ***P <0.001, ns=non‐significant. 
2Pooled standard error of the least‐square means. 
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Discussion
To assess satiating effects of RS, we studied general physical activity during 24 h, 
and feeding behaviour and meal size during an ad libitum meal in growing pigs. In 
addition, we studied the effect of feeding HF diets containing RS and PS on feeding 
behaviour and meal size 7 h postprandial, to test whether satiating effects of RS 
are dependent on fat intake. RS-fed pigs showed less feeder-directed and drinking 
behaviours than PS-fed pigs over 24 h, indicating a long-term satiating effect of RS, 
which corresponds with studies reporting reduced signs of hunger such as decreased 
feeding motivation (17, 133), reduced physical activity and preprandial restlessness, 
and enhanced satiety with dietary RS in restrictedly-fed pigs (189).
 When the PS and RS diets were fed ad libitum, RS-fed pigs decreased 
duration of the first bout of eating and reduced feeder-directed behaviour (including 
eating), suggesting that RS enhanced also short-term satiety in pigs, likely reflecting 
an effect of the previous RS meal (133). These effects of RS were found with RS-fed 
pigs having a 3% lower ME intake than PS-fed pigs. During ad libitum meal, however, 
feed intake was similar for RS-fed and PS-fed pigs. Voluntary feed intake of a mixed 
diet (PS:RS=50:50) 7 h after digestion of a HF diet was numerically reduced in the 
HF-RS-fed compared with the HF-PS-fed pigs, although the ME supply from the HF-
RS diet was expected to be lower than that of the HF-PS diet. Thus, satiating effects 
of RS diets successfully compensated for a reduced ME content of the diet, but were 
apparently not able to further reduce voluntary feed intake during an ad libitum 
meal. Possibly, the drive for lean growth in the growing pigs used in the present 
study partly overruled the satiety-enhancing effect of RS previously observed in 
adult pigs (133). Alternatively, the ad libitum meal test may be less sensitive after 
a prolonged period of restricted feeding (~9 h inter-meal interval), resulting in 
temporary over-feeding and large variation in voluntary feed intake. Remarkably, 
feed intake during ad libitum meals on d8 and d10 was lower for pigs receiving PS in 
period 1 followed by RS in period 2, than for pigs receiving RS-PS (sequence effect), 
which could be due to a decrease in the time needed for adaptation to the RS after 
feeding PS. Adaptation of the intestinal microbiota composition may occur more 
rapidly when pigs are changed from a low to a high fibre diet, which is accompanied 
with increased fermentation capacity (192). This increased fermentation likely 
contributed to the decreased voluntary feed intake in pigs receiving RS as last 
treatment.
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Mechanisms for satiating effects of RS
To explore mechanisms by which RS may promote long-term satiety, we evaluated 
the effect of dietary RS on postprandial satiety-related hormones and metabolites. 
Mechanisms for the satiating effects of RS may be related to increased production 
of SCFAs (188, 190), which can prolong energy supply to the body (190). In the 
present study, peripheral SCFA levels were elevated throughout the day (both 
pre- and postprandial) in RS-fed pigs compared to PS-fed pigs, in accordance with 
previous studies (53, 193). Moreover, postprandial glucose and insulin responses 
were lower in RS-fed pigs than in PS-fed pigs, reflecting a decreased influx of glucose 
by enzymatic digestion of RS as compared with PS, in line with other studies (193, 
194).
 In rats, SCFAs from RS stimulate the release of satiety-related hormones, 
such as GLP-1 and PYY from entero-endocrine cells (138), which could be a 
biological mechanism by which RS promotes satiety. In the present study, however, 
postprandial GLP-1 levels were lower for RS-fed than for PS-fed pigs, and PYY levels 
were similar for both diets throughout the day. The effect found on GLP-1 could be 
attributed to the lower amount of glucose released from the RS diet as compared 
with the PS diet, as it has been shown in pigs that GLP-1 secretion is maintained by 
glucose until 4 h postprandial, and thereafter by SCFAs until up to 10 h postprandial 
(193). In our pigs it was only possible to relate GLP-1 secretion to the differences 
in glucose response, and not to the differences in SCFA levels. SCFAs and glucose 
can stimulate PYY secretion in rat intestine, but both to a smaller extent than fatty 
acids, which are considered the most potent stimulators of PYY secretion (195). 
In the present study, the intake of long-chain fatty acids was identical between 
diets, thus the similar postprandial PYY levels likely resulted from reduced glucose 
and increased SCFA concentrations in RS-fed pigs. It is unknown whether the PYY 
stimulating potential of SCFAs equals that of glucose in pigs, but studies in rats 
suggest that the PYY response may be less strong with normal luminal physiological 
SCFA concentrations than with supra-physiological intestinal infusions (195). The 
absence of a preprandial treatment difference in plasma PYY implies that the 
influence of SCFAs on plasma PYY is limited, as preprandial SCFA uptake likely 
exceeds that of glucose in RS-fed pigs (196). Alternatively, a negative feedback of 
GLP-1 on PYY secretion may exist, as also demonstrated in humans (197), and may 
have contributed to the PYY responses observed in our study.
 Over the three sampling times, blood 5-HT levels were lower, whereas 
MAO activity and Trp levels were higher in RS-fed than in PS-fed pigs, indicating 
dietary effects on 5-HT metabolism. In the present study 5-HT was quantified in 
blood platelets, which possess a high-affinity uptake system and accumulate high 
concentrations of excess 5-HT produced by the intestine (198). Dietary manipulation 
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can influence intestinal 5-HT release (e.g. (199)), which in turn changes intestinal 
motility and transit (200), and thereby potentially affects satiety (25). Intestinal 
motility could be reduced in RS-fed pigs, possibly leading to a reduced passage rate 
of digesta in the colon, in line with a previous study demonstrating increased full 
weights of the caecum and colon in pigs fed native potato starch (201). It should be 
noted though, that the relationship between intestinal 5-HT release and motility is 
not always in the same direction (199). The role of locally produced 5-HT on colonic 
motility, transit time and satiety in relation to dietary RS remains to be elucidated.
 Intestinal 5-HT release may also be related to the activity of the 
gastrointestinal immune system. Some of the 5-HT secreting cells (e.g. 
enterochromaffin and mucosal mast cells) and 5-HT itself are involved in pro-
inflammatory immune responses in the gastrointestinal tract (202). The low blood 
5-HT levels found in the RS-fed pigs could be associated with a downregulation of 
genes involved in both innate and adaptive immune responses found in the colon 
of RS-fed pigs in this study (185). Changes in microbiota composition likely also play 
a role in the downregulated immune response observed in RS-fed pigs (185).
 The increased plasma Trp levels (5-HT precursor) and Trp:LNAA ratios in 
RS-fed pigs, combined with the reduced blood 5-HT levels found in RS-fed pigs may 
reflect a decreased uptake of Trp into peripheral tissues. Plasma Trp:LNAA ratio has 
been shown to be a major determinant of brain 5-HT concentration (203), which 
has been reported to be involved in the regulation of feeding behaviour (204). For 
instance, it has been demonstrated that food-seeking and food-taking behaviours 
are usually reduced in non-human primates with increased brain 5-HT turnover 
(205). Although it is unknown whether the higher Trp levels and Trp:LNAA ratios in 
the RS-fed pigs resulted in higher brain 5-HT levels, this would be consistent with 
the lower level of feeder-directed behaviours in these pigs.
 NEFA levels measured in blood reflect mobilized fatty acids from adipose 
tissues, and were expected to be increased just before the morning meal, particularly 
in PS-fed pigs, likely coinciding with a drop in respiration quotient (RQ) (206) due 
to increased fatty acid oxidation. There were no differences, though, in NEFA levels 
between treatments, likely because in growing animals the majority of nutrients 
is used for muscle and adipose tissue growth, with minimal rates of lipolysis. 
Particularly in pigs, most body lipids originate from de novo fatty acid synthesis, 
and mainly glucose is used as substrate by adipose tissue (major site of fatty acid 
synthesis) for de novo lipogenesis (207).  
 Plasma TG levels were increased after feeding RS-diets, particularly between 
90 and 300 min postprandial, corresponding with our previous observations in pigs 
fed similar diets (126). An explanation is that RS may have increased plasma levels 
of angiopoietin-related protein 4 (Angptl4), which is related to an upregulated 
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expression of Angptl4 in the distal small intestine of RS-fed pigs (126). Angptl4 
inhibits lipoprotein lipase (LPL), which is responsible for the hydrolysis of TGs, 
thereby increasing plasma TG levels (208). The large difference in postprandial 
glucose and insulin responses between treatments occurred predominantly before 
90 min postprandial. It is generally assumed that insulin stimulates TG uptake in 
peripheral tissues and inhibits TG production by the liver (209). Consequently 
this would have led to reduced plasma TG responses in PS fed pigs, particularly 
in the first 90 min postprandial. Such a response was not observed. Moreover, 
no inverse relationship between the area under the curve (AUC) was observed 
between plasma TGs and insulin until 300 min postprandial (r =0.04, P =0.88). In 
contrast, AUC for TGs and SCFAs (particularly acetate) were highly correlated (r 
=0.62, P <0.01), which suggests that increased plasma TG levels are mainly driven 
by increased SCFA levels. The expression of two genes responsible for fatty acid 
transport (fatty acid-binding protein 1, FABP1) and fatty acid synthesis (Acetyl-CoA 
carboxylase alpha, ACACA) were indeed found to be upregulated in the liver of RS-
fed pigs (both P <0.05, 2.58 and 1.33 fold increase, respectively) ((185), unpublished 
results). Inhibition of hepatic fatty acid oxidation seems to increase food intake in 
rats, mice and humans, although a suppressive effect of an enhanced hepatic fatty 
acid oxidation on feeding has not been demonstrated (210). Further studies are 
required to investigate whether TG levels signal satiety.
 In conclusion, although RS-fed pigs showed behavioural signs of increased 
satiety and reduced postprandial glucose and insulin responses as compared with 
PS-fed pigs, we did not find an increase in GLP-1 and PYY plasma levels. Dietary 
RS did, however, affect SCFA and TG plasma levels throughout the day, and 5-HT 
metabolism. The involvement of these in the satiating effects of RS merits further 
research.
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Supplemental Material
Chemical analyses
Diets were analysed for dry matter (ISO 6469/NEN 3332), ash (ISO 5984/NEN 3329), 
Kjeldahl nitrogen (ISO 5983/NEN 3145), crude fat (ISO-DIS 6492), starch and sugars 
(NIKO637MEMO 93–302) as previously described (211), and for gross energy (GE) 
using an adiabatic bomb calorimetry (IKA-C700, Janke & Kunkel). Ti was analysed 
using a method based on Short et al. (212) and Myers et al. (213). Faeces were dried 
at 70°C and ground in a centrifugal mill to pass a 1.0-mm mesh screen (ZM100, 
Retsch B.V.) prior to analyses. Faeces and urine were analysed for GE and faeces for 
Ti as described above. All analyses were carried out in duplicate. 
 Blood plasma was analysed for glucose (Glucose PAP SL; ELITech Group), 
insulin (Porcine/Canine Insulin EIA kit; ALPCO Diagnostics), TGs (Triglycerides 
liquicolor kit; Instruchemie), NEFAs (NEFAc-kit, Wako; Instruchemie), active GLP-
1 (GLP-1 ELISA kit; Millipore, Linco Research), active PYY (PYY EIA kit; Phoenix 
Pharmaceuticals), tryptophan (Trp) (1H-NMR spectroscopy), large neutral amino 
acids (LNAA; sum of isoleucine, leucine, valine, phenylalanine, and tyrosine) 
(1H-NMR spectroscopy) and SCFAs (1H-NMR spectroscopy).
 For NMR measurements, plasma samples were filtered using Nanosep® 
Centrifugal Devices with Omega™ Membrane (Pall Corporation) with a 10K 
molecular weight cut-off. To remove trace amounts of glycerine and sodium azide, 
all filters were washed 6 times (centrifuged at 14000 g for 5 min) with MQ water 
(500 μL), and centrifuged for 10 min after the 6th wash to make sure the filters were 
water free. Plasma samples were diluted 1:1 in a 75 mM phosphate buffer (pH 7.4). 
The diluted plasma (300 μL) was transferred to the filter and centrifuged at 14000 
g for 60 min at 4°C. The extracted solution (200 μL) was transferred to a 3 mm 
NMR tube (Bruker match system), and samples were stored at -20°C until analysis. 
For 1H-NMR spectroscopy, samples were slowly warmed up to room temperature 
and measured at 310K (calibrated temperature) in an Avance III NMRspectrometer 
operated at 600.13 MHz. Each sample was transferred into the magnet, and 
equilibrated at 310K for 5 min. Subsequently, automated locking, shimming and 
90° pulse angle determination was performed. For each sample 1H NMR NOESY 
datasets were acquired, and processed and aligned using the alanine signal (upfield 
resonance of the alanine doublet signal) at 1.49 ppm. From the aligned spectra, 
integrals for resonances of the metabolites of interest were selected and quantified. 
Concentrations of metabolites were calculated based on the number of hydrogen 
atoms for each metabolite selected. 
 The 5-HT concentration in platelet pellets was determined using a protocol 
adapted from Kluge et al. (214). Results were expressed in μmol/109 platelets (i.e. 
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platelet 5-HT) and subsequently over total blood platelets in whole blood in μmol/L 
(i.e. blood 5-HT) by multiplying platelet 5-HT by the number of platelets counted in 
whole blood using a Sysmex (109 platelets/L).
 MAO activity in whole blood was determined using a protocol adapted from 
Van Kempen et al. (215), which represents MAO activity that is almost completely 
(>95%) found on blood platelets. Results were expressed as total amount of formed 
4-hydroxyquinoline in whole blood in μmol/L/h.
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Abstract
Dietary fibres are extensively studied for their potential role in the management of 
food intake and body weight. One of the mechanisms via which fibres can help in the 
prevention of obesity is by enhancing satiety. Fibres with different physicochemical 
properties, e.g. bulkiness, viscosity and fermentability, affect satiety in different 
ways. The aim of this study was to determine the effect of fibres with different 
physicochemical properties on ad libitum food intake and on postprandial plasma 
protein and metabolite profiles in minipigs. Therefore, 5 minipigs were assigned to a 
control (C) diet or a diet containing lignocellulose (LC), pectin (PEC) or resistant starch 
(RS) for periods of 8 d in a 4 x 4 Latin square design. Fibre types were selected based 
on their different physicochemical properties; LC is a bulky fibre, RS is a fermentable 
fibre and PEC is both a viscous and a fermentable fibre. Portal and carotid blood 
samples were collected from catheters on day 8 of each treatment, both before 
and at several time points after the ad libitum morning meal. Plasma protein 
profiles were measured by surface enhanced laser desorption/ionization time-
of-flight mass spectrometry (SELDI-TOF-MS) and used to determine differentially 
expressed proteins. The abundance of 973 peptides and proteins with different 
physicochemical properties could be determined. Plasma protein profiles were 
found to be most similar between the C and LC diet, and between the PEC and RS 
diet. With all diets, the most pronounced shift in the abundance of plasma proteins 
occurred between 240 and 480 min postprandially. Sparse multilevel partial least 
squares-discriminant analysis identified 44 and 65 proteins that were differentially 
expressed in portal and carotid plasma samples, respectively, depending on both 
fibre diet and postprandial time. Furthermore, NMR-based metabolomics was 
applied to identify a set of metabolites in portal plasma. A total of 24 metabolites 
was measured, including the short-chain fatty acids (SCFAs) acetate, propionate 
and butyrate. The concentrations of all SCFAs were significantly higher after RS 
consumption than after C, LC and PEC consumption. This study showed that the 
consumption of diets with fermentable fibres results in a different plasma protein 
and metabolite profile compared to a diet containing a non-fermentable fibre or a 
diet without fibre.
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Introduction
Dietary fibres are an extensively studied food component, because of their potential 
role in the management of food intake and body weight. Several studies have shown 
that consumption of dietary fibre increases insulin sensitivity (8, 9) and that it can 
help with the reduction of body weight in overweight and obese subjects (10, 11). 
Part of these observations can be attributed to effects on appetite control, since 
dietary fibre consumption is suggested to enhance satiety (12-14). 
 Knowledge on the underlying mechanisms responsible for an increase 
in satiety following consumption of a diet high in dietary fibre is limited. A major 
factor complicating the elucidation of these mechanisms is the large variety in fibre 
types, all having different physicochemical properties. These properties, including 
bulkiness, viscosity, and fermentability, should be taken into account, because they 
are expected to influence digestive physiology and feelings of satiety in different 
ways (17). 
 Bulky fibres have a high water-binding capacity, resulting in increased gastric 
distension thereby enhancing feelings of satiety (216). Viscous fibres can form a 
gel in the stomach and the nutrients trapped within this viscous matrix will more 
slowly exit the stomach and therefore delay gastric emptying (217). In addition, in 
the small intestine the presence of viscous fibres and unabsorbed macronutrients 
delays gastric emptying and prolongs transit time, a mechanism known as the 
‘ileal brake’, which enhances digestion and absorption of food (218). The ileal 
brake increases the time that the chyme stays in contact with intestinal absorption 
surfaces, resulting in increased secretion of satiety-related hormones such as 
glucagon-like peptide 1 (GLP-1) and peptide tyrosine-tyrosine (PYY). The secretion 
of these hormones can ultimately contribute to the enhancement of feelings of 
satiety (217). Fermentable fibres are highly fermentable by bacteria in the large 
intestine, resulting in the production of short-chain fatty acids (SCFAs), which may 
also increase satiety (25). SCFAs may induce satiety mainly via 2 mechanisms. SCFAs 
can stabilise levels of glucose and insulin in blood (125), and SCFAs are suggested to 
stimulate the production and release of GLP-1 and PYY by enteroendocrine L-cells 
present in the colon, possibly via G-protein coupled receptors (56-58).
 Plasma proteomics is a technique for measuring the entire set of proteins, 
referred to as the proteome, expressed in plasma. Plasma proteomics has been 
successfully applied in both human and animal studies for the identification of new 
biomarkers of disease and nutritional status (74, 219, 220). Along the same line, all 
metabolites present in a biological sample can be determined using an approach 
called metabolomics. Because metabolomics can be used to determine alterations 
in metabolism under different conditions, the use of this technique in nutrition 
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research is increasing. For instance, metabolomics has been applied in intervention 
studies to assess novel biomarkers of dietary intake (75).
 The objective of the present study was to identify proteins in plasma that 
were differentially expressed in minipigs fed different fibre diets using a plasma 
proteomics approach. Minipigs, in this experiment used as a model for humans, 
were assigned to a control (C) diet or a diet containing pectin (PEC), lignocellulose 
(LC) or resistant starch (RS) for periods of 8 d in a 4 x 4 Latin square design. Fibre 
types were selected based on their different physicochemical properties. From all 
pigs, portal and carotid blood samples were taken from catheters on d 8 of each 
treatment, both before and at several time points after the ad libitum morning 
meal. To determine the plasma proteome, plasma samples were analysed using 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF-MS). In addition, 1H-NMR spectroscopy-based metabolomics was 
applied to increase our understanding of how different fibres can modulate the 
plasma profile of small metabolites. Data sets were subjected to multivariate data 
analysis to identify proteins and metabolites that were differentially regulated after 
feeding the fibre diets.
Materials and methods
Experimental design, pigs and housing 
Five (4 + 1) 2-year-old female Gӧttingen minipigs (Ellegaard, Denmark) with an 
initial body weight of 44 ± 1.5 kg were fitted with catheters and assigned to 4 
dietary treatments in a 4 x 4 Latin square design. An extra pig was included in the 
study as back-up in case of complications due to surgery or blood sampling, and 
this pig (p5) was randomly assigned to one of the treatment orders (p2) (Table 1). 
Each treatment lasted for 8 d, and differed with respect to the type of starch in the 
diet: highly methylated citrus pectin (PEC), lignocellulose (LC), resistant starch from 
native potato starch (RS) or a high-starch control (C). Pigs were individually housed in 
metabolism pens of 2 m2 equipped with a feeder. Artificial lights were on from 6:00 
h until 22:00 h and dimmed during the dark period. The performed research was 
in compliance with the ARRIVE guidelines on animal research (221). Experimental 
protocols describing the management, surgical procedures, and animal care were 
reviewed and approved by the Animal Care and Use Committee of Wageningen 
University and Research Centre (Lelystad, the Netherlands).
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Diets and feeding
The 4 experimental diets used were identical except for type of starch. Fibres were 
selected based on different physicochemical properties that were expected to have 
distinct effects in the gastrointestinal tract: LC is a bulky fibre, RS is a fermentable 
fibre and PEC is both a viscous and a fermentable fibre. The different fibres were 
exchanged for pregelatinized potato starch from the control (C) diet based on GE 
content (Table 2). Diets were produced as a single batch of a basal diet to which 
starch sources were added.
 Diets were fed twice a day at 7:00 h and 15:00 h as a mash by mixing the 
diets with water in the feeders immediately before feeding (ratio water:feed = 
1.5:1). The first 4 d of each treatment period, pigs received a 1:1 mix of the diet 
consumed in the previous period and the experimental diet of the new period to 
allow habituation to the new diet (Table 1). On the last 4 d of each period, pigs 
consumed only one of the experimental diets. From d 1 to d 7 of each period, pigs 
were fed a restricted amount of feed. The feeding level was gradually increased 
during each period. On d 8 of the treatment period, both the morning and afternoon 
meal were provided ad libitum. During the 1-wk adaptation period before surgery, 
pigs were fed the control diet and adapted to the feeding pattern and individual 
housing.
Table 1 Overview Latin square design experimental diets. 
    Pig 
    1  2  3  4  5 
Period 1  d 1‐4  C  C + PEC  C + LC  C + RS  C + PEC 
  d 5‐8  C  PEC  LC  RS  PEC 
Period 2  d 1‐4  C + PEC  PEC + RS  LC + C  RS + LC  PEC + RS 
  d 5‐8  PEC  RS  C  LC  RS 
Period 3  d 1‐4  PEC + LC  RS + C  C + RS  LC + PEC  RS + C 
  d 5‐8  LC  C  RS  PEC  C 
Period 4  d 1‐4  LC + RS  C + LC  RS + PEC  PEC + C  C + LC 
  d 5‐8  RS  LC  PEC  C  LC 
C, control; LC, lignocellulose; PEC, pectin; RS, resistant starch 
Table 2 Ingredient composition of the experimental diets. 
Ingredient, g/kg1    Diet 
  control lignocellulose pectin resistant starch
Pregelatinized potato starch2  350 250 200 ‐
Lignocellulose3  ‐ 100 ‐ ‐
Pectin4  ‐ ‐ 149 ‐
Native potato starch5  ‐ ‐ ‐ 394
Potato protein  50 50 50 50
Maize gluten meal  100 100 100 100
Wheat  249 249 249 249
Barley  150 150 150 150
Soy oil  15 15 15 15
Animal fat  15 15 15 15
Vitamin and mineral premix6  10 10 10 10
CaCO3  17 17 17 17
Ca(H2PO4)2   11 11 11 11
NaCl  5 5 5 5
L‐lysine HCl  1.5 1.5 1.5 1.5
NaHCO3  15 15 15 15
KCl  10 10 10 10
Flavour7  1.5 1.5 1.5 1.5
Total  1000 1000 999 1044
1Ingredients are expressed  in g/kg of the Control diet and sum up to 1000 for all diets  in which the 
gross energy (GE) content of the fibre sources is identical to that of the pregelatinized potato starch. 
2
PaselliTM WA 4 (AVEBE FOOD).  
3ARBOCEL® RC Fine (J. RETTENMAIER & SÖHNE). 
4
UNIPECTINETM RS 150 CITRUS (CARGILL). 
5Native potato starch (AVEBE FOOD). 
6Provided  the  following per kg of  feed: vitamin A: 7500  IU; vitamin D3: 1500  IU; vitamin E: 60 mg; 
vitamin K3: 1.0 mg; vitamin B1: 1.0 mg; vitamin B2: 4.0 mg; vitamin B6: 1.0 mg; vitamin B12: 20 µg; 
niacin: 20 mg; calcium‐D pantothenate: 10.5 mg; choline chloride: 100 mg; folic acid: 0.4 mg; Fe: 120 
mg (FeSO4.H2O); Cu: 15 mg (CuSO4.5H2O); Mn: 60 mg (MnO); Zn: 75 mg (ZnSO4.H2O);  I: 4.0 mg (KI); 
Se: 0.30 mg (Na2SeO3); anti‐oxidant: 75 mg. 
7
Luctarom Advance Cherry Honey, Lucta S.A., Barcelona, Spain. 
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Luctarom Advance Cherry Honey, Lucta S.A., Barcelona, Spain. 
Surgery 
Pigs underwent surgery for the placement of catheters in the external jugular vein, 
the carotid artery and the portal vein. The catheters in the carotid artery and the 
portal vein were used for blood sampling and the catheter in the jugular vein was 
placed as a back-up in case of a malfunctioning arterial catheter.
 After an overnight fast, all pigs were sedated with intramuscular Ketamine 
10 mg/kg (Ketamine, Alfasan) and Midazolam 0.75 mg/kg (Dormicum, Roche) 
and anaesthesia was intravenously induced with the anodyne Sufentanil  1 µg/
kg (Sufenta, Janssen-Cilag). Pigs were intubated and anaesthesia was maintained 
by inhalation of 2% Sevoflurane (Abbott) combined with 40% oxygen and nitrous 
oxide. A Sufentanil infusion was maintained at 1 µg/kg/hour. All pigs were equipped 
with 3 permanent polyethylene blood vessel catheters (Tygon, Norton) as described 
previously (166). The catheters for blood sampling were placed in the external 
jugular vein, in the carotid artery and in the portal vein, fixed firmly at the site of 
insertion, tunnelled subcutaneously to the back of the pig and exteriorized between 
the shoulder blades. The catheters were filled and sealed off with saline containing 
heparin and penicillin (Procpen) and kept in a backpack which was glued to the skin.
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 The first 4 d after surgery, pigs were fed a restricted amount of the control 
diet, i.e. 50, 100, 200 and 300 g per meal on d 1, 2, 3 and 4 respectively, to allow 
a gradual recovery. After that, 300 g per meal was continued into the onset of the 
experimental diets. Pigs were habituated to blood sampling in the first week after 
surgery. After 5 to 7 days of postsurgical recovery, experimental period 1 started. 
On the first 4 d of this period, all pigs received a 1:1 mix of the control diet and the 
experimental diet (Table 1).
Blood sampling 
Blood was drawn from the carotid artery and the portal vein on d 8 of each dietary 
treatment before (at -30 and 0 min) and after (at 30, 60, 120, 180, 240 and 480 
min) the morning meal. Blood was collected in 6 mL Vacutainer EDTA tubes 
(Becton Dickinson) supplemented with protease (Complete, EDTA-free; Roche) and 
dipeptidyl peptidase-4 (Millipore) inhibitors and then placed in ice water. Tubes 
were centrifuged for 10 min at 1300 g at 4°C immediately after blood collection. 
Plasma was aliquoted and stored at -80 °C until further analysis.
 Due to experimental errors or the malfunctioning of some of the catheters 
during the course of the study, not all blood samples could be collected.
SELDI-TOF-MS analysis
SELDI-TOF-MS analysis was performed on both carotid and portal plasma samples 
derived from 5 pigs on 4 different dietary treatments (C, LC, PEC and RS), collected at 
2 time points before and at 6 time points after feeding. First, samples were enriched 
for medium- and low abundance proteins with Proteominer beads according to 
the manufacturer’s instructions (Bio-Rad Laboratories Inc.). In short, filter plates 
(AcroPrep, PALL) were loaded with Proteominer beads, after which 200 µL of each 
plasma sample was transferred to the wells of the filter plate and incubated for 2 hr 
(4 °C, on a platform shaker). Subsequently, the unbound proteins were removed by 
performing 3 washing steps and discarded. The retained proteins were fractionated 
by incubating the filter plate with different elution reagents. Elution reagent 1 (1 
M NaCI 20 mM HEPES pH 7.5), elution reagent 2 (200 mM glycine pH 2.4), elution 
reagent 3 (60% ethylene glycol) and elution reagent 4 (33% isopropylalcohol, 16.7% 
acetonitril, 0.1% trifluoracetic acid) were loaded to the wells of the plate, resulting 
in 4 different eluates. 
 The 4 fractions of each sample were then separately applied to protein 
chip arrays. These arrays are composed of different chromatographic surfaces 
that are designed to retain, not elute, proteins of interest. Each chemically surface 
is designed to retain proteins according to a general or specific physicochemical 
property of the proteins. The weak cation exchanger (CM10), reverse phase (H50) 
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and immobilized metal affinity capture (IMAC30) ProteinChip arrays and binding 
buffer combinations were prepared according to the manufacturer’s instructions 
(Bio-Rad). The different ProteinChip arrays were equilibrated with the respective 
binding buffers. Samples were analysed on 2 different CM10 arrays, one for which 
a low-stringency binding/washing buffer (0.1 M sodium acetate, pH 4.0) was used, 
whereas the other array was treated with a high-stringency binding/washing 
buffer (50 mM HEPES, pH 7.0). Before applying the samples, the active spots of 
the H50 array were preactivated with 75 μL 50% methanol, and the active spots of 
the IMAC30 array were preactivated with 100 μL of 0.1 M copper sulfate solution 
according to the manufacturer’s instructions (Bio-Rad). Samples (10 μL of the eluate 
combined with 90 μL binding buffer) were loaded to each well of the array and were 
allowed to bind (60 min, room temperature, on a platform shaker) to the array. After 
the binding step, the entire array was washed 3 times with the respective binding 
buffers (5 min, with agitation) and then twice with deionized water. After briefly 
drying the arrays, 1 μL of a saturated solution of sinapinic acid (Sigma) dissolved in 
50% (vol/vol) acetonitrile and 0.5% (vol/vol) trifluoracetic acid was applied twice to 
each of the active spots of the array, and was allowed to thoroughly dry. 
 Subsequently, the different ProteinChip arrays were placed in the SELDI 
ProteinChip Biology System Reader 4,000 (Bio-Rad) and scanned with a laser energy 
of 3500 nJ. The SELDI ProteinChip spectra were analysed by using the ProteinChip 
Data Manager Client 3.5 software (Bio-Rad). The instrument was calibrated by using 
the All-in-One ProteinStandard II (Bio-Rad). Spectrum alignment was performed on 
the calibrated spectra to reduce mass variations of peaks within a group of similar 
spectra. Subsequently, baseline subtraction was conducted. Baseline subtraction 
offsets in the spectra set the result of electrical noise and the noise from energy 
absorbing molecules (222). Spectra were normalised to standardise the intensities 
of the spectra. The normalization process involved taking the total ion current used 
for all the spots, averaging the intensity (μA), and adjusting the intensity scales for 
all the spots so that all spectra could be displayed on the same scale (222). The 
peaks ranging from 1,500 to 200,000 mass-to-charge-ratio (m/z) were detected and 
extracted by the ProteinChip 3.5 software. The spectral region from 0 to 1,500 m/z 
was unreliable for normalization and peak detection due to matrix interference and 
was therefore excluded from the analyses. The spectral region above 200,000 m/z 
was also not included in the analyses because the intensity of the laser was too 
small for this region.
 The first step for the initial peak detection was the creation of clusters 
by the ProteinChip 3.5 software. Within a designated mass-to-charge ratio, the 
program grouped peaks that were present across multiple spectra at the same 
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narrow window of 0.3% m/z value. Each cluster was then treated as a single protein. 
Mass spectral data were exported as a profile matrix and used to evaluate the effect 
of diet and time of sampling on the protein profile.
1H-NMR spectroscopy
All portal plasma samples were diluted 1:1 in a 75 mM phosphate buffer (pH 7.4) 
and filtered by using Nanosep centrifugal devices with Omega Membrane (Pall 
Corporation). The molecular weight cut-off of the filter was 10K. In order to remove 
trace amounts of glycerin and sodium azide, all filters were pre-treated with 500 
µL of MQ water, followed by centrifugation at 14.000 g for 5 min. This step was 
repeated 5 times, with a 10 min centrifugation step after the 6th wash, to ensure 
the filters were free of water. Then 300 µL of the diluted plasma was transferred to 
the filter, and centrifuged for 55 min at 14.000 g at 4 °C. Subsequently, 170 µL of the 
eluate was transferred to a 3 mm NMR tube (Bruker match system). Samples were 
stored at -20 °C until analysis by using NMR spectroscopy. 
 Before NMR measurements, samples were slowly warmed up to room 
temperature and measured at 310 K (calibrated temperature) in an Avance III 
NMR spectrometer operated at 600.13 MHz. After transfer of each sample into the 
magnet, the sample was equilibrated at 310 K for 5 min. Subsequently automated 
locking, automated shimming and automated 90 degree pulse angle determination 
was performed. 1H NMR NOESY datasets were acquired for each sample. In addition, 
each dataset was automatically processed and aligned using the alanine signal 
(upfield resonance of the alanine doublet signal) at 1.49 ppm. From the aligned 
spectra, integrals for resonances of the metabolites of interest were selected and 
quantified. Concentrations of metabolites were calculated based on the number of 
hydrogen atoms of each metabolite selected.
Multivariate data analysis
Multivariate analysis and visualization of the SELDI-TOF-MS and 1H-NMR data sets 
were performed in R using the library mixOmics (151). Samples derived from portal 
and carotid blood were analysed separately. Due to problems with the catheter, 
only one carotid blood sample could be obtained from one pig (p2), and this pig was 
therefore excluded from the analysis of the carotid blood samples. The sparse form 
of multilevel partial least squares-discriminant analysis (PLS-DA) was used to select 
proteins that were differentially expressed between diets and time points (149). 
Due to the relatively small size of the dataset, the portal metabolomics dataset 
was analysed using (regular) multilevel PLS-DA. For both forms of multilevel PLS-DA 
the number of discriminant vectors (dimensions) H was set at 3, equalling number 
of treatments minus 1, as recommended (223). The number of proteins to select 
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for sparse multilevel PLS-DA was determined by applying tuning criterion 2, i.e. 
maximized correlation between the 2 factors (fibre and postprandial time) on each 
dimension (149).
Statistical methods 
Food intake was analysed using One-Way ANOVA in IBM SPSS Statistics 19. SCFA 
concentrations determined in portal plasma were analysed using a linear mixed 
model in IBM SPSS Statistics 19. The model included diet, time and interaction of 
diet and time as fixed effects, and pig as random effect. Differences were considered 
significant if P <0.05.
Results
Food intake
On d 8 of each treatment period, meals were provided ad libitum. In the morning, 
pigs fed the RS diet had a significantly higher food intake than pigs consuming the 
C (P = 0.031) or the PEC diet (P = 0.006) (Fig. 1). When adding up food intake in the 
morning with food intake in the afternoon, RS-fed pigs consumed significantly more 
than PEC-fed pigs (P = 0.012) (Fig. 1).
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Figure 1 Food intake on d 8 of each treatment period during the morning meal (7:00), 
the afternoon meal (15:00) and during both meals. Values are means ± SEM, n = 
5 pigs per diet. * and ** indicate that 2 diets differ from each other with P <0.05 
and P <0.01, respectively. C, control diet; LC, lignocellulose diet; PEC, pectin diet; RS, 
resistant starch diet.
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Proteomics analysis
A total of 973 proteins could be determined in both portal and carotid plasma 
samples using SELDI-TOF-MS analysis, with 232, 245, 265 and 231 proteins being 
measured on the CM10 high stringent, CM10 low stringent, H50 and the IMAC30 
array respectively. We were mainly interested to identify the proteins whose 
postprandial expression was different between both time point and the fibre type 
consumed. To this end the sparse multilevel PLS-DA was used.
Protein profile portal blood
The expression of the 973 proteins in 116 portal plasma samples derived from all 
5 pigs was used as input for sparse multilevel PLS-DA. The analysis revealed that 
44 proteins (27 in dimension 1, 14 in dimension 2 and 3 in dimension 3) explained 
most of the variation in the 2 factor dataset (fibre and postprandial time). The 
sparse multilevel PLS-DA plot showed that, based on the expression levels of these 
44 proteins, some diets and time points cluster together (Fig. 2A). Samples taken 
after consumption of the C or the LC diet are mainly located on the right side 
of the plot, with samples taken before (-30 and 0 min) and 30 and 60 min after 
feeding in the upper part of the plot and samples collected after 120, 180 and 240 
min present in the lower part of the figure. Samples corresponding to PEC and RS 
consumption cluster together in the middle of the plot, with samples collected 180 
and 240 min post-feeding located below the samples taken at earlier time points. 
For all diets, samples obtained 480 min after feeding were mainly located on the 
upper left side of the figure. This observed clustering pattern was confirmed with 
a clustered heatmap of the 44 proteins, showing that the C diet clustered with the 
LC diet whereas the PEC diet clustered with the RS diet (Fig. 2B). Furthermore, the 
earlier time points (-30, 0, 30, 60 and 120 min) clustered together, and the late time 
points, most clearly 480 min, also clustered together. The intensity of the colour of 
the proteins measured at later time points indicates that the most extreme (either 
highest or lowest) peak intensities occurred more than 180 min after feeding. The 
expression pattern of representative proteins from the 3 main protein clusters in 
the heatmap are visualised in Fig. 2C. The expression of C217172_H50 from protein 
cluster 1 increased over time, especially with the PEC diet. On the other hand, the 
intensity of C34169_6_CM10low from protein cluster 2 decreased over time and 
the expression of this protein appeared to be unaffected by diet. C36297_5_H50, 
representing cluster 3, did show a highly diet-dependent expression pattern.
 Overall, these data indicate that the protein expression pattern in response 
to dietary fibre is similar between the C and LC diet, and between the PEC and RS 
diet. The major shift in the proteome starts 120 min after feeding, with the most 
pronounced shift between 240 and 480 min postprandially.
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Protein profile carotid blood
The same analysis was performed on plasma derived from the carotid artery. The 
expression of all proteins in 126 carotid plasma samples, derived from 4 pigs, was 
used as input for sparse multilevel PLS-DA analysis. A total of 65 proteins was found 
to be most discriminating between the diets and time points (57 in dimension 1 
and 8 in dimension 2). The resulting sparse multilevel PLS-DA plot showed that the 
C and LC samples are in general located on the left side of the plot, whereas the PEC 
and RS samples are located on the right side of the figure (Fig. 3A). However, the 
clustering according to diet was less pronounced than the clustering observed with 
portal plasma. Samples taken 240 and 480 min after feeding were mainly located on 
the right side of the plot, indicating that the major shift in the proteome occurred 
at these time points. A clustered heatmap of the 65 proteins revealed that samples 
mainly clustered according to diet, and to a smaller extent according to time point 
(Fig. 3B). The highest and lowest peak intensities were observed in plasma collected 
480 min postprandial. The intensity of C217178_IMAC30, a typical protein from 
protein cluster 1 on the clustered heatmap, increased over time with the highest 
expression 480 min after feeding (Fig. 3C). The expression patterns were similar 
in all diets, although the basal levels before feeding were different. C22358_5_
IMAC30, representing cluster 2, showed a diet-dependent expression pattern, 
with the highest expression observed either 180 or 240 min postprandially. The 
intensities of the proteins from cluster 3, as visualised for C15000_8_CM10high, 
slightly decreased over time.
Figure 2 Sparse multilevel PLS-DA analysis of portal plasma samples visualised in a 
scatter plot (A) and a clustered heatmap (B) and the expression pattern of three 
representative  proteins (C). A. Sparse multilevel PLS-DA sample representation for 
dimensions 1-3 of all 116 portal plasma samples, with symbols indicating different 
time points and colours indicating different diets.  X and Y axis represent the subspace 
to project the samples. B. Unsupervised clustering analysis with Euclidian distance 
and Ward method of the 44 proteins selected by sparse multilevel PLS-DA. Samples 
are represented in columns and proteins in rows. Protein identifiers indicate fraction 
(C0 to C3 for fraction 1 to 4), followed by mass-to-charge-ratio and array type. For 
visualization purposes the data were row normalized. Samples with an intensity 
above average are marked red and samples with an intensity below average are 
marked blue (colour gradient). The 3 main protein clusters were arbitrarily labelled 
1, 2 and 3. C. Typical expression pattern of 3 proteins from the 3 different clusters on 
the heatmap (B; circled) before feeding (-30 and 0 min) and after feeding (30 to 480 
min) pigs an ad libitum meal of the control (C), lignocellulose (LC), pectin (PEC) or 
resistant starch (RS) diet in the morning of d 8. C, control diet; LC, lignocellulose diet; 
PEC, pectin diet; RS, resistant starch diet.
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Comparison portal and carotid blood
Subsequently we were interested to know the degree of overlap between the 
differentially expressed proteins observed in portal blood and in carotid blood. Out 
of the 44 proteins identified in portal blood by multilevel PLS-DA, only 19 proteins 
were also found to be differentially regulated in carotid blood, suggesting hepatic 
clearance of these proteins (Fig. 4). Similarly, the liver and extra-hepatic tissues 
may also play a role in regulating the abundance of the 46 proteins that were only 
differentially regulated in carotid plasma. 
Figure 3 Sparse multilevel PLS-DA analysis of carotid plasma samples visualised in 
a scatter plot (A) and a clustered heatmap (B) and the expression pattern of three 
representative  proteins (C). A.  Sparse multilevel PLS-DA sample representation for 
dimensions 1-2 of all 126 carotid plasma samples, with symbols indicating different 
time points and colours indicating different diets. X and Y axis represent the subspace 
to project the samples. B. Unsupervised clustering analysis with Euclidian distance 
and Ward method of the 65 proteins selected by sparse multilevel PLS-DA. Samples 
are represented in columns and proteins in rows. Protein identifiers indicate fraction 
(C0 to C3 for fraction 1 to 4), followed by mass-to-charge-ratio and array type. For 
visualization purposes the data were row normalized. Samples with an intensity 
above average are marked red and samples with an intensity below average are 
marked blue (colour gradient). The 3 main protein clusters were arbitrarily labelled 
1, 2 and 3. C. Typical expression pattern of 3 proteins from the 3 different clusters on 
the heatmap (B; circled) before feeding (-30 and 0 min) and after feeding (30 to 480 
min) pigs an ad libitum meal of the control (C), lignocellulose (LC), pectin (PEC) or 
resistant starch (RS) diet in the morning of d 8. C, control diet; LC, lignocellulose diet; 
PEC, pectin diet; RS, resistant starch diet.
Figure 4 Venn diagram showing the overlap of proteins identified by sparse multilevel 
PLS-DA in portal and carotid plasma.
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Metabolites portal blood
In addition to the proteome analysis, NMR-based metabolomics was performed on 
portal plasma samples. In total, 24 metabolites were measured in these samples. 
The identity of 21 metabolites was determined, whereas 3 metabolites could not 
be identified solely by their 1H-NMR peak pattern. The clustered heatmap resulting 
from multilevel PLS-DA analysis showed the clustering pattern of the metabolites 
(Fig. 5). The branched-chain amino acids (valine, leucine and isoleucine), the 
SCFAs (acetate, propionate, butyrate and butyrate-derivative) and the 3 unknown 
metabolites (unknown 1, 2 and 3) formed separate clusters. Furthermore, a slight 
clustering according to diet was observed, whereas time appeared to have no impact 
on the clustering pattern. The highest concentrations were found for the branched-
chain amino acids and unknown metabolites 1, 2 and 3 after consumption of the 
LC diet.
 Because the SCFAs resulted from the fermentation of fibres, we had a closer 
look at the postprandial pattern of these metabolites (Fig. 6). The concentrations of 
acetate, propionate and butyrate were significantly higher with the RS diet than the 
concentrations after C, LC and PEC consumption. The highest concentrations with 
RS were observed 480 min post-feeding. In addition, acetate concentrations were 
significantly higher with PEC consumption compared to C and LC consumption (P 
values 0.016 and 0.012 respectively).
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Figure 5 
Figure 5 Unsupervised clustering analysis with Euclidian distance and Ward method 
of the 24 metabolites determined in 108 samples by 1H-NMR based metabolomics as 
analysed by multilevel PLS-DA. Samples are represented in columns and metabolites 
in rows. For visualization purposes the  data was row normalized. Samples with 
concentrations above average are marked red and samples with concentrations 
below average are marked blue (colour gradient).
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Discussion
In this study we have shown that protein expression profiles of portal and carotid 
plasma depend on the fibre diet consumed, with a clear distinction between 
samples collected after PEC and RS consumption and samples taken after C and 
LC consumption. With all diets, a pronounced shift in the proteome was observed 
between 240 and 480 min post-feeding. 
 Changes in protein expression were observed at a later time point in carotid 
than in portal plasma samples (around 240 and 180 min after feeding respectively). 
This observation may partially be explained by hepatic clearance and conversion 
of both nutrients and plasma proteins in portal plasma until reaching a threshold, 
resulting in a delayed response in carotid plasma. The proteins exclusively present 
in carotid plasma may be produced by the liver or secreted by extra-hepatic tissues.
 We observed that protein profiles were highly similar between PEC and RS 
consumption. PEC, besides being a viscous fibre, is fermentable by bacteria in the 
large intestine, although to a slightly smaller extent than RS (224). The fermentability 
of the PEC and RS diet is supported by the SCFA concentrations measured in portal 
blood, showing that RS consumption significantly increased concentrations of all 
SCFAs compared to the 3 other diets, and acetate levels were significantly higher 
after PEC consumption compared to the C and LC diet. However, more similar SCFA 
concentrations were expected in the PEC and the RS diet (224), which might be due 
to the significantly higher food intake of RS-fed pigs compared to pigs consuming 
the PEC diet. Despite the different SCFA concentrations in PEC-fed pigs compared 
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Figure 6 Plasma concentrations of acetate (A), propionate (B) and butyrate (C) in 
portal blood collected before feeding (-30 and 0 min) and after feeding (30 to 480 
min) pigs an ad libitum meal of the control (C), lignocellulose (LC), pectin (PEC) or 
resistant starch (RS) diet in the morning of d 8. Statistical significance of effects of 
diet (D) and sampling time (T) is shown with *** indicating P <0.001 and NS indicating 
non-significant effects. C, control diet; LC, lignocellulose diet; PEC, pectin diet; RS, 
resistant starch diet.
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to RS-fed pigs, the plasma protein profile was highly similar between these diets, 
indicating that the protein profile might be SCFA-independent. 
 The reason for studying 3 different fibre types is because these fibres 
each have their own physicochemical properties, which might result in differences 
in degree and mechanism of satiety regulation. Interestingly, the 4 different 
diets tested in our study have previously been used in an experiment on feeding 
motivation in another group of pigs (17), showing that PEC was the least satiating 
fibre and LC and RS were the most satiating fibres. It could be speculated that the 
similarities between LC and RS regarding effects on satiety are reflected at the 
plasma proteome level. However, the protein profiles were very different after LC 
consumption than after RS feeding. If a substantial part of the proteome describes 
what happens with satiety regulation, the mechanisms via which these changes 
occur are very different for RS compared to LC. This is supported by the very distinct 
physicochemical properties of these fibre types, with LC being a bulky fibre and RS 
being a fermentable fibre.
The identification of the measured proteins is a great challenge and beyond the 
scope of this chapter. A limitation of the SELDI-TOF MS technology is that its spectrum 
reports a low-resolution profile of protein species that bound to the protein chip 
arrays, which is due to the relatively low resolution and hence mass accuracy of its 
mass analyser, and lack of tandem MS capabilities (225, 226). Furthermore, proteins 
can be post-translationally modified, e.g. by glycosylation, which also obscures the 
identification of the protein.
 However, although it is not possible to name the measured proteins, the 
proteins in our dataset do provide a number of interesting leads. Among the 973 
proteins we determined, some proteins had a similar mass-to-charge-ratio (m/z) 
and showed a similar postprandial expression pattern, suggesting that 2 forms of 
the same protein may be detected. Moreover, a view proteins with an identical 
m/z ratio were determined on multiple arrays. These observations suggest that the 
number of unique proteins measured was in fact lower than 973. 
 The m/z of a protein can help us determine which metabolic function each 
protein might have. The m/z determined in this experiment varied from 1,504.7 to 
195,739. Usually a compound with a molecular weight below 5,000 Da is defined 
as a peptide, meaning some compounds that we defined as proteins were in fact 
peptides. Examples of peptides are GLP-1 and PYY, with a mass of approximately 
3,298 Da and 4,310 Da respectively.
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 In addition, the type of protein array to which the plasma fractions were 
hybridized may provide clues on the physicochemical property of the proteins. For 
example, CM10 arrays bind molecules with a positive charge on the surface, H50 
arrays capture large proteins through hydrophobic interactions and IMAC30 arrays 
capture molecules that bind polyvalent metal ions.
 The intensities of the peaks measured using SELDI-TOF-MS are indicative 
of the concentration of the proteins in plasma. In our dataset, large differences in 
intensity were observed between the proteins, ranging from almost 0 to over 600. 
Because the proteins that are usually present at high concentrations in plasma are 
largely known, the relative abundance of the proteins may also provide evidence 
about the protein identity.
Analysis of the 1H-NMR-based metabolomics data revealed a mild effect of diet on 
the postprandial concentrations of a variety of amino acids. This suggests that the 
type of fibre may influence protein digestion, which may be due to shifts in the 
composition and activity of the microbiota. 
In conclusion, this study showed that the consumption of diets with fermentable 
fibres results in different postprandial plasma protein and metabolite profiles 
compared to a diet containing non-fermentable fibres or a diet without fibres. 
Among the proteins that explained the majority of the variation between diets 
and time points, potential biomarkers for intake of fermentable fibre or gut-
derived mediators of satiety may be identified. However, this will require further 
investigation.
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Motivation and aim of the research
The objective of the research described in this thesis was to reveal the effects of 
fermentation in the large intestine using a comprehensive approach with focus on 
metabolism and satiety. In order to investigate this, experiments were performed 
in pigs to determine the effect of a diet high in resistant starch (RS) on microbiota 
composition, short-chain fatty acid (SCFA) concentrations and gene expression in 
colon, and on several plasma variables including glucose, insulin, satiety-related 
hormones, SCFAs and serotonin. Results from these studies are described in Chapter 
2, 3 and 5. Chapter 6 shows the result of a proteomics analysis of portal and carotid 
plasma of minipigs fed different fibre diets. In addition, we used a mouse model 
to determine the effect of dietary fat content on colonic gene expression profile 
after colonic administration of SCFAs. In Chapter 4 the main findings from this 
experiment are reported.
Main findings of the research
Essentially 3 major findings are reported in this thesis. First, we showed that the 
consumption of RS changed the microbiota composition in the caecal and colonic 
lumen. The abundance of several potentially pathogenic bacteria was decreased, 
whereas the SCFA-producing populations increased in abundance. Second, 
colonic gene expression changes were observed after RS consumption and after 
colonic administration of SCFAs. With both treatments, among the changes in the 
transcriptional profile of the host were changes in metabolic processes, such as 
energy and lipid metabolism, and immune response. Third, we showed that fat 
content in the background diet had a major impact on gene expression responses 
to SCFAs in colon. Dietary fat appeared to be is an important factor determining 
the metabolic implications of SCFA administration. These main findings will be 
discussed in more detail in the next paragraphs.
RS consumption modulates microbiota composition
We determined caecal and colonic microbiota composition of pigs after 2 wk of 
RS consumption (Chapter 2 and 3). In colon, diet was found to be the main factor 
driving the microbial variation. Among the microbial groups increased in relative 
abundance by RS treatment were the healthy gut-associated butyrate-producing 
Faecalibacterium prausnitzii bacteria, whereas potentially pathogenic members of 
the Gammaproteobacteria, including Escherichia coli, Pseudomonas, Psychrobacter 
and Vibrio spp., were reduced in relative abundance.
 As has been shown in literature, 2 wk of intervention should be sufficient for 
the establishment of a new stable microbial composition (46, 178). Because we did 
not have the opportunity to follow changes in microbiota composition over time, it 
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was impossible to predict in which order colonic changes occurred. In RS-fed pigs, 
we observed an increase in SCFA concentrations in the colonic lumen (Chapter 2 and 
3). These SCFAs were produced by the microbiota. However, consumption of RS for 
a prolonged period resulted in changes in the microbial composition. Determining 
the main factor(s) driving this change is rather difficult. The increased availability of 
substrate for fermentation, in this case RS, might have required a change in microbial 
composition, because the initial microbiota composition did not allow all substrate 
to be fermented. In that case the fibre itself was directly driving the microbial shift. 
In addition, it might be possible that the fermentation products, i.e. SCFAs, have 
resulted in microbial changes. The shift in microbiota composition can in turn result 
in changes in both the total SCFA production and the relative production of the 
individual SCFAs, indicating there is an interaction between SCFAs and microbiota.
 During the experiment described in Chapter 3, luminal content was 
collected to isolate microbial RNA. Recently developed techniques allow the 
determination of the so-called metatranscriptome, which is the gene expression 
profile of all gut microbiota. Information on the microbial activity, for which the 
analysis is currently in progress, in addition to the microbial composition, could 
increase our understanding of the causal relationships. For example, these data 
could help answering the question whether RS consumption enhances the microbial 
fermentation capacity independent of the composition.
 Although the causal relationships remain to be elucidated, the observed 
shift in microbial profile with RS consumption supports the general believe that 
fermentable fibres have a beneficial impact on colonic health.
Fermentation modulates colonic gene expression profile
Comparing genome-wide expression profiles is an unbiased approach for identifying 
genes and processes that are affected by a compound or diet. Both in pigs and 
mice, the whole-genome expression profile of colon was studied (Chapter 3 and 
4). In the mouse study, we investigated the effects of colonic administration of 
SCFAs, whereas the pig study described the effects of fermentable dietary fibre (RS) 
consumption. Although the experimental set-up and aim of the study performed in 
mice were different from those of the pig studies, the fact that SCFAs are products 
of the fermentation of fibres, allows some comparison to be made between the 
results derived from mice and the results derived from pigs. Interestingly, we 
observed a general induction of lipid-related processes after RS consumption in 
pigs, whereas these processes were generally suppressed by SCFA treatment in 
mice. This opposite direction of change was also found for immune response, which 
appeared to be suppressed in pigs and induced in mice.
 In RS-fed pigs, we observed an increased expression of genes involved in the 
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TCA cycle, the pathway responsible for generating energy through the oxidization 
of acetyl-CoA. The increased energy generation in colonocytes upon RS feeding 
was in line with our expectations, as we also observed that RS increases SCFA 
concentrations in the colonic lumen. These SCFAs are taken up by the colonocytes, 
where they serve as a precursor to the TCA cycle. These data are supported by the 
mouse experiment, showing that SCFAs, mainly acetate and butyrate, affect energy 
metabolism. The similarities in gene expression pattern observed between acetate 
and butyrate might be due to the fact that both acetate and butyrate enter the 
TCA cycle as acetyl-CoA, whereas propionate enters as succinyl-CoA (182). Chapter 
4 also showed that propionate affects amino acid metabolism, which could be 
explained by the fact that propionate can be metabolized by the TCA cycle, thereby 
contributing to the generation of TCA-derived amino acids (182). In mice receiving 
acetate or butyrate infusions, highly comparable changes in lipid and lipoprotein 
metabolism were observed, whereas propionate induced very distinct changes in 
gene expression profile. 
 Within our research group a study was performed, in which C57BL/6J mice 
were fed diets containing different fibre types for 10d (Lange et al., unpublished 
data). Among the fibre types included in this study was RS, which was the same 
fibre also added to the pig diets used in Chapter 3. The colonic gene expression 
data showed that RS resulted in positive enrichment of genes involved in immune 
response, whereas metabolic processes such as fatty acid oxidation, oxidative 
phosphorylation, glutathione metabolism, glycolysis, gluconeogenesis and 
branched-chain amino acid processes, were negatively enriched with RS. This mouse 
study revealed that RS consumption induced opposite colonic changes compared 
to the studies performed in pigs. However, the direction in which colonic gene 
expression profile was modulated with RS in mice was quite similar as observed 
with SCFA infusion in mice (Chapter 4). 
 In pigs, the transcription factor PPARG was predicted to be significantly 
activated with RS consumption in pigs, indicating that this upstream regulator 
could explain part of the observed shift in gene expression profile. In addition, the 
transcriptome data were used to identify potentially secreted proteins that may 
mediate effects of RS in liver or other tissues and organs. Among the potentially 
secreted proteins that were expected to increase with RS were IGF1, AGT, VEGFA 
and ANGPTL4, proteins which are all derived from PPARG target genes. These data 
suggest that changes in colonic gene expression can affect whole-body metabolism 
and health.
 Based on these results we assume that the animal model played a major 
role in the observed effects on gene expression level. Differences in microbiota 
composition could partly explain the large discrepancy between the results, as 
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microbial composition is known to be highly different among species (227) and 
dependent on the diet. In addition, it should be noted that colonic gene expression 
is a complex variable. Gene expression changes could have been induced by the 
microbiota or the SCFAs, but also less well characterised factors might be involved.
Dietary fat modulates colonic gene expression profile
In the study described in Chapter 4, mice received rectal SCFA infusions on a low 
fat or a high fat diet background. Dietary fat content was shown to have a major 
impact on colonic gene expression response to SCFAs, especially after propionate 
treatment. For instance, the direction of the changes in fatty acid biosynthesis, 
amino acid metabolism and carbohydrate metabolism induced by propionate was 
highly dependent on background diet. These metabolic processes were induced on 
a low fat diet background, whereas suppression of these processes was observed 
with high fat feeding. Furthermore, SCFA infusion on the high fat diet background 
appeared to partially reverse the gene expression changes induced by high fat 
feeding without SCFA infusion.
 Overall we observed that dietary fat is an important factor determining the 
metabolic implications of SCFA administration. Part of the colonic gene expression 
changes observed on the high fat diet background are likely to be the result of a 
change in microbial composition (43, 48). Based on our findings, it can be concluded 
that standardization of the fat and carbohydrate content in the background diet 
is essential for studying effects of colonic SCFAs, because there appears to be a 
close interplay between dietary fat and colonic SCFAs. The high fat diet used in 
this experiment, containing 45 en% of fat, closely represents the human diet and 
therefore results obtained from mice consuming the high fat diet might best reflect 
what would happen in humans.
SCFA concentrations after RS consumption
In the pig studies described in this thesis, SCFA concentrations were measured after 
RS consumption at different locations of the intestinal lumen (Chapter 2 and 3), and 
in portal (Chapter 6) and peripheral (Chapter 3/5) plasma at several time points. 
Although the studies differed with respect to experimental set-up and the location 
and time of sample collection for SCFA measurement, comparison of the SCFA ratios 
provides some relevant information (Table 1).
 Knowledge about the ratio in which the individual SCFAs are produced 
is mainly derived from in vitro fermentation studies. In vitro fermentation of 
RS using faecal inocula from pigs resulted in a SCFA composition of 65:22:14 
(acetate:propionate:butyrate) (224). This composition is comparable to 
the ratios calculated from the results described in Chapter 3, showing an 
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acetate:propionate:butyrate ratio of 58:31:12 in colon (Table 1). However, the 
relative concentration of butyrate found in Chapter 2 was much lower (i.e. 6%), 
whereas the relative acetate concentration was much higher compared to the study 
described in Chapter 3 (75 vs. 58%). Since diet composition and time of sampling 
were the same in both experiments, the discrepancy between the results might be 
due to difference in age (4 vs. 22 months), body weight (60 vs. 270 kg) and gender 
of the pigs. It should also be noted that concentrations do not necessarily reflect 
production rates, as the rate of SCFA absorption could have differed between the 
individual SCFAs and between the pigs.
 SCFAs are taken up by the colonocytes, after which they can either be used 
as an energy source for the colonocytes, or they are transported to the liver via 
the portal vein to serve as anabolic substrates in tissues other than colon (61, 62). 
SCFA levels were determined in portal plasma collected from minipigs (Chapter 6), 
showing that around 75% of the measured SCFAs was acetate. When comparing 
this number with the 58% measured in the colonic lumen (Chapter 3), this indicates 
that propionate and butyrate are metabolised by the colonocytes to a higher 
extent than acetate. Surprisingly, butyrate levels were slightly higher compared to 
propionate levels, although butyrate is assumed to mainly serve as an energy source 
for the colonocytes (169). In peripheral plasma, collected in the study described 
in Chapter 3/5, approximately 85% of the measured SCFAs was acetate. Relative 
plasma concentrations of propionate and butyrate were lower in peripheral plasma 
than in portal plasma, with again butyrate levels being slightly higher compared to 
propionate levels. Other studies have shown as well that acetate is by far the most 
abundant SCFA in peripheral plasma (228, 229). However, since peripheral blood 
is a complex matrix, it is not possible to explain where the circulating SCFAs were 
derived from or by which organ they will be metabolised.
 It should be taken into account that extensive interconversion between 
acetate and butyrate takes place in the intestinal tract (230), which further 
complicates the determination of acetate, propionate and butyrate production 
resulting from colonic fermentation. 
Animal models
Pigs
In this thesis, effects of dietary fibres were tested in pigs. This model was selected 
because the anatomy and physiology of the gastrointestinal tract of pigs is highly 
similar to those in humans (66), making pigs a suitable invasive model for the 
digestive function in humans. Furthermore, extensive conservation exists between 
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Table 1 SCFA composition measured in intestinal lumen and plasma of pigs after RS consumption. 
 
Study  Location Hours after feeding Acetate:propionate:butyrate1
  Intestinal lumen   
Chapter 2  Distal small intestine  5 91:3:6 
  Caecum 5 75:21:5 
  Colon  5 75:19:6 
Chapter 3  Distal small intestine  5 94:3:3 
  Caecum 5 56:33:11 
  Proximal colon2  5 53:34:13 
  Colon3  5 58:31:12 
  Plasma  
Chapter 6  Portal  4 78:9:13 
  Portal  8 74:10:16 
Chapter 3/5  Peripheral  4 86:5:9 
  Peripheral  5 83:5:12 
1Relative concentrations are expressed as proportion of the sum of acetate, propionate and butyrate 
concentration. 
2SCFAs measured in luminal content collected from the location of the cannula.  
3SCFAs measured in luminal content collected at section. 
the pig and human genome sequence (67, 70). Another advantage is that research 
findings in pigs can be used to improve the welfare of restrictedly fed animals, such 
as adult pigs, which may suffer from hunger and related welfare problems (14).
 However, the use of pig models has some limitations. In pig breeding, 
remarkable progress in reducing backfat and improving growth rate was made 
during the last 100 years (231). It is very likely that the long history of pig breeding 
had a large impact on the genetics of these animals. Domestic pigs can be a suitable 
model for increasing our understanding of mechanisms of fibre-induced satiety, 
but on the level of metabolism, pigs have adapted to rapid growth, which might 
complicate the translation of data obtained from pig experiments to the human 
situation. 
 As observed from the pig studies on the effects of RS (Chapter 2 and 3), the 
inter-individual variation between pigs regarding colonic microbiota composition, 
SCFA concentrations and gene expression was rather high, although pigs were 
genetically related (i.e. siblings were included) in both experiments. This high 
degree of variation is also observed in human intervention studies, underlining the 
similarity between pigs and humans. However, large differences in observations 
between pigs make it more difficult to find robust effects of diet.
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Mice
To determine the effect of rectally administered SCFAs on colonic gene expression 
profile, C57BL/6J mice were the animal model of choice. Among the advantages 
of a mouse model are the low costs, small size and high reproduction rate of mice. 
In addition, mice are relatively easy to house and to handle and inbred strains to 
limit inter-individual genetic variation and transgenic mouse models are available 
(63, 64). To understand basal mechanisms of metabolism and the role of nutrition 
and specific transcription factors in metabolic regulation, mouse models have been 
proven to be very valuable. 
 However, data obtained from mouse experiments should be translated to 
humans with caution, because of large contributions of the genetic background 
caused by the breeding selection (65). In addition, a number of highly important 
differences between metabolism in mice and humans exist, for instance regarding 
cholesterol metabolism.
 Furthermore, collection of a sufficient amount of blood from mice in order 
to measure hormones or metabolites may in some cases be challenging. On the 
other hand, the small size of mice makes organ collection relatively simple, because 
a complete organ, such as colon or liver, can be collected at section.
Relevance to humans
In this thesis, both mice and pigs were used as models for humans, as we were 
interested to know how fermentation of fibres can improve human health. These 
animal studies have been valuable in the identification of metabolic changes 
resulting from fermentation, which could not have been achieved with human 
intervention studies. 
 However, we have shown that identical fibres can induce distinct metabolic 
effects in different species, indicating that species differences should not be 
underestimated. These differences could be attributed to differences in fermentation 
capacity. As shown by in vitro fermentation, human faecal inoculum has a higher 
ability to ferment RS than faecal inoculum of pigs, and human inoculum is able to 
ferment a broader variety of fibres than pig inoculum (224). This difference between 
pig and human inoculum could be due to the consumption of a more heterogeneous 
and uncontrolled diet by humans, resulting in the adaptation of the human gut 
microbiota to a larger variety of fibres. For future research, standardisation of the 
microbiota composition between animals is recommended. Human gut microbiota 
have been successfully transplanted into germfree piglets and mice, resulting in a 
human-like microbial community (48, 232), which seems very promising.
 A highly relevant question is which animal model best reflects what 
would happen in humans. Because higher similarities exist between the anatomy, 
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physiology and metabolism of the gastrointestinal tract of pigs and humans than 
between the intestine of mice and humans, pigs would be the preferred model. 
However, the exact research question largely determines which model would be 
most suitable and most feasible to use. Also, in addition to animal studies, in vitro 
studies or human intervention studies can be performed in parallel to enhance 
mechanistic knowledge and to obtain a clear picture of the actual implications for 
humans.
Implications for human health
The previous paragraphs of this chapter mainly focussed on colonic changes 
induced by fermentation, but eventually these changes are expected to affect 
whole-body metabolism and health. Importantly, RS is suggested to contribute to 
the prevention of obesity (125, 233). This might seem rather contradictory, because 
the fermentation products, i.e. SCFAs, also serve as an energy source for the body, 
suggesting that these fibres would increase body weight and adiposity. However, 
studies showed that RS can enhance satiety (17, 132, 133), which was also supported 
by this thesis (Chapter 5), resulting in decreased food intake. Furthermore, studies 
have shown that RS can reduce weight gain and adiposity (82, 83, 234). These 
beneficial effects are thought to be largely mediated by SCFAs.
Satiety and food intake
Essentially, fermentable fibres can enhance satiety via 3 mechanisms. First, SCFAs 
resulting from fermentation can stabilise glucose and insulin levels, as supported 
by the findings described in Chapter 5. A more gradual increase in glucose and 
insulin levels after a meal is believed to enhance satiety (216). Second, fermentable 
fibres can affect the secretion of satiety-related hormones such as glucagon-like 
peptide 1 (GLP-1) and peptide YY (PYY) (29, 82). SCFAs are agonists for free fatty 
acid receptors (FFA2 and FFA3), which are expressed in enteroendocrine cells in 
the gut epithelium. The activation of these receptors was suggested to trigger the 
production and release of GLP-1 and PYY by enteroendocrine L-cells (91, 92). In 
Chapter 5 we measured a significant decrease in GLP-1 levels after RS consumption, 
which is in line with the changes in glucose and insulin levels. The exact implications 
of this decrease in GLP-1 are however largely unknown. Third, RS was found to 
decrease blood serotonin levels (Chapter 5). Diet was previously shown to influence 
intestinal serotonin release (199), which in turn changes intestinal motility and 
transit (200), thereby potentially affects satiety (25). Intestinal motility could be 
reduced in RS-fed pigs, possibly leading to a reduced passage rate of digesta in the 
colon.
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 Several factors influence the outcome of studies on the satiating properties 
of fermentable fibres. Two of these factors concern the experimental design. First, 
the duration of the intervention can have a major impact on study outcome. In 
our studies, pigs consumed the RS diet for 2 wk. However, experiments have been 
performed with very different study durations, also showing slightly different study 
results (83, 132). In an accompanying project, an experiment was performed in 
which long-term effects of an RS diet on feeding patterns and growth performance 
in growing pigs fed ad libitum for 12 wk were studied (235). Pigs fed RS were shown 
to change feeding patterns compared to DS-fed pigs, i.e RS consumption increased 
feed intake per meal, meal duration and inter-meal intervals, and reduced the 
number of meals per day. However, daily dry matter intake was not affected. 
 Second, the selection of an adequate control diet is highly important when 
studying effects of fibres. In the pig studies described in this thesis, we decided 
to exchange DS for RS on gross energy basis. DS is broken down and absorbed in 
the small intestine, resulting in rapid nutrient uptake, a rapid glucose peak and 
therefore also rapidly available energy. On the other hand, RS escapes digestion in 
the small intestine and is fermented by microbiota in the large intestine resulting in 
the production of SCFAs. Although the amount of gross energy was similar in both 
diets, metabolizable energy was 4.8% lower in the RS diet (14.10 MJ/kg) compared 
to the DS diet (14.78 MJ/kg) (Chapter 3/5). Despite the lower caloric value of the 
RS diet, this diet seemed to be more satiating compared to the DS diet (Chapter 5). 
Therefore, comparison of diets with the same amount of gross energy might result in 
an underestimation of the satiating effects of a fermentable fibre diet, because the 
metabolizable energy is usually slightly lower in these diets. It is important to note 
that the amount of energy that can be obtained from fermentable fibres is highly 
dependent on the fibre type and the species in which the study was performed.
Body weight development
It is important to know whether changes in satiety and/or food intake are reflected 
in changes in body weight or adiposity. The study on the effects of ad libitum 
consumption of RS for 12 wk in growing pigs showed that RS-fed pigs had a reduced 
intake of digestible energy (DE) compared to DS-fed pigs (235). Despite the reduced 
DE intake, RS-fed pigs had similar growth rates as pigs fed DS and at the end of 
the study body weight was similar in all pigs. However, intestinal weights of RS-
fed pigs were higher compared to DS-fed pigs, which could be explained by the 
high fermentation level with RS. This observation is highly relevant to humans, as 
in most human intervention studies no effect of long term fibre consumption on 
body weight can be observed (12). In research on fermentable fibres, determining 
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body composition or intestinal weight in addition to body weight alone, could 
yield completely different conclusions about the effects of fibres on body weight 
development.
Conclusion and recommendations
The main findings of this thesis are summarised in Fig. 1, showing how fermentable 
dietary fibres may ultimately induce satiety and reduce body weight. In this thesis, a 
nutrigenomics approach was used to investigate the effects of fermentable dietary 
fibres, taking full advantage of the current state of art in genomics research (72, 73).
 This thesis supports the implementation of fermentable dietary fibres into 
the human diet to improve colonic health and to reduce energy intake and body 
weight gain, which ultimately may prevent obesity and type 2 diabetes. Increased 
knowledge about the underlying mechanisms by which resistant starch induces 
satiety could facilitate the effective application of resistant starch in human diets. 
More research is required to further elucidate how diet composition, in particular 
the presence of fermentable dietary fibres, can improve human health.
dietary fibre ↑ 
Colonic lumen Colonic mucosa 
SCFAs 
SCFA uptake  
(e.g. MCT1 transporter) 
SCFA signalling  
(e.g. FFA2 and FFA3 receptor) 
Plasma 
secretion of hormones 
(e.g. GLP-1, PYY, 
Angptl4) 
satiety 
Microbiota 
- composition and activity 
dietary fat ↑ 
↑↓ ↑ 
immune response 
SCFAs 
glucose, insulin 
↓ 
↑ 
↑ 
Whole-body implications 
lipid and energy 
metabolism 
↑↓ 
↑↓ 
↑↓ 
↑↓ 
↑↓ 
↑↓ 
↑↓ 
↑ 
food intake 
body weight 
↓ 
↓ 
↑ 
↑ 
↑↓ 
Figure 1 Overview of the variables changed in the colonic lumen, the colonic mucosa 
and in plasma as a result of fermentable dietary fibre consumption, and its ultimate 
implications on satiety, food intake and body weight regulation.
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Samenvatting
194
Samenvatting
Obesitas is wereldwijd uitgegroeid tot een groot probleem voor de volksgezondheid, 
omdat het geassocieerd is met het zogenaamde metabool syndroom, een 
combinatie van risicofactoren die tegelijk aanwezig zijn en die het risico op hart- en 
vaatziekten en type 2 diabetes verhogen. Er is aangetoond dat voedingsvezels, de 
eetbare bestanddelen van planten die niet verteerd en geabsorbeerd worden in de 
dunne darm van de mens, belangrijk zijn ter preventie van obesitas en het metabool 
syndroom. Dit verband kan deels worden verklaard door de toegenomen mate van 
verzadiging als gevolg van de consumptie van vezels. Voedingsvezels kunnen worden 
gefermenteerd door de bacteriën, ook wel de microbiota genoemd, die aanwezig 
zijn in de dikke darm (caecum en colon), wat leidt tot de productie van korte-
keten vetzuren. De invloed van voedingsvezels op verzadiging kan deels worden 
toegeschreven aan de productie van deze korte-keten vetzuren. Het doel van het 
onderzoek beschreven in dit proefschrift was om de effecten van fermentatie in de 
dikke darm in kaart te brengen, met daarbij een specifieke focus op de gevolgen 
voor metabolisme en verzadiging. Gedetailleerde achtergrondinformatie en een 
beschrijving van de zogeheten ‘omics technieken’ die zijn toegepast voor het 
verkrijgen van de resultaten staan beschreven in Hoofdstuk 1.
Resistent zetmeel (RS) is een voedingsvezel die in hoge mate wordt gefermenteerd 
door de microbiota in de dikke darm. Hoofdstuk 2 beschrijft een experiment waarin 
volwassen zeugen gedurende 2 weken een dieet met veel RS consumeerden. 
Monsters afkomstig uit verschillende darmdelen werden verzameld om de 
microbiota samenstelling en de concentraties van de korte-keten vetzuren in het 
lumen te bepalen, en om de expressie van genen die betrokken zijn bij de opname 
en signalering van korte-keten vetzuren en de regulatie van verzadiging in het 
darmweefsel te meten. We laten zien dat RS volledig wordt afgebroken in het 
caecum. Zowel in het caecum als in het colon zagen we verschillen in de microbiota 
samenstelling tussen RS-gevoede varkens en varkens die een verteerbaar 
zetmeel (DS) dieet hadden geconsumeerd. In het colon van RS-gevoede varkens 
namen onder andere de butyraat-producerende Faecalibacterium prausnitzii 
toe, die zijn geassocieerd met een gezonde darm, terwijl potentieel pathogene 
Gammaproteobacteria in verminderde mate aanwezig waren. In RS-gevoede 
varkens waren de korte-keten vetzuurconcentraties in caecum en colon en de 
genexpressie van glucagon (GCG; voorloper van verzadigingshormoon GLP-1) en de 
korte-keten vetzuur transporter SLC16A1 in het caecum significant hoger. Alles bij 
elkaar heeft deze studie laten zien dat RS de microbiota samenstelling, korte-keten 
vetzuurconcentraties en genexpressie in de varkensdarm beïnvloedt.
De effecten van RS zijn tevens onderzocht in een experiment in jonge groeiende 
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varkens. Deze dieren hadden een canule in het voorste deel van het colon voor 
herhaalde afname van weefselbiopten (voor bepaling genexpressieprofielen) en voor 
verzameling van de darminhoud (voor bepaling korte-keten vetzuurconcentraties 
en microbiota samenstelling). Om de interindividuele variatie zo klein mogelijk te 
houden, werden het DS en het RS dieet in een cross-over studie aan de varkens 
verstrekt gedurende 2 weken per dieet. Hoofdstuk 3 beschrijft welke genen en 
metabole processen worden beïnvloed door RS in het voorste deel van het colon, 
zoals gemeten met behulp van microarray analyse. We zagen een verschuiving in 
het genexpressieprofiel van immuun regulatie naar vet- en energiemetabolisme als 
gevolg van RS consumptie. De nucleaire receptor PPARG werd geïdentificeerd als 
een potentiële centrale regulator. Bovendien verhoogde RS de aanwezigheid van 
bacteriën die geassocieerd zijn met een gezonde darm, terwijl de aanwezigheid van 
potentieel pathogene microbiële groepen verminderde.
Daarnaast is er een experiment uitgevoerd in muizen (Hoofdstuk 4), met als doel het 
vaststellen van het effect van het vetgehalte in de voeding op genexpressieprofielen 
in het colon na rectale toediening van de korte-keten vetzuren acetaat, propionaat 
en butyraat. Aan mannelijke C57BL/6J muizen werd een semisynthetisch laag vet 
of hoog vet dieet gevoerd vanaf 2 weken voor de start van de interventieperiode. 
Gedurende de interventie kregen de muizen een acetaat, propionaat, butyraat 
of een controle zoutoplossing rectaal geïnfundeerd op 6 opeenvolgende dagen, 
waarna het colon werd verzameld voor bepaling van de genexpressieprofielen. 
We hebben geconstateerd dat het vetgehalte van het voer een zeer grote invloed 
heeft op de verandering in genexpressie als gevolg van korte-keten vetzuren in het 
colon, voornamelijk na het toedienen van propionaat. Bovendien wijzen de dieet- 
en korte-keten vetzuur-afhankelijke veranderingen in genexpressie op de modulatie 
van diverse metabole processen. Genen betrokken bij oxidatieve fosforylering, 
vetafbraak, lipoproteïne metabolisme en cholesterol transport werden onderdrukt 
door acetaat en butyraat, terwijl propionaat leidt tot veranderingen in vetzuur- en 
sterol-biosynthese, en in aminozuur- en koolhydraat-metabolisme. Daarnaast lijkt 
een infusie met korte-keten vetzuren de genexpressieveranderingen geïnduceerd 
door een hoog vet dieet deels terug te draaien. Samengevat hebben we laten zien 
dat het vetgehalte in het dieet een belangrijke factor is die de metabole effecten na 
toediening van korte-keten vetzuren beïnvloedt.
Hoofdstuk 5 beschrijft de resultaten verkregen uit de studie die ook wordt 
beschreven in Hoofdstuk 3, waarbij echter de nadruk ligt op de tijdsafhankelijke 
veranderingen in gedrag, verzadigingshormonen en metabolieten als gevolg van RS. 
De postprandiale plasmaconcentraties van verzadigingshormonen en metabolieten 
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werden aan het eind van elke 2 weken durende periode gemeten door middel van 
herhaalde perifere bloedafnames via katheters. RS-gevoede varkens vertoonden 
minder voerbak-gericht gedrag en drinkgedrag dan DS-gevoede varkens en hadden 
hogere korte-keten vetzuurconcentraties in het plasma gedurende de dag. De 
postprandiale glucose, insuline en glucagon-like peptide-1 (GLP-1) responsen waren 
lager in RS-gevoede dan in DS-gevoede varkens, terwijl triglyceride concentraties 
hoger waren. Plasma serotonine concentraties, die gezien worden als een indicator 
voor de regulatie van verzadiging, waren lager in RS-gevoede dan in DS-gevoede 
varkens. Ondanks een lagere inname van metaboliseerbare energie, lijkt RS op 
basis van de gedragsobservaties verzadiging te verhogen. Verhoogde korte-
keten vetzuurconcentraties en een verlaagde postprandiale glucose en insuline 
respons in plasma behoren tot de mogelijke onderliggende mechanismen voor RS-
geïnduceerde verzadiging.
Het doel van de studie die wordt beschreven in Hoofdstuk 6 was het achterhalen van 
de effecten van verschillende vezels op postprandiale eiwit- en metabolietprofielen 
in plasma. Minipigs kregen een controle (C) dieet toegewezen of een dieet dat 
lignocellulose (LC), pectine (PEC) of RS bevatte voor een periode van 8 dagen in 
een 4 x 4 Latijns vierkant. Er was gekozen voor vezels met verschillende physico-
chemische eigenschappen; LC is een bulkvormende vezel, RS is een fermenteerbare 
vezel en PEC is zowel een visceuze als een fermenteerbare vezel. Op dag 8 van 
elke periode werden bloedmonsters uit de poortader en de carotus verzameld via 
katheters, zowel voor als op diverse tijdstippen na een ad libitum ochtendmaaltijd. 
In plasma zijn 973 peptiden en eiwitten gemeten. De eiwitprofielen na consumptie 
van het C en het LC dieet en de eiwitprofielen na consumptie van het PEC en 
het RS dieet kwamen het meest met elkaar overeen. Met alle diëten vond de 
grootste verschuiving in de aanwezige plasmaeiwitten plaats tussen 240 en 480 
min na de maaltijd. In plasmamonsters uit de poortader en de carotus kwamen 44 
respectievelijk 65 eiwitten differentieel tot expressie, afhankelijk van het vezeldieet 
en het postprandiale tijdstip. Verder zijn 24 metabolieten gemeten in portaal 
plasma, waaronder de korte-keten vetzuren acetaat, propionaat en butyraat. 
De concentraties van alle korte-keten vetzuren waren significant hoger na RS 
consumptie dan na C, LC en PEC consumptie. Dit experiment heeft laten zien dat de 
consumptie van diëten met fermenteerbare vezels resulteert in een ander plasma 
eiwitprofiel dan een dieet zonder vezels of een dieet dat een niet-fermenteerbare 
vezel bevat.
Drie belangrijke bevindingen worden beschreven in dit proefschrift. Ten eerste 
hebben we aangetoond dat de consumptie van RS de microbiota samenstelling 
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in het lumen van het colon verandert, met een afname in potentieel pathogene 
bacteriën en een toename in korte-keten vetzuur-producerende populaties. Ten 
tweede hebben we laten zien dat zowel na RS consumptie als na rectale toediening 
van korte-keten vetzuren veranderingen optreden in de genexpressie in het colon. 
Beide behandelingen induceerden veranderingen in metabole processen zoals 
energie-en vetmetabolisme en in immuun respons. Tot slot zagen we dat het 
vetgehalte in het dieet een grote invloed heeft op de veranderingen in genexpressie 
als gevolg van rectale toediening van korte-keten vetzuren. Deze belangrijkste 
resultaten worden in detail bediscussieerd in Hoofdstuk 7, evenals de voordelen 
en beperkingen van de gebruikte diermodellen en de betekenis van de bevindingen 
voor de humane gezondheid. Alles bij elkaar ondersteunt dit proefschrift de 
implementatie van fermenteerbare voedingsvezels in het humane eetpatroon met 
als doel het verbeteren van de darmgezondheid en het beperken van energie-
inname en gewichtstoename, wat uiteindelijk kan helpen bij de preventie van 
obesitas en type 2 diabetes. Aanvullend onderzoek is echter noodzakelijk om de 
mechanismen te achterhalen die ten grondslag liggen aan de verbetering van de 
humane gezondheid door consumptie van fermenteerbare voedingsvezels.
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Vol trots presenteer ik jullie mijn proefschrift! Het was hard werken, maar gelukkig 
stond ik er niet alleen voor. Graag zou ik daarom alle mensen willen bedanken die me 
de afgelopen jaren hebben geholpen met het tot stand komen van dit proefschrift. 
Jullie steun was onmisbaar!
 
Allereerst wil ik mijn promotor en co-promotoren bedanken. Michael, dankzij je 
kritische houding wist je mijn onderzoek in de juiste richting te duwen. Bovendien 
heb ik veel van je geleerd en heeft je visie op de voedingswetenschap me 
geïnspireerd. Bas Kemp, hoewel we elkaar niet heel regelmatig zagen, kijk ik met 
een goed gevoel terug op de samenwerking binnen ons interdisciplinaire project. 
Je inbreng tijdens vergaderingen is de voortgang van het project sterk ten goede 
gekomen. Guido, als mijn directe begeleider wil ik je bedanken voor alle tijd en 
energie die je hebt gestoken in mijn project. Hoewel je altijd druk in de weer bent 
met duizend verschillende dingen kon ik op je rekenen wanneer ik je input echt 
nodig had. Ook tijdens de experimenten en op het lab heb je me geholpen, terwijl 
dat absoluut niet de fijnste klusjes waren. Je energie en optimisme hebben me 
gemotiveerd op de momenten dat ik dreigde vast te lopen. Ik weet niet hoever ik 
zou zijn gekomen zonder jouw inzet, ik ben je heel erg dankbaar!
Graag wil ik alle andere mensen bedanken die betrokken waren bij het IP/OP 
project. Bedankt voor de samenwerking! Liesbeth Bolhuis, Walter Gerrits, Monica 
Mars en Henk Schols wil ik in het bijzonder bedanken voor de relevante input 
tijdens project meetings. Carol, thank you so much for the nice collaboration in the 
past years! I could always count on quick replies to my e-mails whenever I had a 
question, and I’m happy you taught me a lot about pigs. I was particularly happy to 
have you around during the study in Lelystad, where we stayed over in the middle 
of the Flevopolder, seemingly disconnected from the world outside. Good luck 
in your future career! Joost, ik vond het erg jammer dat je zo vroeg het project 
moest verlaten, want je had altijd een duidelijk overzicht van wat er zich afspeelde 
binnen het project en je brede kennis van mijn onderwerp heeft me echt geholpen 
tijdens de opstartfase. Guido Bosch, bedankt voor het leveren van een belangrijke 
bijdrage aan de voorbereiding, uitvoering en de data analyse (korte-keten vetzuren, 
statistiek) van de varkensproeven! Bovendien was je inzet essentieel voor het 
plannen van meetings en het op elkaar afstemmen van papers. Anne and Melliana, 
it was very nice collaborating with you as fellow PhD students on the same project.
 Graag bedank ik iedereen die betrokken was bij de experimenten in Lelystad. 
Sietse Jan, heel erg bedankt voor je hulp tijdens de voorbereidingen, de uitvoering 
en de dataverwerking. Jan van der Meulen, bedankt dat we gebruik konden maken 
van je expertise. Leo Kruijt, jou wil ik bedanken voor het uitvoeren van de SELDI-
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TOF-MS analyses. Je was een goede begeleider op het lab van wie ik veel heb 
geleerd. Je nam de tijd om alles goed uit te leggen en ik vond het fantastisch dat je 
bereid was om flink door te pakken in de decembermaand om alle analyses voor de 
jaarwisseling af te krijgen. 
 I’d also like to thank Jing, Hauke and Odette  from the Microbiology 
Department for the fruitful collaboration. The results on microbiota composition 
have become an essential part of my thesis, which I could not have imagined 
beforehand. Thanks for your efforts!
Daarnaast wil ik graag de mensen van het CKP bedanken, in het bijzonder Judith, 
Bert, Wilma en Rene. Bedankt voor jullie hulp bij de voorbereiding en de uitvoering 
van de muizenexperimenten!
Van IP/OP en het CKP door naar NMG. Ik wil graag al mijn (oud) NMG collega’s 
bedanken voor hun hulp, de input tijdens lab meetings, maar natuurlijk ook voor de 
gezelligheid tijdens de lunch en uitjes wat maakt dat ik met een fijn gevoel terugkijk 
op mijn aio-tijd.
 In het bijzonder wil ik mijn (oud)kamergenoten bedanken. Ageeth, Sandra, 
Maryam en Noortje, het was erg gezellig om met jullie de kamer te delen. Juri, je 
werkt nog niet zo heel lang bij ons, maar ik waardeer je ontspannen houding die 
zorgt voor wat rust op de kamer. Veel succes de komende jaren! Rinke, fijn dat ik 
zo vaak op je aanwezigheid kon rekenen als ik in het weekend moest doorwerken. 
Diederik, de kamer zou een stuk minder levendig zijn geweest zonder jou. Het was 
bovendien erg handig dat je 3 weken eerder promoveert dan ik, zodat ik alles een 
beetje van je kon afkijken. Bedankt voor het delen van documenten, ideeën en 
promotiestress! De tijd zal nu moeten leren of ik bepaalde gewoonten waar onze 
kamer zo berucht om is ga overnemen. Maar aangezien ik dit alles al jaren heb 
weten te verdragen, denk ik toch echt dat ik immuun ben ;-).
 Graag bedank ik ook de andere aio’s van NMG en Pharma. Frits, Fenni, Ya, 
Parastoo, Wieneke and Neeraj, it was nice to get to know you and good luck during 
the rest of your PhD project! Nikkie, Jvalini en Inge, jullie wil ik bedanken voor de 
prettige sfeer iedere keer als ik een bezoekje bracht aan jullie kamer, maar ook voor 
de gezelligheid buiten de werkuren. Katja, it was nice collaborating with you. Your 
sense of humour really helped me through my moments of doubt and stress. I think 
we can be proud of our joint paper, which really improved thanks to your ideas and 
knowledge. Keep up the good work! I’m already curious about your propositions ;-).
 I’d also like to thank the students who helped me during my project. Ingrid, 
thanks for your help with the pilot mouse experiment. Marlene and Natasa, thank 
you for helping me in the lab with the data collection.
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 Dan zijn er nog meer mensen die ik zeker niet wil vergeten te noemen. 
Sander, bedankt voor je interesse in mijn project. Ik ben blij dat mijn resultaten van 
waarde waren voor een prachtige publicatie. Shohreh, thank you for performing an 
enormous amount of lab work for me. I could always count on you and you gave me 
confidence in my lab work. Jenny en Mechteld, bedankt voor het uitvoeren van de 
microarray-analyses. Jessica, bedankt voor het delen van je ideeën over mijn data, 
je hulp bij de varkensproef en voor de gezelligheid tijdens de iets minder werk-
gerelateerde activiteiten.
Daarnaast wil ik graag mijn opponenten bedanken voor het plaatsnemen in mijn 
promotiecommissie en voor de tijd die ze hebben gestoken in het lezen van mijn 
proefschrift.
Uiteraard wil ik ook mijn paranimfen Rianne en Milène bedanken. Ik ben heel blij 
dat jullie allebei meteen enthousiast waren toen ik vroeg of jullie aan mijn zij wilden 
staan tijdens mijn verdediging. Rianne, bedankt voor de vele goede gesprekken 
tijdens onze duurloopjes en etentjes over de ups en downs waar elke aio mee te 
maken krijgt. Ik vind het ook heel fijn dat je inmiddels hebt meegemaakt hoe het 
is om te promoveren. Je hebt me echt het vertrouwen gegeven dat het mij ook 
zal lukken. Milène, als kamergenootje wil ik je bedanken voor de gesprekken als 
we allebei even geen zin hadden om te werken. Helemaal in de meest recente 
samenstelling van de kamer was ik blij dat je zo goed tegen de bizarre uitlatingen in 
kon gaan ;-). Bovendien ben je altijd heel behulpzaam geweest, of het nu ging om 
het oplossen van een computerprobleem of een lift naar Hoofddorp. Thanks!
Graag wil ik ook mijn vrienden bedanken die de afgelopen jaren veel interesse 
hebben getoond in het verloop van mijn aio-project. Jullie zijn heel belangrijk voor 
me geweest! Ik wil ook de mensen bedanken die ik heb leren kennen bij WSKOV en 
die ervoor gezorgd hebben dat de repetities voor mij een perfecte manier waren 
om te ontspannen. Al mijn hardloopmaatjes bij Tartlétos en Pallas: dankzij jullie 
ging ik altijd met plezier naar de trainingen! In het bijzonder wil ik de dames uit 
de lustrumcommissie (Hannie, Esther, Carolien, Mieke, Paulien en Imke) bedanken 
voor hun betrokkenheid en de gezellige etentjes, feestjes en uitjes.
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Dit laatste paragraafje heb ik gereserveerd voor het bedanken van mijn familie. Ik 
wil mijn oma’s bedanken voor de goede zorgen en voor hun interesse in hoe het 
op mijn werk gaat. Mark, fantastisch dat je bereid was me te helpen met de lay-out 
van mijn boekje en met het ontwerpen van de cover! Het kostte alles bij elkaar nog 
best veel tijd, maar het resultaat is prachtig. Bedankt, ik ben super trots op je! Pap 
en mam, op jullie onvoorwaardelijke steun heb ik altijd kunnen rekenen. Wanneer 
de zaken iets anders liepen dan ik had gehoopt dan waren jullie er voor me met 
bemoedigende woorden, advies of gewoon een luisterend oor. Jullie vertrouwen in 
mij heeft me de afgelopen jaren gemotiveerd om door te zetten. Jullie betekenen 
alles voor me.
Daniëlle
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